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Genomic instability is one of the enabling characteristics of cancer. DNA damage
response pathways are important for genomic integrity and cell cycle progression.
Defects in DNA damage repair can often lead to cell cycle arrest, cell death, or
tumorigenesis. The activation of the DNA damage response includes tightly regulated
signaling cascades that involve kinase phosphorylation and modular domains that
scaffold phosphorylated motifs to coordinate recruitment of DNA repair proteins. Modular
domains are conserved tertiary structures of a protein that can fold, function, and evolve
independently from an intact protein. One of the most common modular domains
involved in DNA damage repair is the BRCA1 C-Terminal (BRCT) domain. The BRCT
domain is approximately 90-100 amino acids long and functions as a scaffolding domain
to help recruit DNA damage-related proteins for DNA repair. Mechanisms in which
BRCT domains regulate DNA repair have yet to be fully elucidated. Studying proteinprotein interactions mediated by these domains can improve our understanding of how
BRCT domains function in DNA repair. The goal of this dissertation is to characterize the
scaffolding functions of BRCT domains and how their interactions contribute to DNA
damage repair pathways dysregulated in cancer.
BRCA1, the protein in which the BRCT domain was first identified, is the most
well-known cancer susceptibility gene, often mutated in cases of breast and ovarian
cancers. Our research has identified that BRCA1 BRCT domain-mediated interactions
with the mTORC2 complex disrupt the complex and impair Akt activation, which is
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critical for cancer cell growth, proliferation, and survival. We have sought to identify how
mTORC2 activity may regulate BRCA1 function as a DNA damage regulator and a
transcriptional co-activator and contribute to the DNA damage response. We have found
that rapamycin treatment increases BRCA1 transcriptional coactivation activity. Also,
mTORC2 activity prevents cisplatin-induced cell death. Repression of mTOR signaling
reduces gH2AX-BRCA1 foci formation. More importantly, this dissertation work highlights
a novel chemotherapeutic strategy of targeting the mTOR pathway for breast cancers
with BRCA1 mutations or loss of BRCA1 function. BRCA1 loss sensitizes breast cancer
cells to mTOR inhibition. Since the PI3K-mTOR-Akt pathway is upregulated in over 70%
of breast cancer cases, breast cancer patients with defective BRCA1 may be ideal
candidates for mTOR inhibitor therapeutics.
While BRCT domains are largely associated with DNA repair proteins, there are
some BRCT domain-containing proteins for which their DNA repair roles are not fully
characterized, such as RNA Polymerase II Subunit A C-Terminal Domain Phosphatase
1 (CTDP1). Our research has revealed CTDP1 as a regulator of FANCI in the Fanconi
anemia pathway, a pathway important for the repair of interstrand crosslinks (ICLs).
CTDP1 influences FANCI chromatin localization, FANDC2 foci formation, sensitivity to
ICL-inducing drugs, and homologous recombination repair. In addition, CTDP1 has also
been found to be highly expressed in breast cancer cell lines. CTDP1 knockdown in
murine mammary orthotopic models prevents tumor formation, thus rendering CTDP1 as
a potential target for breast cancer therapeutics.
The findings in this dissertation work contribute to our overall understanding of
how BRCT domains use their scaffolding function to regulate the DNA damage
response. Elucidating the biological importance of these domains can improve our
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understanding of cancer susceptibilities, tailor chemotherapeutic strategies, and make
better informed decisions in cancer therapies.
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CHAPTER 1: INTRODUCTION
Genomic Integrity
Genomic integrity is essential to the viability of the cell. Failure to repair DNA can
result in cell cycle arrest, cell death, or oncogenic transformation. DNA repair
mechanisms are tightly regulated to maintain genomic integrity and protect the cell from
oncogenic transformation. These same processes work in concert with cell cycle
checkpoints, including the intra S phase checkpoint. During late S phase and early G2
phase, double strand break repair via homologous recombination (HR) is active to
ensure the fidelity of replicated DNA by using a host of DNA repair proteins to restore
the DNA double strand helix. Some of these major recruitment factors include BRCT
domains. BRCT domains are evolutionarily conserved domains that have a shared
involvement in the DNA damage response (DDR) and use their scaffolding functions to
ensure genomic integrity 1. BRCT domains do not have intrinsic enzymatic activity of
their own. BRCA1 and CTDP1 are two examples of BRCT domain-containing proteins
that have multiple functions within and outside of DNA repair. The goal of this
dissertation is to present the importance of BRCT domains and how these domains use
their roles in DNA damage repair and recruit many factors, including kinases,
phosphatases, ubiquitin ligases, and others, to execute their functions.
Cancer
Hanahan and Weinberg characterized the six hallmarks of cancer—a set of
common characteristics that are associated with cancer initiation and progression 2. The
six hallmarks include self-sufficiency in growth signals, insensitivity to anti-growth
signals, tissue invasion and metastasis, limitless replicative potential, sustained
angiogenesis, and evasion of apoptosis 2. A decade later, they described an additional
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set of emerging hallmarks and enabling characteristics that were also associated with
the hallmarks of cancer previously established 3. One of the enabling characteristics of
cancer is genomic instability, a key mishap that cancer cells use to override DNA repair
mechanisms and checkpoints and proliferate in an unregulated manner. Often,
mutations in DNA repair genes give rise to defects in DNA repair mechanisms,
chromosomal rearrangements and abnormalities, and increase the likelihood of cancer
incidence.
It is widely accepted that genetic mutations occur prior to the onset of cancerous
lesions. The Knudson hypothesis, also known as the two-hit hypothesis, is a hypothesis
that acknowledges that two mutational events can give rise to cancer occurrence 4. This
hypothesis is credited to the cancer-associated alterations of known oncogenes and
tumor suppressors in the human genome. These alterations cause genotypic and
phenotypic effects that lead to a gain of function or loss of function. In cancer,
oncogenes are associated with gain-of-function mutations, while tumor suppressors are
associated with loss-of-function mutations. A combination of these events is what
contributes to genomic instability, cancer initiation, and progression.
Cancer cells, while genetically unstable and proliferative in nature, are sensitive
to DNA damaging chemotherapeutics and radiation. Chemotherapy agents, which
promote DNA damage, target proliferative cells in a non-specific manner. The first set of
chemotherapeutic agents used in cancer patients were alkylating agents 5. These agents
are often used to induce molecular changes to DNA alkyl groups, and therefore are
deemed to be DNA damage-inducing agents. DNA damage-inducing agents cause large
amounts of DNA damage that the cancer cells fail to repair. Accumulation of unrepaired
DNA lesions causes cancer cells to undergo cell death.
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Cancer patients often have genetic mutations that results in loss-of-function for
many DDR-related genes including ATM, BRCA2, PALB2, and BRCA1 6,7. These genes
have been found to be prevalent in familial and spontaneous cases of pancreatic,
ovarian, prostate, and breast cancers 6-15. Breast cancer susceptibility gene 1 (BRCA1)
is the most well-characterized tumor suppressor associated with breast cancer. Breast
cancer patients with BRCA1 mutations are more likely to be diagnosed with triplenegative breast cancer, the most aggressive form of breast cancer, which is often
resistant to standard chemotherapeutics 16. With this information, researchers have also
found that PARP inhibitors demonstrate clinical benefits in breast cancer patients with
BRCA1 mutations due to synthetic lethality 17. Synthetic lethality is the process in which
the combination of defects in two or more genes induces cell death, whereas defects in
each gene alone still allow cell viability 17. Loss of BRCA1 in addition to PARP inhibition
induces synthetic lethality in cancer cells. While there are still unknown mechanisms for
resistance to PARP inhibitors, it is imperative that we understand the underlying
molecular and biological mechanisms and key players that protect the cells from
transformation, tumorigenesis, and chemotherapeutic resistance.
BRCA1
Structure/Function
BRCA1 is a tumor suppressor protein of 1863 amino acids that contains three
modular domains that contribute to its overall function in the regulation of the DDR.
BRCA1 contains a N-terminal really interesting new gene (RING) domain, a coiled-coil
domain, and a BRCA1 C-terminal (BRCT) domain (Figure 1.1). For the purpose of this
dissertation, the following subsections will focus on the functions of the modular domains
found in BRCA1 and how each domain contributes to its tumor suppressive function.
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Figure 1.1: The domain structure of BRCA1.
(Top panel) This is a representation of the domain organization in BRCA1. BRCA1 has
an N-terminal RING domain that spans the first 109 amino acids. Within this domain is
the nuclear export signal (NES), which spans from 81-99 amino acids. BRCA1 also has
two nuclear localization signals (NLSs). The coiled-coil domain spans from 1364-1437
within the serine cluster region (1280-1524). The tandem BRCA1 C-Terminal (BRCT)
domain spans from 1642-1855 and contains a linker region between the two BRCT
domains. (Bottom left panel) Structure of the RING domain in BRCA1 from the Protein
Data Base (PDB). (Bottom right panel) Structure of the BRCA1 tandem BRCT domain
from PDB.
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RING Domain
The RING domain of BRCA1 is located in the N-terminus of the protein (amino
acids 24-65). RING domains are about 40-60 amino acids long and commonly present in
the structure of ubiquitin ligases 18,19. The RING domain of BRCA1 interacts with the
RING domain of BRCA1-associated RING domain protein 1 (BARD1) and this
interaction is required to generate a functional E3 ubiquitin ligase 20. The ubiquitin ligase
function of BRCA1 is critical for the activation of certain cell cycle processes with specific
substrates. BRCA1 and BARD1 co-localize in the nucleus during S phase and are
stabilized by the a-helices that flank their RING domains 19. Inside the RING domain are
conserved residues that are responsible for binding to two zinc ions in a core of antiparallel b-sheets 19. The zinc-binding capacity of RING domains is critical for BRCA1’s
role as a functional ubiquitin ligase.
The BRCA1-BARD1 ubiquitin ligase complex is well-known for its role in cell
cycle checkpoint regulation for its ubiquitination of substrates, such as CtIP and H2AX 21.
Ubiquitination of CtIP allows for CtIP-mediated chromatin binding, and ubiquitination of
H2AX allows for chromatin remodeling to occur for DNA repair proteins to access the
DNA helix 21. BRCA1 and BARD1 together can ubiquitinate a serine-5-phosphorylated
RNA Polymerase II (RNA Pol II) on its RPB1 subunit in response to DNA damage to
stimulate DNA repair 22. The BRCA1-BARD1 heterodimer also participates in autoubiquitination, in which it stimulates its own ubiquitin ligase activity towards its targets
while being polyubiquitinated 23.
Coiled-coil Domain
The serine cluster region (amino acids 1280-1524) within BRCA1 is the site
where ATM and/or ATR can phosphorylate BRCA1 during the DDR to recruit BRCA1 to
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sites of DNA damage 24. The coiled-coil (CC) domain of BRCA1 is located within the
serine cluster between amino acids 1364-1437. The CC domain is mainly recognized for
its interaction with the protein partner and localizer of BRCA2 (PALB2). PALB2 and
BRCA1 interact through their respective CC domains 24. PALB2 serves as a bridge
between BRCA1 and BRCA2, and this protein complex functions in strand invasion to
stabilize the nucleoprotein filament with RAD51 for HR repair 20,21,25. There have been
reported cases of breast cancer in which patients harbor mutations within the coiled-coil
domain of BRCA1 or PALB2, suggesting that this interaction may be critical for tumor
suppression 6,13,26-29.
BRCT Domain
Mutational analysis of BRCA1 led to the discovery of the modular BRCT domain
and its characterization as an essential component of the tumor suppressive function of
BRCA1 30. Since its discovery, the BRCT domain has been found only in 23 human
proteins, most of which have known functional involvement in maintaining DNA integrity
31-38

. BRCA1 contains a pair of tandem BRCT (tBRCT) domains at its C-terminus

between amino acids 1642-1855. Functional and structural characterization of the
BRCA1 tBRCT revealed that it is essential for the recognition of DNA damage-induced
serine phosphorylations (binding the consensus sequence phospho-Ser-X-X-Phe
(pSXXF) 39,40), enabling recruitment of these proteins to sites of DNA damage 41-43. This
domain has no intrinsic enzymatic activity but is essential for organization of
macromolecular complexes that mediate the DDR 44-46. As scaffolding domains,
delineating the protein-protein interactions mediated by the tBRCTs is essential to
understanding the mechanisms by which this domain controls the DDR.
BRCA1 participates as an active component of its own macrocomplexes. Using
its BRCT domain, BRCA1 forms three major macrocomplexes: the BRCA1-Abraxas

28
(BRCA1-A) complex, the BRCA1-BACH1 (BRCA1-B) complex, and the BRCA1-CtIP
(BRCA1-C) complex 47,48. Each of these complexes are formed by the interaction of the
BRCA1 BRCT domain and the phosphopeptide motif pSer-Pro-X-Phe (pSPXF) from
Abraxas, BACH1, and CtIP, respectively 48,49.
The BRCA1-A complex—consisting of BRCA1, BARD1, Abraxas, RAP80, BRE,
BRCC36, and NBA1—is recruited upon DNA damage-induced ubiquitin signaling 47,48. It
is also known as a deubiquitinating complex through the actions of BRCC36 48. The
BRCA1-A complex is important for controlling the G2/M cell cycle checkpoint, which
includes HR repair 47.
The BRCA1-B complex—consisting of BRCA1, BARD1, BACH1 (BRIP1/FANCJ),
and TOPBP1—is responsible for the progression through S phase and replication stress
47,48

. TOPBP1, another BRCT-domain containing protein, has been found to be critical in

the response to the G1/S checkpoint 50. The BRCA1-B complex, with the help of
TOPBP1 and BACH1, is important for DNA interstrand crosslink repair upon the
recognition of stalled replication forks 48.
The BRCA1-C complex—consisting of BRCA1, BARD1, CtIP, and the MRE11RAD50-NBS1 (MRN) complex—is important for DNA end resection for double strand
break (DSB) repair. This macrocomplex recognizes DSBs with the help of the MRN
complex 21. CtIP is required for the interaction between BRCA1 and the MRN complex
and, together, aid in the regulation of the transition from S phase to G2 phase 21.
Cancer Predisposition
Mutations Associated with Cancer
Breast cancer is the most frequently diagnosed cancer in women with an
estimated 266,120 new cases diagnosed and approximately 40,920 fatalities in 2018,
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according to National Cancer Institute’s Surveillance, Epidemiology, and End Results
Program (SEER, seer.cancer.gov). In breast cancer, roughly 5-10% of cases can be
attributed to inherited mutations found in the tumor suppressor BRCA1 51-53, and
inactivation of the wild type allele is required for tumor initiation 54. Inherited mutations of
BRCA1 increase the lifetime risk of developing breast cancer from 11% in the general
population to 50-80% and ovarian cancer from 1.4-2.5% to 15-60% 53. Epigenetic
silencing of BRCA1 is also associated with increased cancer risk 55,56.
There are many mutations found in BRCA1 that are associated with an increased
risk for developing breast and ovarian cancer. Some of these mutations were found in
the RING domain of BRCA1. One of the most commonly characterized BRCA1 RING
domain mutations is the 185delAG mutation. This mutation causes a frameshift and
leads to a truncation of the BRCA1 protein 57. There are other documented mutations
that also disrupt the folding of the BRCA1 RING domain, including the C61G, C64G, and
C64Y mutations 57. These mutations are targeted key sites that are critical for the metalbinding capacity for zinc, as required by RING domain function 19. Thus, these mutations
result in a loss of BRCA1 E3 ubiquitin ligase activity 58.
Rare, biallelic mutations of BRCA1 have also been found in a small subset of
cancer patients 59-64. Sawyer et al. found that their reported patient presented features
phenotypical of a Fanconi anemia patient 61. Fanconi anemia (FA) is an autosomal
recessive, cancer-prone disease that arises from a biallelic mutation in one of the 22 FA
genes. This disease presents a wide array of distinct, physical characteristics. More
importantly, patients with this disease lack the ability to repair ICLs. This disease will be
further discussed in Chapter Four. Because of the genotypic and phenotypic
observations found in this cancer patient that were similar to FA patients, these results
implicated BRCA1 as a new FA complementation group. This landmark study was
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groundbreaking because it has been suggested and previously shown in mammalian
models that biallelic mutations in BRCA1 were embryonic lethal 60,65,66. Interestingly, a
few of the reported patients had one mutation located outside the BRCA1 RING domain
and the other mutation within the BRCA1 BRCT domain 59,61. More studies will have to
be conducted to determine how these mutations compensate reduced functionality and
embryonic viability.
Mutations in the BRCT Domain
There are many reported variants in BRCA1 from cancer cases, and many of
these mutations are found in the BRCT domain. Most of the pathogenic mutations found
in the BRCT domain of BRCA1 result in truncated forms of the protein in which one or
both of the BRCT domains are deleted 67. The BRCT domain is essential to the tumor
suppressive nature of BRCA1. Mutations found in this domain are often characterized as
loss-of function mutations, leading to a sensitivity to DNA-damaging agents, disruption of
the G2/M cell cycle checkpoint, and ablation of the DNA damage repair function of
BRCA1 67.
One of the earliest reported BRCA1 BRCT missense mutations was the M1775R
mutation, which was linked to reported cases of breast cancer 53,55. Studies have shown
that this mutation leads to many functional defects of BRCA1 in the areas of cell cycle
control, recognition of DNA damage repair proteins, and DSB repair 68. Another
missense mutation found in the BRCA1 BRCT domain was the A1708E mutation. This
mutation, like the M1775R mutation, also led to defects in BRCA1 transcription coactivation, DSB repair, and recognition of DNA repair proteins, such as BACH1 21. These
mutations, which are located in the phosphobinding cleft of the BRCT tandem in BRCA1,
have been found to significantly alter the structure of the cleft, which impairs the ability
for the BRCT tandem to bind pSXXF/Y motifs 21,68.
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BRCT Domains
Structure/Function
BRCT domains are evolutionarily conserved across many species, from bacteria,
archaea, and eukarya superkingdoms 69,70. They are about 90-100 amino acids long and
can be structured into singletons (one BRCT domain), tandems (a pair of BRCT
domains), and in complex, higher structures (triplets, quartets, etc.) (Figure 1.2). The
conventional topology of a BRCT domain is a tertiary structure composed of four parallel
b-sheets (b1-b4) surrounded by two a-helices on one side (a1 and a3) and one a-helix
on the other (a2), resulting in a b1-a1-b2-b3-a2-b4-a3 pattern 71. While the BRCT
domain is found throughout many organisms, the structure—not the primary amino acid
sequence—is what is conserved throughout evolution. The most conserved residues of
BRCT domains are found in the hydrophobic core and particular residues that can
recognize phosphorylated peptides 49,67. Currently, there are 46 identified BRCT
domains in the human proteome. BRCT domains are restricted to a specialized group of
only 23 proteins that are predominantly associated with DDR pathways (Figure 1.3)
1,69,70,72

.
The BRCT domain is a phospho-peptide binding domain that interacts with DDR-

dependent phosphorylations and serve as a scaffold for organizing multi-protein
complexes that orchestrate the decision between HR and non-homologous end joining
(NHEJ) through the recruitment of specific repair proteins to sites of DNA damage 73-76.
Because of their role as protein scaffolds, the mechanisms by which BRCT domains
perform their unique functions in the DDR can be elucidated through analysis of their
protein interactions.
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Singleton

Tandem

Triplet
Figure 1.2: Three-dimensional structures of the BRCT superfamily.
BRCT domains can be identified as singletons, tandems, triplets, and quartets. These
domains in multiplicity coordinate a specific interaction interface that binds particular
substrates, thus demonstrating different specificities. (Top left panel) BRCT singleton
from CTDP1 (PDB: 4XPZ). (Top right panel) Tandem BRCT domain from BRCA1 (PDB:
1JNX). (Bottom left panel) Triplet BRCT domain from TOPBP1 (PDB: 2XNK).
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Figure 1.3: The BRCT superfamily.
The BRCT superfamily is composed of 23 proteins in the human proteome that contain a
BRCT domain. BRCT domains are structurally conserved and largely involved in proteinprotein interactions in the DNA damage response. BRCT domains can be identified as
singletons, tandems, triplets, and quartets. These domains in multiplicity coordinate a
specific interaction interface that binds specific substrates, thus organizing different
protein complexes.
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Singletons
A BRCT domain singleton is commonly found in about half of the BRCT domaincontaining proteins currently known. BRCT singletons do not have the same ability as
BRCT tandems to bind and recognize phospho-SXXF/SXXY motifs; however, this does
not limit their roles in DNA damage repair and replication. Evolutionarily, singleton BRCT
domains developed prior to tBRCT or higher order BRCT domains. Bacterial DNA
ligases and RFC1 proteins are some of the earliest BRCT domains identified, and these
domains are known to bind to the 5¢-phosphorylated ends of damaged DNA. It is from
here that the well-known phospho-peptide binding function is thought to have evolved.
Indeed, it has been documented that certain BRCT singletons can bind to
phosphorylated peptides. CTDP1 is one example of a protein that has a BRCT singleton
that binds to phosphorylated targets. Its BRCT domain binds phosphorylated RNA
Polymerase II (RNA Pol II) on the C-terminal domain (CTD) tail 1,68,77. Also, the sixth
BRCT domain in TOPBP1 alone can bind to phosphorylated E2F1 77. The BRCT
singletons of terminal deoxynucleotidyl transferase (TdT), Y-family polymerase REV1,
and DNA ligase III (LIG3) also have been found to have preferential binding to
phosphopeptides 77. These collective data suggest that the ability of higher order BRCT
domains to bind phosphorylated peptides is evolutionarily conserved from the BRCT
singletons.
Importantly, BRCT domains are not restricted to binding phosphorylated
peptides. BRCT singleton domains can interact with other proteins, as well as other
BRCT domains, in a phosphorylation-independent manner. One example of this is the
interaction of the second BRCT domain of XRCC1 and the BRCT domain of LIG3 during
short-patch base excision repair 49. Another example in a similar context is the XRCC1
BRCT domain interacting with the PARP1 BRCT domain for base excision repair 49.
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Tandems
There are a few theories surrounding the origins of the tandem BRCT. The
tandem BRCT domain could have resulted from a duplication of a singleton domain 69.
Mesquita & Woods et al. have also suggested that the origin could have been from a
special subclass of BRCT domain-containing proteins 69. This particular subclass of
proteins has a distinct structural difference in their BRCT domains, in which an Nterminal a-helix outside of the BRCT domain can coordinate and bind to DNA 69. One
example is that of replication factor C subunit 1 (RFC1). RFC1 binds to the 5¢-phosphate
of the DNA strand, binding to the primer-template strand for the loading of the PCNA
sliding clamp 78,79. This binding demonstrated by RFC1 is also similar to that of bacterial
NAD+-dependent ligases, in that they both have conservation in their residues that
mediate DNA binding 69. Interestingly, according to a BRCT clustering tree generated by
Mesquita & Woods et al., RFC1 was found to cluster with the archaeal BRCT domains
69

. PARP1, a BRCT domain-containing protein that also binds to DNA, also clusters right

below the archaeal BRCT domains 69. This evidence further suggests that the
functionality of BRCT singleton domains binding to DNA phosphates likely is the
precursor of the evolved BRCT tandems that have the ability to bind to specific
phosphopeptide motifs.
Woods et al. developed unrooted trees to determine the evolutionary sequence
conservation of the 23 proteins with singleton and tandem BRCT domains as it relates to
clustering amongst characteristics specific to singleton and tandems separately 72. This
diagram provided some evidence that the evolutionary diversion of the singletons and
tandems do not necessarily diverge by specific characteristics differing between
singletons and tandems, but as a multitude of different branches. Another unrooted tree
was generated amongst the tandem BRCT domains to determine their relationships 72. It
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was observed that the proteins with BRCT tandems had BRCT singletons (which made
up the tandem) that had different evolutionary origins, and suggested that this may be
for varying structural requirements for specificity and recognition of its targets 72.
Tandem BRCT domains are believed to have a preferential binding to
phosphorylated SXXF/SXXY motifs. The first tandem BRCT domain structurally
characterized was that of XRCC1 68. There are structural studies that show the binding
motif and how critical folding is to recruitment of particular substrates. Despite the cleftlike structure with a very specific motif interaction, the tandem BRCT domain does not
elicit any enzymatic activity in nature. Binding to phosphorylated peptides of target
proteins requires both BRCT domains of the tandem pair. The first BRCT domain of the
tandem (BRCT1) binds the phosphorylated Serine or Threonine (pS/T) of the target
peptide while the amino acid of the +3 position of the target protein is coordinated by the
hydrophobic cleft formed by the interface between BRCT1 and BRCT2 24. The amino acid
of the +3 position is usually a phenylalanine or a tyrosine.
The variable linker region between the tandem BRCT domains is a critical
component that contributes to substrate binding specificity. This feature allows the two
BRCT domains to fold in a head-to-tail manner 80. The linker region spans up to 24
amino acids; however, there are identified linker regions that are either 0-5 amino acids
or 18-24 amino acids that seem to be preferred 81. Longer linker regions can help the
tandem become more flexible for substrate binding and create larger scaffolding
structures for more binding partners to form multiprotein complexes 43.
Tandem BRCT domains are not limited to binding to phosphopeptides. Like
singletons, tandems also have phosphorylation-independent interactions with other
proteins, which have been previously reported 72. Most notably, 53BP1 binds the tumor
suppressor p53 through its tBRCT domain using the face opposite of the
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phosphopeptide binding region, which includes the linker region 69,82,83. Also, LIG4
interacts with XRCC4 using its BRCT tandem linker region to facilitate the final steps of
NHEJ 69.
Higher Order or “Complex” Domain Structures
There are four BRCT domain-containing proteins that encode more than 2 BRCT
domains (MCPH1, TOPBP1, ECT2, and PAXIP1) (Figure 1.3). MCPH1 has one
singleton domain at its N-terminus and a pair of BRCTs that function as a tandem at its
C-terminus. However, TOPBP1, ECT2, and PAXIP1 are unique in that they have at least
three BRCT domains in close proximity that facilitates the formation of triplet (TOPBP1
and ECT2) and even quartet BRCT domains (PAXIP1). The only identified BRCT
domain triplets to date are found in TOPBP1 and ECT2 49,71,84,85. Each of these triplets
include two canonical BRCT domains (identified as BRCT1 and BRCT2) and an Nterminus BRCT0 domain. The BRCT0 domain is different from the canonical BRCT
domain in that it contains four b-sheets and four surrounding a-helices in which the bsheets are perpendicular rather than parallel 84,85. Also, it was reported that this
particular domain has a different surface pocket characteristic in which the residues are
hydrophobic 84,85. Deletion of the BRCT0 domain from the triplet of TOPBP1 only slightly
reduced the phosphopeptide binding of DNA damage partner RAD9 49,84. This indicated
that this pocket may not have phosphobinding capability like the subsequent tandem
BRCT domains, and it is unclear what role it plays in regulating interacting complexes in
coordination with BRCT1-2 of TOPBP1. The triplet BRCT domain found in ECT2 is
slightly different from the triplet BRCT domain in TOPBP1. The ECT2 BRCT2 domain
does not have an a2 helix, thus resulting in a different hydrophobic pocket with different
phosphobinding abilities and providing a unique substrate specificity for protein-protein
interactions, exhibited by its interaction with phosphorylated CYK-4 71.
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The only documented BRCT quartet has been found in PAXIP1, also known as
PTIP. PAXIP1 has a total of six BRCT domains in its protein structure that act as three
tandems. The last two tandems (BRCT3/4 and BRCT5/6) are very unique in that this set
functions as a collective tandem with four domains to bind to phosphopeptides. PAXIP1
uses its quartet domain to bind to phosphorylated Serine-25 on 53BP1 86. While this site
is phosphorylated by ATM, the individual C-terminus tandems of PAXIP1 could not bind
to this site alone 86. The quartet BRCT domain was also found to be important for proper
PAXIP1 foci formation and recruitment to sites of DNA damage 86,87. These results
suggest that there is an evolutionary importance of the BRCT quartet for an efficient
DDR.
Role as Scaffolds
Transcription
In addition to scaffolding roles in the DDR, some BRCT domain-containing
proteins have additional roles in the cell. Two of them—BRCA1 and CTDP1—serve
critical roles in transcription and share interactions with RNA Pol II.
BRCA1
BRCA1 is a transcriptional transactivator that plays a role in the transcription of a
number of genes. Chapman and Verma reported that the C-terminal domain of BRCA1
is instrumental for its transcriptional activity 88. Monteiro et al. observed that mutations in
the BRCT domain associated with breast and ovarian cancers disrupted transcriptional
activation 89. Similar results have also been reported with other groups, suggesting that
alterations in the BRCA1 BRCT domain exhibit more of a detriment to cellular functions
outside of BRCA1’s canonical function in DNA damage 90.

39
BRCA1 interacts with influential transcription-related proteins, including RNA Pol
II and p53 91. Scully et al. found that BRCA1 copurified with an active RNA Pol II
holoenzyme, including transcription factors TFIIE, TFIIF, and TFIIH 92. Anderson et al.
further demonstrated that the connection between BRCA1 and the RNA Pol II
holoenzyme was through RNA helicase A (RHA) 93. BRCA1 interacts with p53 through
its BRCT domain to promote the transcription of p21 94. Transcription of p21 can be
regulated through the interaction of CtIP with the BRCT domain of BRCA1 95. CtIP, and
its co-repressor CtBP, interact with BRCA1 and repress the transcriptional
transactivation capability of BRCA1, thus repressing transactivation through the p21
promoter 95. BRCA1 does not require DNA binding to a TATA promoter to induce its
function as a transcriptional coactivator 96.
In addition to its transcriptional coactivation of p21, BRCA1 has also been found
to regulate transcription activation of other known transcription-related genes, as well as
cell cycle proteins, growth factor receptors, and DDR factors 97-101. BRCA1 interacts with
STAT1-a to stimulate transcription of IFN-g target genes and co-activates transcription
factors 14-3-3s, NFkB, and HPV18 E2 102-105. BRCA1 has been noted to regulate
transcription by RNA Pol I, RNA Pol II, and RNA Pol III 106-108. BRCA1 has also been
shown to have a regulatory role in VEGF transcription with ER-a and IGF1R
transcription in a AR-dependent manner, respectively 109,110. BRCA1’s transcriptional coactivator activity can be negatively regulated, however, by SUMO1 and BARD1 111,112.
This suggests that while BRCA1 is involved with many cellular processes, it also can be
regulated to properly ensure that each of these processes is carried out in a sequential
manner.
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CTDP1
RNA Pol II is regulated by phosphorylation during rounds of transcription. The Cterminal tail of RNA Pol II contains the heptapeptide repeat Tyr1-Ser2-Pro3-Thr4-Ser5Pro6-Ser7, which is necessary for transcription 113. Phosphorylated RNA Pol II CTD tail is
associated with the preinitiation step of transcription, and dephosphorylated RNA Pol II
CTD tail is associated with the elongation step of transcription 113. These observations
implicate that there must be a phosphatase that is responsible for dephosphorylation of
the RNA Pol II CTD tail to progress into the consequential steps of transcription. CTDP1
was discovered in HeLa cells as a 150-kD protein that was expressed in extracts that
exhibited depleted amounts of the phosphorylated form of the RNA Pol II CTD tail 113.
The activity of this phosphatase was dependent on magnesium ions and stimulated by
transcription factor IIF (TFIIF), thus it was later named TFIIF-associating component of
CTD phosphatase, or FCP1 114-116. CTDP1 dephosphorylates RNA Pol II at serines 2
and 5 on the CTD tail 117.
CTDP1 is a haloacid dehalogenase (HAD) that contains an FCP1 phosphatase
homology domain and a BRCT domain. Like other HAD phosphatases, CTDP1 contains
an aspartic acid residue inside the active site that is used for nucleophilic attack 118.
While the HAD superfamily of phosphatases is a small subgroup of phosphatases,
CTDP1 is the only phosphatase in the human proteome that contains a BRCT domain,
which could give further specificity for its substrates. The BRCT domain of CTDP1 is
essential for its role in transcription. Mutations or deletions of the CTDP1 BRCT domain
have been shown to compromise the viability of yeast cells and result in a
hyperphosphorylated RNA Pol II, further confirming the importance of the integrity of the
BRCT domain as it relates to its phosphatase activity 119,120.
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DNA Damage Response
The DDR is a major cellular process in which cells utilize machinery in a
regulated and sequential manner to repair damaged DNA lesions in the form of bulky
DNA adducts, crosslinks, single-strand breaks (SSBs), and double strand breaks
(DSBs). Failure to remove these lesions can result in mutations, stalled replication forks,
cell death, chromosomal aberrations, or tumorigenesis. The following subsections
outline some of the DNA damage repair processes that cells utilize to repair damaged
DNA. These pathways, in particular, involve BRCT domain-containing proteins and their
scaffolding capabilities to aid in DNA repair (Figure 1.4). Most of the known BRCT
domain-containing proteins are characterized in the DDR, such as BRCA1, BARD1,
53BP1, TOPBP1, REV1, and MDC1. The following are DNA repair mechanisms that
involve BRCT domain-containing proteins to execute proper repair of DNA strands and
replication continuity:
Base Excision Repair
Base excision repair (BER) is a DNA repair pathway that is activated upon
deamination, oxidative damage, and alkylation damage 121. This repair pathway begins
with a DNA glycosylase that recognizes the damaged nitrogenous base, cleaves the Nglycosidic bond, and leaves an apurinic/apyrimidinic or abasic (AP) site as an
intermediate 122. An incision at the AP site is then made by an DNA endonuclease or
hydrolysis of the bond by a DNA lyase 121. There are two forms of BER that can be used
to repair the AP site: short-patch BER (removal of 1 nucleotide) and long-patch BER
(removal of 2-13 nucleotides) 123. During short-patch BER, the resulting 5¢-deoxyribose5-phosphate (5¢-dRP) is removed by the lyase activity of Pol b, while the 3¢ abasic
terminus is cleaved by a DNA endonuclease 124. Pol b synthesizes a new DNA base to
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Figure 1.4: Types of DNA damage and their respective repair mechanisms.
Cells utilize specific DNA repair mechanisms to fix different DNA replication stresses and
induced damage. Base excision repair (BER) is used to repair single-strand breaks
(SSBs). Translesion synthesis (TLS) is a DNA tolerance mechanism in which the lesion
is bypassed with additional replication. Double-strand breaks (DSBs) are largely repaired
by either non-homologous end joining (NHEJ) or homologous recombination (HR).
Microhomology-mediated end joining (MMEJ) is another form of NHEJ in which small
lengths of homology are used to guide in DNA repair.
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fill the gap, or nick. Then, the nick is sealed by DNA ligase I or DNA ligase III 123. In longpatch BER, Pol b displaces the DNA strand and allows for Pol d or Pol e to synthesize
new DNA bases, creating a flap structure 125. This flap is removed by FEN1, a flap
endonuclease, which results in a nick that is sealed by DNA ligase I 125.
There is a group of BRCT domains that aid in the BER pathway. XRCC1, PARP1
and LIG3 are all key components in BER. XRCC1 is a major scaffolding protein in BER
that uses its BRCT domain to interact with PARP1 and LIG3 125,126. PARP1 localizes to
sites of SSBs for DNA repair 124. PARP1 recruits XRCC1 to sites of SSBs generated
during BER 127. XRCC1 is recruited to the nick created from the excised base and
interacts with LIG3 for the ligation of the nick to the newly synthesized base. These data
support the evidence that the scaffolding function of BRCT domains is essential to the
DDR.
Translesion Synthesis
Translesion synthesis (TLS) is a DNA repair pathway that is a bypass
mechanism used to synthesize DNA beyond the damaged lesion. TLS is a temporary fix
in which an insertion of bases is made by a certain set of DNA polymerases and then the
lesion is later corrected by another round of replication or repair mechanism 128. There
are two different mechanisms for TLS: error-free and error-prone. The mechanism is
largely dependent on the type of damaged lesions that are present and the DNA
polymerases recruited to the damaged lesion 129.
BRCT-domain containing Y-family polymerase REV1 has been found to be an
influential player in TLS. REV1 is a deoxycytidine monophosphate (dCMP) transferase
that acts as a scaffold to bind to the processive sliding clamp PCNA using its BRCT
domain located at the N-terminus of the protein 130. REV1 also interacts with Pol z and
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coordinates a mechanism called polymerase switching in which DNA polymerases are
substituted to fulfill replicative roles during TLS in a specific and sequential manner 131.
More importantly, polymerase switching depends on the mono-ubiquitination status of
PCNA by the RAD6/RAD18 E3 ubiquitin ligase enzyme 132. REV1 interacts with the other
Y-family DNA polymerases (Pol h, Pol i, and Pol k) at the REV1-interaction region (RIR)
located at the C-terminus of the protein to carry out its polymerase switching function
133,134

. The other Y-family DNA polymerases also interact with PCNA with their PCNA-

interacting protein (PIP) motifs 132. Together, the Y-family polymerases synthesize
additional bases to bypass the damage lesion.
Non-homologous End Joining
Non-homologous end joining is an error-prone pathway that repairs DNA double
strand breaks by ligating broken ends of DNA with little to no homology 135. While it is
widely known for its association with G1 phase due to the inhibition of end resection in
G1, NHEJ is unique in that it occurs in various phases of the cell cycle 135. Ku70 and
Ku80 form a heterodimeric complex to localize to these broken ends and stabilize while
recruiting the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) that serves
as a kinase 25. Artemis and DNA-PKcs work together in a complex to aid in DNA end
processing 25. The MRN complex is recruited to the complex for further end processing.
This complex then recruits the XRCC4-XLF-LIG4 complex for the ligation step.
There are many BRCT domain-containing proteins that are involved in NHEJ. Xfamily DNA polymerases POLL (Pol l), POLM (Pol µ), and DNTT (TdT) are the main
DNA polymerases that synthesize new DNA bases during NHEJ repair 136. NBS1 from
the MRN complex as well as LIG4 are also key components in recognition, recruitment,
and ligation, respectively. Upon DNA damage, the MRN complex recognizes the DSBs
and recruits ATM, which then phosphorylates H2AX to become g-H2AX. MDC1, a BRCT
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domain-containing protein, is phosphorylated by ATM, binds to g-H2AX with its tandem
BRCT domain, and recruits E3 ubiquitin ligase RNF8 137. RNF8 recruits another E3
ubiquitin ligase, RNF168, which ubiquitinates g-H2AX 137. This then signals either 53BP1
or BRCA1/RAP80/Abraxas complex recruitment for DSB repair via NHEJ or HR,
respectively 47,138. For the promotion of NHEJ, 53BP1 interacts with MDC1 with its
respective BRCT domains 139.
Tumor suppressor p53-binding protein 1 (TP53BP1), also referred to as 53BP1,
is known to engage in foci formation with g-H2AX at sites of DNA damage and protects
DNA ends from resection during G1 as a key indicator of cells prepared to undergo
NHEJ 140,141. PAXIP1 is required for ATM-mediated phosphorylation of p53 at Serine-15
87

. PAXIP1 has been noted to interact with 53BP1 with its BRCT domains upon ionizing

radiation (IR), and this interaction is required for a complete DDR 86,87,142. The 53BP1PAXIP1 interaction at Serine-25 is necessary for the subsequent ATM-mediated
phosphorylation of BRCA1 and CHK2, which further indicates the importance of this
interaction for ATM-mediated repair of DSBs 86. In addition, this interaction prevents
recruitment of CtIP and BRCA1 to DSBs, which inhibits the onset of HR and promotes
NHEJ 143. It is important to note that BRCA1, which is mostly known for its association
with HR, has also been found to have some roles in NHEJ 20. However, more evidence
is needed to resolve these emerging reports.
Microhomology-mediated End Joining
Microhomology-mediated end joining (MMEJ) is an additional pathway that is
error-prone like NHEJ. MMEJ is an alternative pathway of NHEJ that uses
microhomology with 5-25 nucleotides at the ends of DNA DSBs prior to end joining 144.
This pathway often results in variable amounts of DNA deleted from the break lesion and
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subsequent chromosomal aberrations, such as translocations and deletions 144,145.
Additional studies suggest that the insufficient binding of RPA to single-stranded DNA
allows for incorrect annealing steps, thus leading to MMEJ and further error-prone
consequences 145.
There are a few DNA repair factors that have been identified in other singlestrand DNA repair mechanisms—such as BER—and also have been implicated in the
MMEJ repair pathway. BRCT domain-containing proteins PARP1, NBS1, XRCC1, and
Ligase III (LIG3) have all been deemed to be critical for the function of MMEJ 146,147. The
role of NBS1 in the MRN complex is important for DNA binding and the initiation steps of
resection, which is also seen in both NHEJ and HR 146. MRE11 is also an endonuclease
needed for resection at the 3¢ end of DNA. PARP1 is involved in the annealing step of
MMEJ 148. XRCC1 phosphorylation by casein kinase 2 (CK2) is necessary for its
interaction with MRE11 and CtIP after irradiation 149. Polymerase theta (Pol q) has been
the polymerase implicated for its role in promoting MMEJ. LIG3 is the ligase in MMEJ
that is responsible for the ligation of the microhomology ends 146. Together, these
findings provide evidence of involvement of BRCT domain-containing proteins in a noncanonical DSB repair pathway.
Homologous Recombination
Homologous recombination is an error-free DNA repair mechanism that involves
the repair of DNA double strand breaks with homologous ends using a structure known
as the Holliday junction. HR requires a sister chromatid as a template for repair; thus,
this repair process is primarily utilized during S/G2 phases when sister chromatids are
available 21,150,151. HR is a complex mechanism that requires a number of proteins critical
for ensuring proper DNA repair. Similar to NHEJ, the ATM-DSB repair signaling pathway
is activated, phosphorylating H2AX to become gH2AX. MDC1 is recruited to scaffold
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gH2AX, prompting ubiquitin signaling from RNF8 and RNF168. For the promotion of HR,
the BRCA1/RAP80/Abraxas complex is recruited to sites of DSBs. HR begins with end
resection by the MRN complex in a CtIP-dependent manner, in which single-stranded
overhangs are created at the 3¢ ends of DSBs 152. Replication protein A (RPA) coats the
single-stranded overhangs 151,153. The BRCA1-PALB2-BRCA2 complex is responsible for
strand invasion in HR, which is then followed by filament formation and strand exchange
with the help of RAD51 20,25. After strand invasion, a displacement loop (D-loop) is
formed as the sister chromatid is displaced 21. This D-loop anneals to the 3¢-end of the
overhang and is used for the 5¢-end DSB template 21. From this step, the Holliday
junction is made, composed of four DNA strands, and DNA synthesis and resolution
ensues 154.
BRCA1 is one of the most notable BRCT domain-containing proteins that plays
an influential role in the promotion of HR. While it is known that the presence of CtIP at
the site of the MRN complex induces its nuclease activity, BRCA1 is the scaffolding
protein that stabilizes this complex and ensures proper DNA end resection for HR that
occurs during late S phase 47. DNA end resection is made possible by the inhibition of
RIF1 recruitment to DSBs by BRCA1 and CtIP 151. Also, BRCA1 shifts 53BP1 away from
DSBs, further repressing NHEJ 135,151. BRCA1 is the primary recruiter for its own
complex with PALB2, BRCA2, and RAD51. Loss of BRCA1 diminishes foci formation for
PALB2, BRCA2, and RAD51 155. PALB2 is required for BRCA2 and RAD51 foci, but not
BRCA1 foci 155. Loss of BRCA2 only affects RAD51 foci, not BRCA1 or PALB2 155.
Without BRCA1, the process of HR repair cannot fully function; therefore, BRCA1 is an
important mediator of error-free HR, ensuring proper DNA repair and genomic integrity.
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Summary
BRCT domains are important domains that contribute to DNA repair signaling
pathways and genomic stability. BRCT domains use their scaffolding abilities to interact
with other signaling molecules—including other BRCT domains—to help recruit proteins
to aid in repairing DNA damage. While BRCT domains are commonly referred to as
phosphopeptide-binding modules, these modular domains are special in that they are
organized as singletons, tandems, triplets, or quartets. These characteristics allow for
additional specificity in binding capability. BRCT domains can interact in a
phosphorylation-independent manner, interacting with other BRCT domains and ends of
DNA structures.
BRCA1 is the most well-characterized BRCT domain-containing protein in the
human proteome. Mutations in the BRCA1 gene have been largely associated with
hereditary cases of breast and ovarian cancers. These mutations in BRCA1 alter
important cellular processes that BRCA1 regulates, including cell cycle checkpoint
regulation, transcription coactivation, E3 ubiquitin ligase activity, and promotion of errorfree HR. While these mutations are prevalent, there are other signaling pathways that
could be affected due to the loss of functionality in BRCA1. Our work in characterizing a
novel interaction with BRCA1 and components of mTOR complex 2 (mTORC2) identifies
another mechanism in which BRCA1 acts as a tumor suppressor. BRCA1 regulates the
activation of Akt through the kinase activity of mTORC2. Loss of BRCA1 function
disrupts this check on cancer cell survival. Targeting the mTOR pathway, which is
known for growth, proliferation, and survival, could become an effective therapeutic
strategy for cancer patients with BRCA1 loss-of-function mutations.
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CHAPTER 2: FUNCTIONAL IMPACTS OF THE BRCA1-MTORC2 INTERACTION IN
BREAST CANCER
Abstract
Deleterious mutations in BRCA1 are associated with an increased risk of breast and
ovarian cancer. In particular, mutations in the tandem BRCA1 C-terminal (tBRCT)
protein domain disrupt critical protein interactions required for the faithful repair of DNA
through homologous recombination. The impaired DNA damage response (DDR) in cells
lacking functional BRCA1 contributes to oncogenesis. Our studies evaluated the full
protein interactome of the BRCA1 tBRCT domain, which has identified RICTOR, PRR5,
and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as
interacting partners, and BRCA1 expression can disrupt the mTORC2 complex.
However, the interplay between mTORC2 signaling and BRCA1 function in the DDR
remains to be determined. Yeast two-hybrid and co-immunoprecipitation experiments
were conducted to explore the specificity of BRCA1 tBRCT domain interactions with the
three accessory proteins of the mTORC2 complex – PRR5, RICTOR, and SIN1. The
BRCA1 transcriptional activation assay was conducted to evaluate the impact of mTOR
inhibitors on BRCA1 function. The impact of mTOR inhibition on BRCA1 foci, gH2AX
foci, and BRCA1 co-localization with gH2AX was evaluated with immunofluorescence.
Breast cancer sensitivity to mTOR inhibition in the presence or absence of functional
BRCA1 was evaluated with cell viability assays. PRR5, RICTOR, and SIN1 were all
found to interact with BRCA1 tBRCT in both yeast two-hybrid and coimmunoprecipitation experiments. Inhibition of mTORC1 with rapamycin, but not
mTORC1 and mTORC2 inhibition with PP242, increases BRCA1 transcriptional
activation activity. Treatment with pan-mTOR inhibitor PP242 diminishes gH2AX-BRCA1
foci formation. BRCA1 knockdown in MCF-7 and MDA-MB-231 cells sensitizes breast
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cancer cells to mTOR inhibitors PP242 and PKI-179. HCC1937 cells, lacking functional
BRCA1, are also more sensitive to mTOR inhibitors than HCC1937 with restored
BRCA1 expression. These data suggest that mTOR signaling is required for BRCA1
response to DNA damage and breast cancer cells lacking BRCA1 are more sensitive to
pan-mTOR inhibition. Understanding the functional impacts of the mTORC2-BRCA1
interaction is important to delineate the relationship between the DDR and survival
signaling.
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Introduction
mTOR/Akt Signaling
The mTOR/Akt signaling pathway regulates the cell’s ability to grow, proliferate,
and survive. There are two major complexes that are found in this pathway: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC2, composed of
mTOR, mLST8, RICTOR, SIN1, and PRR5, is upstream of the Akt kinase 156. mTORC1,
composed of mTOR, mLST8, and RAPTOR, is downstream of the Akt kinase. mTORC2
phosphorylates Akt at Serine 473, which activates Akt. Akt phosphorylation at Threonine
308 by PDK1 is also required for its activity 157. Akt is then able to indirectly activate
mTORC1 via phosphorylation by inhibiting upstream TSC2 158. Once mTORC1 is active,
it can phosphorylate many of its substrates, including p70 S6K, which promotes mRNA
translation 159. RAPTOR and RICTOR are important scaffolding proteins that regulate
the formation and localization of mTORC1 and mTORC2 respectively 158. The mTORC1
complex regulates many cellular processes, such as autophagy, transcription,
translation, ribosome biogenesis, and nutrient transport 156. The mTORC2 complex is
important for the polarization of the actin cytoskeleton, which is cell cycle-dependent
156,158

. Mechanisms of mTORC1 activation are well-established; however, mechanisms

of mTORC2 activation have yet to be defined. While extracellular growth factor signaling
has been implicated, there has not been a direct target identified that activates mTORC2
or induces RICTOR interaction with the mTOR kinase 160.
Targeting mTOR
There are many mTOR inhibitors that have been developed over the past 30
years. Rapamycin was the first compound extracted to inhibit mTOR. From rapamycin,
scientists have developed a group of allosteric, irreversible analog drugs called rapalogs,
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including temsirolimus and ridaforolimus 158. Rapamycin, as well as rapalogs, inhibits the
FATC domain of mTOR kinase. While they inhibit mTOR, they are only effective for
inhibition of mTORC1—not mTORC2. Rapamycin inhibits mTORC1 activity but activates
mTORC2 activity through the inaction of RICTOR inhibition 158. To date, there is no
mTORC2 specific inhibitor. There have been numerous efforts to target mTORC2 by
interfering with formation of the complex, but they have not been successful. Therefore,
the use of ATP-competitive mTOR inhibitors that target both mTORC1 and mTORC2
have been widely used in basic science and preclinical models and have been used in
Phase I/II clinical trials for multiple myeloma, lymphomas, and many advanced solid
tumor cancers, such as glioma and hepatocellular carcinoma, in recent years 161.
Akt and the DNA Damage Response
In recent years, Akt has been implicated as a critical mediator for the DDR. Akt
signaling has been found to participate in upstream events prior to BRCA1’s role in the
DDR. Hinton et al. concluded that Akt phosphorylation of BRCA1 at Threonine-509
within its nuclear localization signal led to the heregulin b1-mediated accumulation of
BRCA1 in the nucleus 162. However, there is not enough evidence to show that this
specific phosphorylation site is necessary for this effect 157.
There have also been conflicting reports of Akt and the regulation of HR.
Recently published works include evidence of Akt positively regulating HR repair. Mueck
et al. found that Akt simulates HR through RAD51 163. Akt knockdown prevented RAD51
foci formation and its co-localization with gH2AX. A similar result was found in
Udayakumar et al. in which they found that pan-mTOR inhibitor Torin2 suppressed
RAD51 foci formation 164. However, there are many studies that show that Akt
diminishes DSB repair 157. Plo et al. reported that Akt inhibited BRCA1 foci formation by
blocking its nuclear localization, reducing HR in breast cancer cell lines MCF-7 and
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MDA-MB-231 165. Tonic et al. also have observed Akt activation negatively regulating
BRCA1 localization to DNA damage foci 166. Jia et al. found that Akt induction observed
in Brca1-deficient mouse fibroblasts promoted chromosomal instability 167.
Akt has also been implicated in the promotion of the NHEJ pathway. Golding et
al. have found that Akt inhibitor SH-5 treatment significantly reduced the amount of cells
utilizing NHEJ 168. Toulany et al. reported that targeting Akt inhibits double strand break
repair that is DNA-PKcs-dependent 169. Results from these studies may be in parallel to
the suggested evidence that Akt negatively regulates HR to promote NHEJ. More
studies must be conducted in order to arrive at a more conclusive theory.
BRCA1 and its Regulation of Akt
BRCA1 has many different functions in the cell, including recruitment of DDR
proteins for HR and transcription coactivation 170. The BRCA1 C-Terminal (BRCT)
Domain, which was first discovered in BRCA1, is largely responsible for many of
BRCA1’s DNA damage-related functions. There have been two published works to date
that have demonstrated BRCA1-mediated negative regulation of Akt 72,171.
Xiang et al. observed that BRCA1 interacts only with phosphorylated Akt, not
unphosphorylated Akt 171. BRCA1 regulates phospho-Akt in an PTEN-independent
manner. An intact BRCA1 BRCT domain is important for the interaction with Akt as well
as its E3 ubiquitin ligase activity. BRCA1 ubiquitinates phospho-Akt, which leads to its
degradation via the proteasomal pathway. This work shows a direct regulation of Akt by
BRCA1; however, there is another mechanism that suggests BRCA1 regulates the
upstream activation of Akt through inhibition of mTORC2 signaling.
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BRCA1 and the mTORC2 Complex
According to TAP-MS data published from Woods et al., three members of the
mTORC2 complex were found to have interactions with the BRCT domain of BRCA1—
PRR5, RICTOR, and SIN1 (Figure 2.1) 72. The mTORC2 complex is known to activate
Akt by phosphorylating the Serine-473 site on Akt, priming it for downstream kinase
activity on other substrates. The BRCA1 BRCT domain was found to prevent Serine-473
phosphorylation by dissociating the members of the mTORC2 complex from the mTOR
kinase. The mTORC2 complex is involved in many other processes of the cell, such as
growth, proliferation, survival, cytoskeletal organization, apoptosis, metabolism, and
stress response. From our observations, we believe that BRCA1 recruits members of the
mTORC2 complex in order to carry out its own function in the DDR, especially in cancer.
The PI3K/AKT/mTOR pathway is hyperactivated in more than 70% of breast
tumors 172, but therapeutic targeting can produce unexpected results due to the complex
nature of its regulation. Therefore, biomarkers are required to reliably target this pathway
in cancer patients. Given the role of BRCA1 in regulation of mTORC2, the mutation and
expression status of BRCA1 may provide such as a biomarker. In addition, mTORC1
signaling inhibition by rapamycin suppresses double-strand break repair 173, targets of
mTOR show decreased phosphorylation upon inhibition of ATM 174, and mTORC2
protects yeast from replication associated DNA damage 175. These findings clearly
implicate mTORC1/2 in the DDR network, yet the exact mechanisms remain poorly
defined.
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Figure 2.1: BRCA1 interacts with members of the mTORC2 complex.
The mTORC2 complex is a kinase that phosphorylates Akt at Serine 473 for its
activation. The BRCA1 BRCT domain has been found to interact with members of the
mTORC2 complex (PRR5, RICTOR, and SIN1). BRCA1 associates with these members
to dissociate them from the mTOR kinase, thus impairing Akt activation. Mutations of
BRCA1 BRCT domain impairs BRCA1 function and disrupts these interactions. This
check is lost, and the mTORC2 complex activates Akt.
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Results
The BRCA1 tBRCT Domain Directly Interacts with each RICTOR, PRR5, and SIN1
mTORC2 Complex Subunits
The experiments performed in this study were designed to identify the mTORC2
subunit(s) that directly interact with the BRCA1 BRCT domain. The Yeast Two-Hybrid
(Y2H) system can identify binary interactions between two proteins. To decipher the
binary protein interactions, we implemented the ProQuest Two-Hybrid system
(Invitrogen). The BRCA1 tBRCT domain baits used in this assay included wild type (WT)
or the negative control M1775R mutant that disrupts the phospho-peptide binding. These
tBRCT bait constructs were cloned into the pDEST32 vector to generate GAL4 DNA
binding domain (GAL4-DBD) fusions (Figure 2.2). The bait proteins (PRR5, SIN1, and
RICTOR) were cloned into the pDEST22 vector to generate GAL4 activation domain
(GAL4-AD) fusions (Figure 2.2). The survival and growth of the yeast colony on
selective media (-Leu, -Trp, -His) are dictated by intermolecular interactions that induce
gene expression. In these Y2H experiments, there were twelve different gene
expression combinations tested (Figure 2.2). The yeast strain MaV203 used in this
study allows the interrogation of 3 selection markers, of which we focused on HIS3,
which is optimal for relatively weak interactions, commonly found for BRCT domain
interactions. Liquid cultures were serially diluted ten-fold to test limiting numbers of cells
in the samples and plated with increasing amounts of HIS3 inhibitor 3-amino-1,2,4triazole (3AT) (Figure 2.3). With increasing amounts of 3AT up to 100 mM, the
interactions between BRCA1 WT, PRR5, RICTOR, and SIN1 constructs remained
visible in the yeast cultures. These results suggest that the BRCA1 interaction with
mTORC2 proteins is dependent on a functional tBRCT domain.
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Figure 2.2: Schematic of yeast two-hybrid experiment with the BRCA1 BRCT
domain and the three accessory mTORC2 proteins.
(Top panel) Representation of the N-terminus GAL4-DBD and GAL4-AD protein fusion
constructs (cloned in Gateway cloning vectors pDEST32 and pDEST22, respectively)
used for the yeast two-hybrid experiment. pDEST32 constructs have a tryptophan
selection marker, and pDEST22 constructs have a leucine selection marker. Competent
MaV203 yeast cells were co-transformed with the indicated gene pairs using the
subcloning scale protocol. (Bottom panel) Experimental plate schematic of the Y2H
interaction study displaying empty vector, BRCA1 WT, and BRCA1 mutant M1775R.
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Figure 2.3: The interaction with BRCA1 and the mTORC2 proteins is only
maintained with a functional BRCT domain.
(Top panel) Plates of yeast co-transfected with pDEST22 constructs of members of the
mTORC2 complex (PRR5, SIN1, and RICTOR) and pDEST32 constructs (empty vector,
BRCA1 WT, and BRCA1-M1775R). Each master colony was grown in selective -his, leu, and -trp liquid medium to saturation with increasing concentrations of 3-amino-1,2,4triazole (3AT). (Bottom panel) Dilution scale for yeast cultures.
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To confirm these interactions in a mammalian model, TAP-tagged BRCA1 tBRCT
and Myc-tagged RICTOR, PRR5 and SIN1 constructs were co-transfected into human
embryonic kidney 293FT cells and their expression was confirmed by immunoblotting
(Figure 2.4). Immunoprecipitation was performed using α-MYC antibody. The
immunoprecipitation shows that each RICTOR, PRR5, and SIN1 construct was able to
pull-down the TAP-tagged BRCA1 tBRCT domain. However, CBP blots developed at a
shorter exposure time indicate that the interaction between the BRCA1-BRCT domain
and Rictor may be slightly stronger than the interactions between PRR5 and SIN1
(Figure 2.4). Together, these results suggest that RICTOR, PRR5, and SIN1 each
interact with the BRCA1 tBRCT domain and that the interactions can occur independent
of the other mTORC2 subunits.
Rapamycin Increases BRCA1 Transcriptional Activation Activity
BRCA1 is a transcriptional coactivator and is responsible for the transcription of a
number of genes, including IFNg response genes, NF-kB target genes, p21WAF1/Cip1,
p27Kip1, and Gadd45a 176. In addition, BRCA1 has also been found to repress ERa gene
expression, which has been a point of focus for hormone-related cancers, such as
breast cancer 176. The tBRCT domain of BRCA1 is the mediator for the transcriptional
activation activity of BRCA1 and this functionality can be used to classify variants of
unknown significance 27,89. The impact of rapamycin on mTORC1 inhibition and PP242
on mTORC1 & mTORC2 inhibition was confirmed by western blot (Figure 2.5). The
inhibition of the mTORC1 and mTORC2 pathways was measured by p70 S6K
phosphorylation and Akt phosphorylation at Ser473, respectively (Figure 2.5).
We utilized the established BRCA1 tBRCT transcriptional activation assay based
on the BRCA1 (aa 1315-1863) N-terminal fusion with GAL4-DBD, which recruits the
construct to the Gal4-upstream activation signal that promotes transcription of the
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Figure 2.4: The BRCT domain of BRCA1 interacts with PRR5, RICTOR, and SIN1.
(Top panel) Schematic of constructs used for co-immunoprecipation experiment.
(Bottom left panel) Western blot displaying whole cell lysates of CBP-BRCA1 and mycPRR5, -SIN1, and -RICTOR constructs co-overexpressed in 293FT cells. (Bottom right
panel) Co-immunoprecipitation of CBP-tagged BRCA1 and myc-tagged PRR5, RICTOR,
and SIN1.
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Figure 2.5: Effects of mTORC1 and mTORC2 activation upon mTOR inhibition.
Human embryonic kidney 293FT cells were used for the BRCA1 transcriptional
activation assay and treated with DMSO control, rapamycin, or PP242 prior to luciferase
detection. Rapamycin is an mTORC1 inhibitor, while PP242 is a pan-mTOR inhibitor.
Western blotting was used to detect activating phosphorylations for downstream
effectors of mTORC1 and mTORC2. The mTORC2 complex phosphorylates Akt at
Serine 473. The mTORC1 complex phosphorylates p70 S6K kinase.
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luciferase gene when functional BRCA1 tBRCT is present (Figure 2.6) 27. Following
transfection of the BRCA1 BRCT domain, cells were treated with either rapamycin
(mTORC1 inhibitor), PP242 (pan-mTORC1/2 inhibitor), or DMSO control. Luciferase
reporter activity was plotted onto a bar graph in a ratio of Firefly to control Renilla
luciferase for each of the three experiments (Figure 2.7). Rapamycin treatment
significantly increased BRCA1 transcriptional activation activity compared to DMSO
control. Treatment with pan-mTOR inhibitor PP242 did not affect BRCA1 transcriptional
activation activity compared with DMSO control. These results suggest that inhibition of
mTORC1 with rapamycin treatment increases BRCA1 transcription activation, but this
effect is abrogated when both mTORC1 and mTORC2 are both inhibited with PP242.
mTORC2 Activity Prevents Cisplatin-Induced Cell Death in MCF-10A Cells
PP242 was the preferred mTOR inhibitor for this study because of its marked
specificity to the mTOR kinase as opposed to other second-generation mTOR inhibitors
that have off-target effects on other PIKK family kinases, such as ATM, ATR, and DNAPK 164. To determine the concentration of PP242 that effectively inhibits Akt
phosphorylation at Ser473, a dose-escalation experiment was conducted on MCF-10A
cells (Figure 2.8). Akt Ser473 phosphorylation was found to be reduced at 1 µM PP242
in MCF-10A cells (Figure 2.8). In addition, we chose to use the DNA damaging agent
cisplatin to explore mTORC2 effects in response to DNA damage because it is known to
preferentially induce cancer cell death when functional BRCA1 is absent 177. A doseescalation of cisplatin was used to determine that a 25 µM concentration was required to
generate a DDR indicated by the appearance of phosphorylated H2AX (gH2AX) (Figure
2.9). We also observed that MCF-10A cells exhibit a dose-dependent decrease of Akt
Ser473 phosphorylation up to 25 µM cisplatin and a nearly complete loss of Akt and p70
S6K expression at 50 µM cisplatin where the DDR
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Figure 2.6: Schematic of BRCA1 Transcriptional Activation Assay
The BRCA1 transcriptional activation assays were performed using a TA luciferase
reporter assay as previously described 27. The BRCA1 construct utilized in this assay
spanned from amino acids 1315-1863 of the protein. The BRCA1 BRCT domain is fused
with a GAL4 DNA binding domain (DBD). This DBD domain localizes to the GAL4
upstream activation signal (UAS), which is upstream of the promoter. BRCA1 constructs
were co-transfected in 293FT cells with the pG5Luc plasmid, encoding a Firefly
luciferase reporter gene driven by GAL4 binding sites and the adenovirus major late
promoter, and the phGR-TK plasmid, which constitutively expresses the internal control
Renilla luciferase. When this localization occurs, the luciferase gene is then able to
become transcribed. Cells were either treated with 10 nM rapamycin, 1 µM PP242, or
DMSO control 24 h after transfection. Transcriptional activity was assayed with the DualLuciferase Reporter Assay System (Promega) 24 hours after treatment. The cells emit
luciferase signal, which can be detected with a plate reader. Each experiment measuring
transcription activity was calculated by using a ratio of Firefly luciferase units to Renilla
luciferase units. The average of three ratios from three experiments (n = 3) was
quantified and plotted onto bar graphs. Student’s t-test was used to measure statistical
significance.
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Figure 2.7: mTOR inhibition and its effects on BRCA1 transcriptional coactivation.
Human embryonic kidney 293FT cells were used for the BRCA1 transcriptional
activation assay and treated with DMSO control, rapamycin, or PP242 prior to luciferase
detection. To determine the ratio of luciferase units (RLU), the averaged Firefly
luciferase units were divided by the averaged Renilla luciferase units. The ratios were
compared across samples. Statistical significance was calculated by using Student’s ttest.
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Figure 2.8: Dose escalation of PP242 treatment in MCF-10A cells.
Human non-transformed, immortalized breast MCF-10A cells were treated with
increasing doses of PP242 over 24 hours. To determine inhibition of both mTORC1 and
mTORC2 function, phosphorylated and total levels of Akt and p70 S6K were detected
using western blot.
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Figure 2.9: Dose escalation of cisplatin treatment in MCF-10A cells.
Human non-transformed, immortalized breast MCF-10A cells were treated with
increasing doses of cisplatin over 24 hours. To determine levels of both activated
mTORC1 and mTORC2, phosphorylated and total levels of Akt and p70 S6K were
detected using western blot. A panel displaying g-H2AX levels were used as a positive
control for the activation of DNA damage signaling.
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was the highest according to gH2AX levels (Figure 2.9). To evaluate the impact of
mTORC1/2 signaling on cell death in response to cisplatin, we performed combination
treatments using 25 µM cisplatin and 1 µM PP242 and western blotting for cleaved
PARP, which is cleaved during the execution of apoptosis (Figure 2.10). MCF-10A cells
treated with both cisplatin and PP242 had little to no Akt phosphorylation and a
significant increase in PARP cleavage in comparison with cisplatin alone (Figure 2.10).
This suggests that mTORC1/2 signaling promotes resistance to cisplatin-induced cell
death.
Repression of mTOR Signaling Significantly Reduces gH2AX-BRCA1 Foci
Formation
It has been previously established that BRCA1 colocalizes with gH2AX to recruit
DDR proteins to repair DNA double strand breaks 178. To evaluate how the inhibition of
mTORC1/2 signaling may play a role in BRCA1 function and the DDR, nonmalignant
breast cell line MCF-10A was used to observe foci formation for both gH2AX and
BRCA1. MCF-10A cells were treated with control, cisplatin (a DNA damage-inducing
agent commonly used as chemotherapy for breast cancer), PP242, and cisplatin in
combination with PP242 (Figure 2.11). Foci formation of both BRCA1 and gH2AX were
analyzed as well as BRCA1 localization to gH2AX (Figures 2.12-2.14). As expected,
there was an induction of BRCA1 foci, gH2AX foci, and BRCA1-gH2AX co-localization in
response to treatment with cisplatin. However, there was a significant decrease in
BRCA1 foci, gH2AX foci, and BRCA1-gH2AX co-localization in response to PP242 or the
combination of cisplatin plus PP242 in comparison to the cisplatin-only treated cells.
These results suggest that mTORC1 and
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Figure 2.10: Combination treatment with cisplatin and PP242 in MCF-10A cells.
Human non-transformed, immortalized breast MCF-10A cells were treated with no
treatment control, cisplatin, PP242, or cisplatin + PP242 for 24 hours. To determine
inhibition of both mTORC1 and mTORC2 function, phosphorylated and total levels of Akt
and p70 S6K were detected using western blot. A panel displaying g-H2AX levels were
used as a positive control for the activation of DNA damage signaling. A panel displaying
cleaved PARP levels was used to determine relative amounts of cell death.
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Figure 2.11: Effects on BRCA1 foci, gH2AX foci, and BRCA1-gH2AX localization
upon cisplatin and PP242 treatment.
Human non-transformed, immortalized breast MCF-10A cells were treated with no
treatment control, cisplatin, PP242, or cisplatin + PP242 for 8 hours. Panels displayed
includes BRCA1 foci formation, gH2AX foci formation, and BRCA1 co-localizing to sites
of DNA damage with gH2AX.
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Figure 2.12: mTOR inhibition reduces levels of BRCA1 foci formation.
Human non-transformed, immortalized breast MCF-10A cells were treated with no
treatment control, cisplatin, PP242, or cisplatin + PP242 for 8 hours. Over 300 cells were
counted to determine the percentage of cells with BRCA1 foci across the samples.
Statistical significance was determined by using Student’s t-test.
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Figure 2.13: mTOR inhibition reduces levels of gH2AX foci formation.
Human non-transformed, immortalized breast MCF-10A cells were treated with no
treatment control, cisplatin, PP242, or cisplatin + PP242 for 8 hours. Over 300 cells were
counted to determine the percentage of cells with gH2AX foci across the samples.
Statistical significance was determined by using Student’s t-test.
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Figure 2.14: mTOR inhibition prevents BRCA1-g-H2AX co-localization.
Human non-transformed, immortalized breast MCF-10A cells were treated with no
treatment control, cisplatin, PP242, or cisplatin + PP242 for 8 hours. Over 300 cells were
counted to determine the percentage of cells with BRCA1 co-localizing with gH2AX
across the samples. Statistical significance was determined by using Student’s t-test.
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mTORC2 signaling is required for DNA damage-induced gH2AX and BRCA1 foci
formation.
BRCA1 Loss Sensitizes Breast Cancer Cells to mTOR Inhibition
We have previously established that impaired BRCA1 expression is associated
with the hyperactivation of Akt 72. Therefore, we sought to examine the therapeutic
effects of mTOR inhibition in relation to BRCA1 expression in breast cancer cell lines.
MCF-7 breast cancer cells with BRCA1 knockdown were more sensitive to pan-mTOR
inhibitor PP242 and pan-PI3K/pan-mTOR inhibitor PKI-179 than cells with the nontargeting scrambled control (Figure 2.15). Similar results were also observed in the
triple-negative breast cancer cell line MDA-MB-231 (Figure 2.16). To further validate our
findings, we used a genetic model comparing HCC1937, which naturally expresses nonfunctional, truncated BRCA1, and HCC1937(BRCA1+) cells with restored full-length
BRCA1 expression. We treated this isogenic cell line pair with PKI-179 and found that
HCC1937 cells were more sensitive to PKI-179 than the HCC1937(BRCA1+) (Figure
2.17). These data suggest that breast cancer cells that lack functional BRCA1 are more
sensitive to mTOR inhibition.
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Figure 2.15: BRCA1 knockdown sensitizes MCF-7 cells to mTOR inhibitors.
(Left panel) Western blot displaying confirmation of BRCA1 knockdown in MCF-7 cells.
(Top right panel) Sigmoidal curve representing the percentage of survival from the cell
viability assay used to determine the half maximal effective concentration (EC50) of
PP242 in MCF-7 cells (n = 3 independent experiments). (Bottom right panel) Sigmoidal
curve representing the percentage of survival from the cell viability assay used to
determine the half maximal effective concentration (EC50) of PKI-179 in MCF-7 cells (n =
3 independent experiments). Statistical significance was determined using Student’s ttest.
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Figure 2.16: BRCA1 knockdown sensitizes MDA-MB-231 cells to mTOR inhibitors.
(Left panel) Western blot displaying confirmation of BRCA1 knockdown in MDA-MB-231
cells. (Top right panel) Sigmoidal curve representing the percentage of survival from the
cell viability assay used to determine the half maximal effective concentration (EC50) of
PP242 in MDA-MB-231 cells (n = 3 independent experiments). (Bottom right panel)
Sigmoidal curve representing the percentage of survival from the cell viability assay
used to determine the half maximal effective concentration (EC50) of PKI-179 in MDAMB-231 cells (n = 3 independent experiments). Statistical significance was determined
using Student’s t-test.
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Figure 2.17: HCC1937 breast cancer cells, which lack full-length, functional
BRCA1, are more sensitive to mTOR inhibition.
HCC1937 cells, which lack the BRCA1 BRCT domain, were used to test sensitivity of
mTOR inhibitors. (Left panel) HCC1937 cells with empty vector control and HCC1937
with restored BRCA1 were used in western blot to confirm the status of BRCA1
expression as well as Akt activation. (Right panel) HCC1937 cells with and without fulllength BRCA1 were subjected to treatment with PKI-179, a pan-PI3K, pan-mTOR
inhibitor. The maximum effective concentration (EC50) was determined for each sample.
Statistical significance was determined using Student’s t-test.
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Discussion
The regulation of mTORC2 signaling by BRCA1 is important to understand the
underlying molecular mechanisms that increase breast and ovarian cancer susceptibility
caused by BRCA1 mutation or epigenetic silencing. The ability of BRCA1 tBRCT domain
to disrupt the mTORC2 complex is a direct indication of the crosstalk between the DDR
and the mTORC2-Akt pro-survival signaling. The results here confirm that the BRCA1
tBRCT domain interacts with mTORC2 complex subunits RICTOR, PRR5, and SIN1
individually, although the affinity of the RICTOR interaction may be slightly higher than
PRR5 or SIN1. If the tBRCT domain can interact with RICTOR, PRR5 and SIN1
simultaneously, this would suggest a large interaction area on the tBRCT domain is
being occupied. Additional research is required to identify the specific interaction surface
that could exist between these proteins.
We previously observed that the interaction between BRCA1 tBRCT and
RICTOR was phosphorylation independent and was not disrupted by phosphatase
treatment 72. Both the Y2H and co-IP experiments in this study were performed without
the exogenous induction of DNA damage, but interactions with the mTORC2 subunits
were still observed. While normal replicative stress can produce low levels of DDR
pathway activation, it is probable that these interactions are independent of
phosphorylation status. It is important to note that while tBRCT domains were initially
characterized as phospho-peptide binding motifs, the majority of BRCA1 tBRCT
interactions we discovered by Y2H were not disrupted by phosphatase treatment and
presumably phosphorylation-independent 72. Indeed, the phospho-peptide binding region
of tBRCT domains occupies only a small portion of the solvent accessible surface of this
modular domain 70. Thus, phosphorylation-independent tBRCT domain interactions
require additional characterization.
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The transcriptional activation activity of BRCA1 is central to its role in the DDR
and requires a functional tBRCT domain. We sought to investigate the possible role
mTORC1/2 signaling could play in BRCA1 transcriptional activation. At the concentration
and exposure times used in our rapamycin treatment experiments, rapamycin
specifically inhibited mTORC1 activity but not mTORC2. BRCA1 transcriptional
activation increased significantly upon rapamycin treatment but not when panmTORC1/2 PP242 inhibitor was used, indicating that mTORC1 negatively regulates
BRCA1 transcriptional activation only when mTORC2 is active. The activity of mTORC2
is negatively regulated by mTORC1 in a negative feedback loop. It will be important to
determine the mechanisms associated with mTORC1/2 regulation of BRCA1
transcriptional activity and the impact on the DDR.
Our results show that there is depletion of BRCA1 foci upon inhibition of
mTORC1/2. Similar results have been published that reveal Akt signaling regulates the
localization and transcriptional activation of BRCA1 162. Impaired BRCA1 localization to
DNA damage-induced foci may be the result of impaired signaling that disrupts phosphopeptide binding of the tBRCT. Indeed, our results indicate PP242 treatment in
combination with cisplatin also inhibits gH2AX formation. This suggests a defect prior to
BRCA1 recruitment to DNA damage foci potentially affecting upstream kinase signaling,
such as ATM/ATR that specifically phosphorylate gH2AX. However, other mechanisms
may also impact BRCA1 localization, such as disruption in its nuclear localization.
In conclusion, the results of this study implicate mTORC2 signaling in the
regulation of BRCA1 functions in the DDR. Components of the mTORC2 complex have
been found to interact with the BRCA1 tBRCT domain. Rapamycin, which fails to inhibit
mTORC2 activity, increases BRCA1 transcriptional co-activation. We have also found
that mTORC2 activity protects cells from cell death induced by cisplatin treatment. Also,
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mTOR inhibition prevents gH2AX-BRCA1 co-localization, thus impairing proper DDR.
More importantly, sensitivity to mTOR inhibitors is dependent on BRCA1 status. The
information gained in this study could also be applied to a number of different cancers
because the BRCA1/mTORC2 interaction is broadly translatable. BRCA1 expression
regulates response to therapies, and both BRCA1 levels and mTORC2 activity are
variable in tumors. Incorporation of metrics such as status of BRCA1, RICTOR, and
activation of mTORC2 could guide patient selection for personalized therapies that may
significantly increase the survival of breast cancer patients.
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Materials and Methods
Cell culture and treatment
MCF-10A cells were cultured in DMEM/F12 medium (Invitrogen), containing 5% horse
serum (Invitrogen, No. 16050-122), 20 ng/mL EGF (Sigma), 0.5 μg/mL Hydrocortisone
(Sigma), 100 ng/mL Cholera toxin (Sigma), 10 μg/ml insulin (Sigma), and 1% penicillinstreptomycin (Invitrogen) at 37°C in 5% humidified CO2 incubators. MDA-MB-231 cells
were cultured in RPMI medium (Invitrogen), containing 10% FBS and 1% penicillinstreptomycin. MCF-7 and 293FT cells were cultured in DMEM medium (Invitrogen),
containing 10% FBS and 1% penicillin-streptomycin. HCC1937 cells with pcDNA3-empty
and pcDNA3-BRCA1 expression were a kind gift from the laboratory of Simon N. Powell.
Transfection of 293FT cells to generate lentiviral particles was performed using the
calcium phosphate method and the ViraPower system (Invitrogen). Target cells were
transduced with virus, and 48 hours later, selected on puromycin (1 μg/mL) for 5-7 days.
Plasmids, Primers, and shRNAs
Lentiviral shRNA constructs in pLK0.1 vectors targeting BRCA1, as well as nontargeting
scrambled control, were purchased from Open Biosystems. The Gateway cloning
system (Invitrogen) was used for the yeast two-hybrid screen. The amino acids 16501863 encompassing the two BRCA1 BRCT domains were used to clone constructs for
both the yeast-two hybrid and co-overexpression experiments. The BRCA1 tandem
BRCT domain baits (WT and M1775R) were cloned into the pDEST32 vector to
generate GAL4 DNA binding domain fusions. The bait proteins (PRR5, SIN1, and
RICTOR) were cloned into the pDEST22 vector to generate GAL4 activation domain
fusions. The Myc-tagged vectors for the co-overexpression experiments were purchased
from Origene.
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Yeast Two-Hybrid Screen
The Gateway-based ProQuest Two-Hybrid system (Invitrogen) was used to design and
develop the yeast-two hybrid screen. MaV203 yeast cells were used for transformation
of the corresponding GAL4 DNA binding domain and activation domain DNA constructs.
After transformation, the cells were plated on dropout minimal media lacking amino acids
leucine and tryptophan to select clones containing both the bait and prey vectors. Once
acceptable growth was shown on the double minus plates, two colonies were chosen
from each plate to serve as “master colonies” for the further selective media plates. Each
master colony was grown in selective -leu, -trp liquid medium to saturation. Prior to
plating, each liquid culture was serially diluted 10-fold in phosphate buffered saline to
test limiting numbers of cells in each singular sample. The yeast plates were also made
with increasing concentrations of 3-amino-1,2-triazole (3AT), an inhibitor of the HIS3
gene.
Transcriptional Assays
The BRCA1 transcriptional activation assays were performed using a TA luciferase
reporter assay as previously described 27. The BRCA1 construct utilized in this assay
spanned from amino acids 1315-1863 of the protein. BRCA1 constructs were cotransfected in 293FT cells with the pG5Luc plasmid, encoding a Luciferase reporter
gene driven by GAL4 binding sites, and the phGR-TK plasmid, which constitutively
expresses the internal control Renilla luciferase. Cells were either treated with 10 nM
rapamycin, 1 µM PP242, or DMSO control 24 hours after transfection. Transcriptional
activity was assayed with the Dual-Luciferase Reporter Assay System (Promega) 24
hours after treatment. Each experiment measuring transcription activity was calculated
by using a ratio of Firefly luciferase units to Renilla luciferase units. The average of three
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ratios from three experiments (n = 3) was quantified and plotted onto bar graphs.
Student’s t-test was used to measure statistical significance.
Immunofluorescence
Cells were grown on coverslips and treated with 25 μM cisplatin, 1 μM PP242, or 10 nM
rapamycin for 24 hours or control and fixed in 4% paraformaldehyde for 15 minutes.
Coverslips were washed in 0.5% Triton X-100/PBS for one minute. Coverslips were then
incubated with primary antibody in 3% BSA for one hour. After coverslips were washed
three times with PBS, anti-rabbit AlexaFluor-488 secondary antibody and anti-mouse
AlexaFluor-647 secondary antibody was added for one hour. Coverslips were finally
washed three times with PBS and mounted with DAPI counterstain mounting solution
onto microscope slides. Foci from ³ 300 cells were quantified and plotted onto bar
graphs. Student’s t-test was used to determine statistical significance.
Western Blotting and Antibodies
Whole cell lysates were prepared using NETN lysis buffer (10 mM HEPES pH 7.4, 10
mM KCl, 0.05% NP-40). The lysis buffer contained phosphatase inhibitors (50 mM NaF,
10 mM b-glycerophosphate, 0.1 mM NaVO4) and protease inhibitor cocktail (Sigma).
Samples were mixed 1:4 with 5X Laemmli buffer and incubated at 95°C for five minutes.
Approximately 50-150 μg of protein was prepared for loading. The membrane was
blocked in 5% non-fat milk and incubated with the primary antibody. BRCA1 (Ab-1)
(OP92-100UG) antibody was purchased from Calbiochem. CBP (07-482) and RICTOR
(05-1471) antibodies were purchased from Millipore. Phospho (Ser473)-AKT (#4691),
phospho (Thr412/Thr398)-p70S6K I and II (#9204), AKT (#4060), and total p-70S6K
(#9202) antibodies were purchased from Cell Signaling Technology. MYC (MA1-21316)
antibody was purchased from Thermo Scientific. HSC70 (sc-7298), b-actin (sc-47778),
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and α-tubulin (sc-53030) antibodies were purchased from Santa Cruz Biotechnology.
Gamma-H2AX (NB100-384) antibody was purchased from Novus Biologicals. Protein
expression was visualized with ECL (Thermo Scientific) or near-IR secondary antibodies
(LI-COR) on the Odyssey Fc Imaging System (LI-COR).
Cell Viability Assays
Approximately 10,000 cells were plated into each of the wells of a black 96-well plate.
Treatments were given 24 hours after plating. After 72 hours from plating, the Cell Titer
Glo Luminescence Cell Viability Assay (Promega) was used to determine the cell
viability of each of the experiments. The results of the plates were interpreted by using a
96-well plate reader. The averages of the intensity units were calculated and plotted onto
a graph corresponding to the concentration of drug given using GraphPad Prism. For the
EC50 studies, the averaged intensity units were normalized to percentages and plotted
onto a graph with the corresponding concentration of drug given using GraphPad Prism.
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CHAPTER 3: CTDP1 REGULATES BREAST CANCER SURVIVAL AND DNA REPAIR
THROUGH BRCT-SPECIFIC INTERACTIONS WITH FANCI
Abstract
BRCA1 C-terminal domains are found in a specialized group of 23 proteins that function
in the DNA damage response to protect genomic integrity. C-terminal domain
phosphatase 1 (CTDP1) is the only phosphatase with a BRCA1 C-terminal domain in the
human proteome, yet direct participation in the DNA damage response has not been
reported. Examination of the CTDP1 BRCA1 C-terminal domain-specific protein
interaction network revealed 103 high confidence interactions enriched in DNA damage
response proteins, including FANCA and FANCI that are central to the Fanconi anemia
DNA repair pathway necessary for the resolution of DNA interstrand crosslink damage.
CTDP1 expression promotes DNA damage-induced FANCA and FANCD2 foci formation
and enhances homologous recombination repair efficiency. CTDP1 was found to
regulate multiple aspects of FANCI activity, including chromatin localization, interaction
with γ-H2AX, and SQ motif phosphorylations. Knockdown of CTDP1 increases MCF-10A
sensitivity to DNA interstrand crosslinks and double-strand breaks, but not ultraviolet
radiation. In addition, CTDP1 knockdown impairs in vitro and in vivo growth of breast
cancer cell lines. These results elucidate the molecular functions of CTDP1 in Fanconi
anemia interstrand crosslink repair and identify this protein as a potential target for
breast cancer therapy.
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Introduction
Fanconi Anemia
Fanconi anemia (FA) is an autosomal recessive disease that is genetically
characterized by a biallelic mutation resulting in a loss-of-function for any of the 22 FA
genes 179. These genes code for proteins that are in the Fanconi anemia pathway, a
pathway critical for DNA interstrand crosslink repair. Fanconi anemia is typically
diagnosed in children and young adolescents 180. The most common molecular
characteristics of this disease include chromosomal aberrations, sensitivity to ICLinducing agents, and cell cycle defects 181. Fanconi anemia is phenotypically
characterized as a spectrum disorder with a wide array of physical characteristics. Some
of the classical, physical characteristics of these patients include café-au-lait spots,
hypogonadism, short stature, microcephaly, and loss of radial thumb 180. Fanconi anemia
patients have disease complications that include endocrinopathies, myelodysplastic
syndrome and bone marrow failure 181. Fanconi anemia patients are often later
diagnosed with various cancers, sometimes multiple cancers within an individual patient.
The most commonly diagnosed cancer among FA patients is acute myelogenous
leukemia. Other commonly diagnosed cancers are solid tumor cancers, including head &
neck cancer, anal & vulva cancers, esophageal cancer, and gastrointestinal cancers 182.
Because of the pleiotropic nature of the disease, initial diagnosis of FA is often
difficult; about 30% of patients do not exhibit congenital abnormalities 183. Thus, patients
are diagnosed after tests for bone marrow failure, response to DNA-damaging agents,
and chromosomal breakage analyses are conducted. Cellular hypersensitivity to ICLinducing agents is the main feature amongst FA patients that could help lead to a
diagnosis. Bona fide FA genes are classified after at least two patients with biallelic
mutation in the same gene are identified with bone marrow failure and chromosomal
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abnormalities 181. FA-associated genes are often classified in observed cases exhibiting
chromosomal abnormalities without bone marrow failure 181. Thus, the study of genomic
instability and sensitivity of ICLs observed in FA patients is critical to understanding the
molecular etiology of FA and ICL repair.
Interstrand Crosslinks and ICL-Inducing Agents
ICLs are covalently linked DNA crosslinks that are oriented across the double
strands of the DNA helix 184. ICLs can occur during replication and transcription—two
cellular processes that are necessary for cell viability and survival 185. These lesions in
DNA are extremely genotoxic and involve tightly regulated DNA repair processes
involving FA proteins to remove them 186. ICL repair must take place in order for the cell
cycle to progress and continue towards additional cellular growth and cell division. In the
event that the cell is unable to undergo correct removal of ICLs, the replication fork is
stalled, leading to replication fork collapse and cell death. Inherently improper ICL repair
can become problematic, increasing the likelihood for cancer incidence.
Sources of ICLs can be endogenous—generated within the cell—or
exogenous—introduced from an external source 185. Endogenous sources of ICLs can
arise from metabolism intermediates and products, such as reactive aldehydes and nitric
oxide 184. These products can be produced during ethanol metabolism and lipid oxidation
184

. Exogenous sources of ICLs can come from environmental exposure to sources of

cigarette smoke or exhaust fumes 184. Also, chemical compounds extracted from plants
and/or chemically modified could also be used to induce extreme amounts of DNA
damage to force cancer cells to undergo cell death.
ICL-inducing agents are commonly used as chemotherapeutic agents for cancer
patients. FA-impaired cells are hypersensitive to ICL-generating compounds, such as
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diepoxybutane (DEB), mitomycin c (MMC), melphalan, and cisplatin 187. It has been well
documented that cells from FA patients exhibit a wide variety of chromosomal
abnormalities as a result of treatment with ICL-inducing agents, including chromosomal
breaks, gaps, radial chromosomes, and telomeric fusions 187. FA patients are extremely
sensitive to these agents because of the defects in their ability to repair the ICLs via the
Fanconi anemia pathway 186.
Fanconi Anemia Pathway
Activation of the FA pathway occurs once a replication fork encounters an ICL,
either from endogenous or exogenous DNA damage induction (Figure 3.1). DNA
damage kinase ATR is activated by phosphorylation, which then begins a
phosphorylation cascade, including ATR phosphorylation of CHK1. ATR and CHK1 then
phosphorylate many members of the FA pathway, such as FANCA (S1449, by ATR),
FANCE (S346 and S374, by CHK1), FANCG (S7, by ATR), and FANCM (S1045, by
ATR), leading to the formation of the FA core complex and the activation of FANCI and
FANCD2 via phosphorylation by ATR at their SQ motifs and mono-ubiquitination at sites
Lysine-523 (K523) and Lysine-561 (K561), respectively 184. Once FANCI and FANCD2
have recruited the FA downstream effector proteins to aid in HR, FANCI and FANCD2
are de-ubiquitinated and the FA pathway is reset for additional repair of ICLs and the
restart of replication fork progression.
The FA pathway consists of three major complexes: the FA core complex, the
FANCI-FANCD2 (ID2) complex, and the FA downstream effector complexes.
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Figure 3.1: The Fanconi anemia pathway for ICL repair.
This figure is a simplified version of the Fanconi anemia pathway, which is responsible
for the repair of interstrand crosslinks (ICLs). The ATR-CHK1 signaling pathway
becomes activated upon DSBs and replication stress. Replication stress occurs when
DNA polymerases encounter an ICL. RPA coats single-stranded DNA to prevent
cleavage from endonucleases and recruit ATR and ATRIP for activation of the ATRCHK1 signaling pathway. Once ATR is activated, it phosphorylates CHK1. ATR and
CHK1 together phosphorylate components of the Fanconi anemia core complex. ATR
also phosphorylates both FANCI and FANCD2. The Fanconi anemia core complex, with
the help of E3 and E2 ubiquitin ligases FANCL and FANCT, respectively, monoubiquitinates the FANCI-FANCD2 (ID2) complex. The ID2 complex localizes to sites of
ICL damage to recruit Fanconi anemia downstream effector proteins. These downstream
effectors include nucleases (such as FANCP (SLX4), FANCQ (ERCC4), and FAN1),
helicases (FANCJ), and proteins that are involved in homologous recombination repair
(FANCN, FANCO, FANCR, FANCS, FANCD1, FANCU, FANCW). FANCV, however,
has been known to promote translesion synthesis (TLS). The role of FANCV, as it
relates to ICL repair, is still yet to be explored. Once the DNA strand is repaired, the
USP1-UAF1 complex deubiquitinates FANCI and FANCD2 to reset the pathway. It has
also been hypothesized that a phosphatase would also remove the activating
phosphorylations of FANCI and FANCD2 to also reset the FA pathway. CTDP1 is the
interacting phosphatase that was found to interact with FANCA, FANCD2, and FANCI. I
hypothesize that CTDP1 is the phosphatase that is necessary for proper reset of the FA
pathway.
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FA Core Complex
The FA core complex consists of FANCA, FANCB, FANCC, FANCE, FANCF,
FANCG (XRCC9), FANCL (PHF9), FANCM, FANCT (UBE2T), and FA-associated
proteins FAAP10 (MHF2), FAAP16 (MHF1), FAAP20, FAAP24, and FAAP100.
Formation of the FA core complex occurs during S phase of the cell cycle 188. The main
function of the FA core complex is to act as a ubiquitin protein ligase through FANCT
and FANCL to mono-ubiquitinate both FANCI and FANCD2, which is required for their
activation and repair of ICLs. Within the FA core complexes, there are subcomplexes
that carry out specific functions to aid in the recruitment of the entire FA core complex
and activation of the ID2 complex at sites of interstrand crosslinks (Figure 3.2).
FA Core Subcomplexes
There have been many publications that have annotated specific subcomplexes
within the FA core complex. Thomashevski et al. described fractionation methods in
which they extracted different molecular weight fractions, the largest bound to chromatin
after DNA damage 189. Waisfisz et al. found that FANCA and FANCG were in a complex
in FANCD2-, FANCE-mutant patient cell lines and non-FA cell lines and its expression
was reduced in other FA cell lines that were not of FANCA or FANCG 190. Medhurst et al.
found that FANCB interacts with FANCL and that FANCL and FANCA interact through
other FA proteins, yet functional FANCA was required for FANCL function 191. FANCF
was found to be an adaptor protein, suggesting roles of FANCF to connect and interact
with other FA core subcomplexes 192. Thus, the FA core subcomplexes are important to
study for their functions towards the overall goal to activate the ID2 complex for ICL
repair. The following subcomplexes make up the entire FA core complex:
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Figure 3.2: The FA core subcomplexes come together to act as a ubiquitin ligase
for ID2 complex function.
The ATR-CHK1 signaling pathway becomes activated upon DSBs and replication stress.
Replication stress occurs when DNA polymerases encounter an ICL. RPA coats singlestranded DNA to prevent cleavage from endonucleases and recruit ATR and ATRIP for
activation of the ATR-CK1 signaling pathway. Once ATR is activated, it phosphorylates
CHK1. ATR and CHK1 together phosphorylate components of the Fanconi anemia core
complex. The FA core complex is made up of subcomplexes that serve different
functions. The BL100 complex is important for the ubiquitin ligase function via FANCL.
The AG20 complex is critical for the recruitment and stability of FANCA, which is a
central component of the FA core complex. The FANCM-FAAP10-FAAP16-FAAP24
complex is critical for the surveillance of interstrand crosslinks. The CEF complex serves
as an adaptor for the core complex with ubiquitin ligase to localize to sites of ICL
damage.
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FANCA-FANCG-FAAP20 Complex
FANCA is the most important recruiting factor for the FA pathway. Its activation
via phosphorylation at Serine 1449 by ATR primes FANCA during ICL-induced damage
and is necessary for subsequent FANCD2 mono-ubiquitination 193. FANCG is also a
phosphoprotein in the FA core complex. FANCG is important for FANCA stability, and its
phosphorylation at Serine 7 is also critical for FA core complex function to monoubiquitinate FANCD2. FAAP20 is a FA-associated protein that is also important for the
stability of FANCA 194,195. While FAAP20 may not be a FA gene, its role in the FA core
complex is critical for its binding to double strand breaks. FAAP20 interacts with FANCA
at the N-terminus of the protein and interacts with poly-ubiquitinated chains generated by
RNF8 and UBC13 through its ubiquitin-binding ring finger (UBZ) domain 194,196. Together,
the FANCA-FANCG-FAAP20 (AG20) complex is a subcomplex that binds to chromatin
197

. While this subcomplex is important for chromatin binding, it has been found that it is

not required for mono-ubiquitination of FANCI and FANCD2 in vitro 198. This result is
conflicting, since loss of any of the components prevents FANCD2 mono-ubiquitination.
Also, the ubiquitin ligase FANCL, as well as FANCB, is mislocalized in the absence of
FANCA, which would further suggest that FANCA is critical for mono-ubiquitination to
occur 199,200. Therefore, the in vitro system to determine that result may have been
limited in scope. An in vivo model may address the underlying mechanisms for these
conflicting data.
FANCB-FANCL-FAAP100 Complex
The FANCB-FANCL-FAAP100 (BL100) complex is an important subcomplex that
houses the ubiquitin ligase FANCL. This complex is a dimer of dimers that is first formed
as a FANCB homodimer and a FAAP100 homodimer (Figure 3.2) 198. The dimer is
formed with the help of the FANCB homodimer, which binds to both FANCL and
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FAAP100 with each monomeric unit. The formation of this subcomplex is extremely
critical for the activation of the FANCI-FANCD2 complex via mono-ubiquitination of both
FANCI and FANCD2.
FANCC-FANCE-FANCF Complex
The FANCC-FANCE-FANCF (CEF) complex acts as an adaptor protein that
bridges the BL100 complex to FANCI and FANCD2 for mono-ubiquitination 198. Lack of
formation of the CEF complex, whether due to inherent mutation or genetic
manipulation, leads to deficient mono-ubiquitination of both FANCD2 and FANCI.
FANCF was found to have a chromatin binding role that is dependent on its interaction
with FANCM 197,201. This signifies the importance of the interactions between the
subcomplexes and their interdependent functions for ICL repair.
FANCM-FAAP24-FAAP16-FAAP10 Complex
The FANCM-FAAP24-FAAP16-FAAP10 complex is responsible for the detection
and interaction of the FA core complex with the interstrand crosslink. It has been
reported that FANCM and FAAP24 form a heterodimer, and with the help of FANCM,
acts as a translocase to localize the FA core complex to DNA replication fork and
Holliday Junction structures 202-204. FAAP16 (MHF1) and FAAP10 (MHF2) are histone
fold-containing proteins that interact as a heterodimer, like FANCM and FAAP24. This
heterodimer, together with FANCM and FAAP24, recognizes branched DNA structures.
This selective recognition is what guides the entire FA core complex to sites of ICL
damage. Without the role of FANCM translocase and FAAP24, as well as the MHF
proteins, the FA core complex will not be able to be localized to ICLs and the FANCIFANCD2 complex cannot be mono-ubiquitinated.
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FANCL-FANCT Complex
The FANCL-FANCT complex perform the most critical function of the FA core
complex. This particular complex acts as a ubiquitin-protein ligase that monoubiquitinates FANCI and FANCD2. FANCL is an E3 ubiquitin-protein ligase that uses its
RING domain to bind to the E2 ubiquitin-conjugating enzyme FANCT, also known as
UBE2T 205,206. FANCT is necessary for the mono-ubiquitination of FANCD2, but is
dispensable for FA core complex formation 205,206. Also, it was found that UBE2T is
constitutively bound to chromatin. This suggests that FANCT is somewhat independent
of the FA core complex upstream but is important to carry out the ubiquitin conjugation
step as FANCL arrives at the site of ICLs with the FA core complex.
FANCI-FANCD2 Complex
In the FA-BRCA pathway, the ID2 complex is activated by mono-ubiquitination
via the FA core complex and phosphorylation by the DNA damage kinase ATR (Figure
3.3) 207-209. Activation of the ID2 complex is responsible for the recruitment of
downstream proteins necessary for the removal and repair of ICL 210,211. Over 90% of FA
patients do not have the cellular ability to mono-ubiquitinate the ID2 complex due to their
mutations of various FA core complex genes, thus illustrating the importance of the ID2
complex and this critical post-translational modification step 212.
Post-translational modifications in the FA pathway play critical roles in the
concerted regulation of ICL repair and replication fork restart. During replication, RPA is
present on single-stranded DNA to protect it from cleavage by endonucleases and
prevent secondary structure formation 153,213,214. In the event that a DNA polymerase
encounters an ICL, RPA coats single-stranded DNA and triggers sensing from the DNA
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Figure 3.3: Post-translational modifications regulate the ID2 complex and
subsequent ICL repair.
In order for ICL repair to occur, both FANCI and FANCD2 must localize to sites of ICL
damage. ATR phosphorylates FANCI and FANCD2 at their respective SQ motifs after
the complex is localized. Serine 556 at FANCI is phosphorylated prior to monoubiquitination. Once the FA core complex mono-ubiquitinates FANCI and FANCD2,
Serine 559 and Serine 565 are also phosphorylated by ATR. In order for subsequent
rounds of repair and replication fork restart, the ID2 complex must be deubiquitinated by
the USP1-UAF1 complex and removed from the replication fork. Without USP1, the ID2
complex remains ubiquitinated and cannot be removed from the replication fork. This
sensitizes the cells to ICL damage, leading to replication fork collapse and limited cell
survival.
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damage kinase ATR and its partner ATRIP to localize and bind to sites of ICL damage
214,215

. ATR then phosphorylates its substrates at sites that resemble a Serine/Threonine-

Glutamine (S/TQ) motif 207. FANCI and FANCD2 localize to branched DNA structures
and are then activated by ATR 216.
There have been a number of efforts to determine the posttranslational
modifications of FANCI and FANCD2 that regulate their activation state. Consensus
sequence analysis of FANCI revealed that there is an S/TQ motif immediately
downstream of the K523 mono-ubiquitination site 207. Six phosphorylation sites (S556,
S559, S565, S596, S617, and S629) were hypothesized and tested to have a functional
role in FANCD2 mono-ubiquitination 207. Combinations of three or more phosphorylationdead mutants in a cluster, as well as mutations of all six sites together, reduce FANCD2
foci formation and mono-ubiquitination 207. This finding has been confirmed in other
published works, including the recent findings of FANCI phosphorylation being critical for
dormant origin firing, proper mono- and de-ubiquitination, and ICL repair 208,217. It has
been published that the ID2 complex must localize to ICLs prior to the monoubiquitination step 218. The Tower domain of FANCD2 is important for DNA binding as
well as mono-ubiquitination 218. Yuan et al. observed that FANCI interacts with FANCD2
and binds to branched DNA structures with its C-terminal domain, suggesting that the
ID2 complex has a preference for binding to replication fork structures 216.
Mono-ubiquitination of the ID2 complex is the nexus of the whole FA pathway for
ICL repair. This step is crucial for determining a patient’s ability to repair its DNA. Most
FA patients have biallelic mutations in FA genes that are upstream or include one of the
ID2 complex genes. While biallelic mutations in the downstream effector genes are also
detrimental, the overall integrity of the FA pathway is still measured by the cell’s ability to
mono-ubiquitinate FANCI and FANCD2. Without this step, there is no double strand
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break repair by HR because of the lack of recruitment capabilities exhibited by FANCI
and FANCD2.
While FANCI and FANCD2 work together to aid in ICL repair, they both have
independent functions outside of their complex 219. FANCI has been found to be critical
for the recruitment of the FA core complex independent of its functions with FANCD2 211.
Dephosphorylated, deubiquitinated, chromatin-unbound FANCI was instrumental for FA
core complex formation 211. This suggests that FANCI is upstream of its canonical
function and perhaps may be just as critical as FANCA for the activation of the pathway.
FANCI DNA binding activity—independent of FANCD2—has been shown to be required
for RAD51-DNA filament stabilization 220. Also, FANCI and FANCD2 show opposing
roles in the process of dormant origin firing during mild replication stress. FANCI is
important for dormant origin firing, but FANCD2 negatively regulates this process 208.
Also, FANCD2 plays a more critical role than FANCI in replication fork restart after
hydroxyurea (HU)-induced replication stress 219. FANCD2 regulates the assembly,
stability, and recruitment of BLM complex to chromatin independently of FANCI 221.
FA Downstream Effector Complexes
After the ID2 complex is fully activated, the FA downstream effector proteins
localize to the interstrand crosslinks and help to repair the double strand breaks using
HR repair. Incision of the ICL must occur prior to the repair of the DNA double strand.
Nucleases, such as FANCP (SLX4), FAN1, and FANCQ (XPF/ERCC4), cleave the
interstrand crosslink and allow for DNA damage repair proteins FANCJ (BRIP1/BACH1),
FANCR (RAD51), FANCS (BRCA1), FANCN (PALB2), FANCD1 (BRCA2) and FANCO
(RAD51C) to repair the double strand break using HR 222. FANCJ is a protein that was
the original interacting protein found with BRCA1 that functions as a helicase to unwind
the DNA 223. FANCR is a critical protein responsible for the strand invasion step that
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initiates the HR process 61. FANCN acts as a bridge between FANCD1 and FANCS 61.
Also, FANCN interacts with FANCO to help recruit it for recombination.
There have recently been three newly identified FA genes within the past few
years. FANCU (XRCC2), FANCV (REV7), and FANCW (RFWD3) were all identified to
have roles that are downstream of the ID2 complex and assist in DNA repair. FANCU is
known to promote RAD51 DNA binding, as it is a part of the RAD51 paralog complex
212,224

. FANCW is an E3 ligase that ubiquitinates RPA and RAD51, promoting the

continued progression of fork repair 224. While FANCU and FANCW have both been
implicated in important roles in HR, FANCV has been influential in its role for the
promotion of NHEJ and the regulation of the mitotic checkpoint 212. FANCV is a subunit
of the DNA polymerase Pol z, which is also involved in translesion synthesis 225. The role
in which FANCV contributes to the FA pathway at-large is still yet to be elucidated.
Reset of the FA Pathway
In order to have continued DNA replication after HR with the help of the FA
downstream effector proteins, the ID2 complex must be removed from the stalled
replication fork. Removal of ID2 from stalled replication forks is regulated by the
deubiquitinating enzyme USP1-UAF1 and is necessary following repair to allow for
replication restart 226. UAF1 is important for the selectivity of substrates that undergo
USP1 de-ubiquitination. The N-terminus of USP1 interacts with FANCD2 and facilitates
its function once the interaction is made 227. It is important to note that the interaction of
FANCI with FANCD2 is required for deubiquitination after its removal from the DNA
198,204,228

. Once both FANCD2 and FANCI are deubiquitinated, the two proteins can be

deactivated and allow for additional rounds of replication to follow. This tight regulation of
the ID2 complex is necessary for proper repair. Any deficiency in either UAF1 or USP1
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leads to the accumulation of mono-ubiquitinated ID2 complex and a failure of complete
repair and restoration of the replication fork 228.
It has been hypothesized that dephosphorylation, in addition to deubiquitination,
must occur in order to remove the ID2 complex from the replication fork. The
phosphatase(s) regulating ID2 activation status and chromatin localization state is
unknown, but the interactions we identified between FANCA and FANCI with CTDP1
strongly implicated this phosphatase in the regulation of these proteins in response to
ICL 1.
FA Proteins and Their Non-canonical Functions Outside of the FA Pathway
While the proteins of the FA pathway are critical for their role in ICL repair, these
proteins also have non-canonical functions outside of DNA repair and HR. FA is a
spectrum disease that inflicts many different complications, including endocrinopathies
and bone marrow failure. Research groups in the field of FA have investigated the roles
of FA proteins in these disease phenotypes. For example, our research group has
identified a role for FANCA and insulin secretion from pancreatic b islet cells 179. FANCA
has also been implicated in the promotion of single-strand annealing, another homologydirected repair pathway involving the annealing of complementary single strands after
DNA DSB resection 229-232.FANCC has been found to activate STAT1 during hemopoietic
growth factor signaling 233. FANCL has also been found to ubiquitinate b-catenin for its
nuclear functions 233,234. Many FA genes, including FANCA, FANCC, FANCD1, FANCD2,
FANCF, FANCL, and FANCS, have been found to be implicated in mitophagy, a process
that degrades the mitochondria by autophagy 235. These collective findings about noncanonical FA pathway functions can help us further understand the molecular
underpinnings of the disease complications associated with FA.
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CTDP1 and its Role in the FA Pathway
The cellular response to DNA damage is balanced by posttranslational
phosphorylation modifications regulated by specialized kinases and phosphatases. In
the human proteome, CTDP1 is the only phosphatase that also encodes a BRCT
domain 72, suggesting it could play a unique role by regulating the phosphorylationmediated signaling involved in the DDR. Several studies have suggested a functional
role for CTDP1 in the DDR without mechanistic detail. Knockout of CTDP1 (Fcp1) in
yeast increases sensitivity to DNA damaging agents methyl methanesulfonate (MMS)
and 4-nitroquinoline-1-oxide (4NQO) 236. CTDP1 knockout-induced sensitivity of yeast to
these DNA damaging agents did not affect DNA damage-induced serine-2
phosphorylation in the DNA-directed RNA polymerase II subunit RPB1 c-terminal
domain 236, suggesting that CTDP1 may could participate in the DDR in a transcriptionindependent manner.
In an effort to investigate CTDP1’s potential role in the DDR, Hu & Krieger et al.
have found that protein-protein interactions with the BRCT domain of CTDP1 include
proteins that are involved in DNA replication and repair pathways 1. One of the enriched
pathways identified in the analysis was the FA pathway. CTDP1 interacts with FA
proteins FANCA, FANCD2, and FANCI – all critical proteins for the execution of
localization and recruitment of necessary DNA repair factors for ICL repair. CTDP1 is
critical for proper localization of FANCI to sites of DNA damage with g-H2AX as well as
FANCD2 foci formation. CTDP1 expression promotes HR. CTDP1 knockdown also was
critical for sensitivity to ICL-inducing agents, particularly IR, MMC, melphalan, 5-FU, and
cisplatin—all of which are associated with DNA damage that is repaired by HR.
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Results
CTDP1 BRCT Domain Interactions Reveal Interactions with FA Proteins
The CTDP1 protein includes both a phosphatase domain (FCP1 homology) and
BRCT domain (Figure 3.4). We used a domain-centric approach to study the CTDP1
BRCT-dependent interactions (Figure 3.4). Human embryonic kidney 293FT cells were
used because they are highly transfectable with excellent protein production
characteristics 237. Enrichment of the CTDP1 BRCT domain and its interacting partners
was achieved through tandem affinity purification coupled to mass spectrometry (TAPMS) (Figure 3.4) 72. Affinity purifications were performed two hours following 20 Gy
ionizing radiation to induce DDR kinases that phosphorylate BRCT domain-interacting
motifs 238. In total, 1422 proteins were identified in the CTDP1 BRCT TAP-MS
experiments. High confidence CTDP1 BRCT interactors were distinguished from low
confidence and contaminating proteins using TAP-tagged green fluorescent protein
(pNTAP-GFP) interaction experiments (n = 6) along with data deposited in the
CRAPome (n = 282) as control dataset inputs into the Significance Analysis of
Interactome (SAINT) algorithm 239,240. The high confidence TAP interaction dataset for
CTDP1 contains 103 proteins identified with a Bayesian false discovery rate (BFDR) ≤
0.05 (Figure 3.5). These 103 CTDP1 BRCT interacting proteins were incorporated into a
Cytoscape 241 network and 49 known protein-protein interactions were imputed from
BisoGenet 242 (Figure 3.6). We were particularly interested in identifying CTDP1 BRCTdependent interactions with DDR-associated proteins because of the conserved role of
BRCT domains in this pathway 40,69,70,72. A total of 15 proteins representing more than
14% of this interaction network were identified with gene ontology (GO) associations for
DNA damage and DNA replication (Figure 3.6). Prominent DNA damage proteins
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Figure 3.4: Schematic of the CTDP1 BRCT domain protein-protein interaction
study.
(Top panel) Representation of CTDP1 and its modular domain organization. The BRCT
region cloned for TAP-MS experiments is indicated between amino acids 619-738.
(Bottom panel) Workflow diagram of the TAP-MS experiment.
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Figure 3.5: High confidence protein-protein interactions from the CTDP1 BRCT
interactome.
SAINT output for Bayesian False Discovery Rate (SAINT-BFDR) was used to create a
high confidence interaction list. Graph represents the fold change in protein
representation between CTDP1 BRCT purification and control and the number of
proteins at binned intervals of 0.05 SAINT-BFDR scores.
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Figure 3.6: Annotated CTDP1 BRCT domain interaction network.
TAP-MS experiments generate a comprehensive interaction network of 103 proteins
interacting with the CTDP1 BRCT domain. Red outlined nodes indicate proteins with GO
annotations for DNA damage (GO:0006281) and DNA replication (GO:0006260). Edge
color represents source of protein interactions (grey: TAP-MS, blue: BisoGenet).
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include ATM kinase, mismatch repair protein MSH3, and ICL repair proteins FANCA and
FANCI.
An enrichment analysis was performed on the 103 high confidence interactions
to evaluate guilt-by-association roles of the CTDP1 BRCT domain using ClueGO 243.
This analysis revealed mismatch repair, Fanconi anemia, and long-term potentiation
KEGG pathway enrichments (Figure 3.7). This analysis also identified a cluster of
biological processes gene ontology terms related to nuclear DNA replication
(GO:0033260) (Figure 3.7). This was confirmed using an orthogonal analysis pipeline of
BiNGO 244 and Enrichment Map 245, which identified two predominant clusters associated
with both DNA replication/nucleotide excision repair and DNA damage repair (Figure
3.8). These findings support the predicted function of the CTDP1 BRCT domain with
DNA repair processes.
FANCI and FANCA were plotted on an interaction specificity map using ProHitsviz 246, which reveals that both interactors are specific to the CTDP1 BRCT domain
compared to other BRCT domain interactomes (Figure 3.9). FANCI had the highest
representation of ICL repair associated protein spectra and percent protein coverage
(Figures 3.9), which provided the justification for further analysis of the impact of CTDP1
on the ICL repair pathway through FANCI. Co-immunoprecipitation confirmed the
protein-protein interaction between endogenous full-length CTDP1 and FANCI in 293FT
cells (Figure 3.10). The interaction between exogenously expressed CTDP1 and FANCI
was also examined in the presence and absence of ICL damage, but the interaction
remains unaltered in response to this stimulus (Figure 3.10). Co-overexpression of
CTDP1 with FANCI results in a decrease in full-length FANCI and the appearance of
distinct lower molecular weight products (Figure 3.10).
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Figure 3.7: Gene ontology biological processes and KEGG pathway enrichment
analysis identifies DNA damage repair pathways as enriched pathways amongst
CTDP1 BRCT domain interactions.
(Left panel) Gene ontology enrichment of biological processes determined by ClueGO of
the 103 CTDP1 interacting proteins identified by TAP-MS, excluding CTDP1 itself. The
most significant term for each cluster is presented in bold font and term P-value
corrected with Bonferroni step down is presented in parentheses. Threshold for
visualization was P-value ≤ 0.05 and represented inversely proportional to node size.
Exact p-values are displayed under most significant group node determined by twosided hypergeometric test corrected using Bonferroni step down method. (Right panel)
KEGG pathway enrichment determined by ClueGO of the 103 CTDP1 interacting
proteins identified by TAP-MS, excluding CTDP1 itself. The most significant term for
each cluster is presented in bold font and term p-value corrected with Bonferroni step
down is presented in parentheses. Threshold for visualization was P-value ≤ 0.05 and
represented inversely proportional to node size. Exact p-values are displayed under
most significant group node determined by two-sided hypergeometric test corrected
using Bonferroni step down method.
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Figure 3.8: Functional annotation of CTDP1 BRCT interacting proteins.
The results from BiNGO were used as input into the Enrichment Map application in
Cytoscape. Significant terms (P-value ≤ 0.05) were visualized and clusters of related
terms are shown as connected clusters of nodes.
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Figure 3.9: FANCI was found to be one of the most abundant and specific
interactors of the CTDP1 BRCT interactome.
(Left panel) Specificity of protein interactions with the CTDP1 BRCT domain in
comparison to 27 other BRCT domain interaction datasets. FANCI and FANCA passing
SAINT-BFDR cutoff of ≤0.05 are represented as red circles. (Right panel) Table detailing
central FA pathway proteins’ (FANCA, FANCI, and FANCD2) average spectrum
abundance (Ave. Spec.), peptide coverage of protein sequence (Percent Coverage), and
SAINT BFDR from TAP-MS.
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Figure 3.10: Confirmation of the CTDP1-FANCI interaction using
immunoprecipitation.
(Left panel) Analysis of CTDP1 and FANCI expression in the input and
immunoprecipation (IP) of control (IgG) or endogenous CTDP1 in complex with FANCI
from untreated 293FT cells. (Top right panel) Whole cell lysate (WCL) blot of GFPFANCI and CTDP1-DDK constructs co-overexpressed in 293FT cells with and without
0.1 μM MMC treated for 24 h. (Bottom right panel) IP of DDK-tagged CTDP1 coimmunoprecipitates GFP-tagged FANCI independent of MMC treatment.
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CTDP1 Regulates FANCI Chromatin Localization and S/TQ Motif Phosphorylations
FANCI phosphorylation at amino acid S556 in the S/TQ motif is a marker of early
FANCI activation prior to ubiquitination 217. Overexpression of wild-type CTDP1 in 293FT
cells promotes the robust phosphorylation of endogenous FANCI at S556 in both the
absence and presence of MMC treatment (Figure 3.11). The phosphorylation of the
S/TQ motif sites is dependent on activation of DNA damage kinases ATM and ATR, and
we observed an interaction between CTDP1 and ATM in the TAP-MS experiments
(Figure 3.6). Overexpression of CTDP1 produces an increase in the activating
phosphorylation of ATR at S428, but did not affect the ATM activation-associated
phosphorylation at S1981. The amount of phosphorylated S556 FANCI observed is
more in the untreated CTDP1-overexpressing cells where ATR activation is slightly lower
than in the treated empty vector (EV)-transfected cells (Figure 3.11). These results
suggest that the induction of FANCI S556 phosphorylation could be partially dependent
upon CTDP1-induced activation of ATR signaling, but other unknown mechanisms could
also be affecting these FANCI phosphorylations. We confirmed that the levels of CTDP1
expression are directly related to FANCI S556 phosphorylation using shRNA-mediated
knockdown of CTDP1 (Figure 3.12).
FANCI phosphorylation at both the S556 and S559 sites was elevated by the
overexpression of wild-type CTDP1, but not phosphatase-dead D302K mutant (Figure
3.13). Two CTDP1 mutations (R270Q and V705M) found in TCGA and classified as
“probably damaging” by Polyphen-2 were also evaluated. However, both mutations are
still catalytically active toward RPB1 and promote elevated phosphorylation of FANCI at
S556 comparable to wild-type CTDP1, but phosphorylation at S559 is elevated in
comparison to wild-type CTDP1 (Figure 3.13). The induction of FANCI S556
phosphorylation by CTDP1 overexpression was confirmed using the triple-negative
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Figure 3.11: Overexpression of CTDP1 induces phosphorylation of FANCI at S556.
FANCI SQ motif phosphorylation at S556 (pS556) and activation of ATM and ATR was
evaluated with the indicated antibodies in 293FT cells transfected with control empty
vector (EV) or CTDP1-DDK tagged constructs in the presence and absence of DNA
damage with 0.1 μM MMC for 16 h.
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Figure 3.12: CTDP1 knockdown reduces FANCI S556 phosphorylation.
FANCI SQ motif phosphorylation at S556 (pS556) upon CTDP1 knockdown and MMC
treatment.
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Figure 3.13: Overexpression of phosphatase-dead CTDP1 mutant D302K reduces
FANCI S556 phosphorylation while R270Q and V705 mutants induce FANCI S556
phosphorylation similar to wild-type.
Wild-type (WT), phosphatase-dead (D302K), and cancer mutants (R270Q & V705M)
constructs of CTDP1 were expressed in 293FT cells treated with MMC, and the impact
on SQ motif phosphorylation sites at S556 and S559 were evaluated by western blot
with the indicated antibodies.
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breast cancer cell line MDA-MB-231 (Figure 3.14) but was lower in signal intensity than
the experiments performed in 293FT cells.
HCT116 is a colon cancer cell line routinely employed to evaluate the
ubiquitination and chromatin localization of FANCI in the evaluation of the ICL repair
pathway 217,219,247,248. FANCI is ubiquitinated and localized to chromatin even in the
absence of exogenous ICL damage with melphalan when CTDP1 expression is knocked
down in HCT116 cells (Figure 3.15). Immunoprecipitation of FANCI in 293FT cells with
knocked down expression of CTDP1 leads to a decrease in the FANCI interaction with
the DNA damage foci marker γ-H2AX following treatment with cisplatin (Figure 3.16).
Immunoprecipitation of FANCI also reveals a banding pattern of FANCI indicative of
posttranslational modifications that are only observed with expression of CTDP1 (Figure
3.16). These results suggest CTDP1 affects multiple aspects of FANCI activation,
including phosphorylation, mono-ubiquitination, and recruitment to sites of DNA damage
necessary for ICL repair.
CTDP1 Promotes Homologous Recombination DNA Repair
Proteins that participate in the ICL repair pathway, including FANCA and BRCA2,
regulate HR repair efficiency that can be quantified using the DR-GFP assay (Figure
3.17) 229,249,250. The impact of CTDP1 protein expression on HR efficiency was evaluated
with the DR-GFP assay using established HeLa-DR and U2OS-DR cell models with
chromosomal integration of the DR-GFP reporter construct. DDK epitope-tagged wild
type CTDP1 (CTDP1-DDK) was overexpressed in HeLa-DR cells, leading to a more
than two-fold increase in HR efficiency (Figure 3.18). CTDP1 knockdown using lentiviral
delivered shRNA in HeLa-DR cells produced an approximately four-fold decrease in HR
efficiency (Figure 3.19), suggesting that HR efficiency is directly correlated with CTDP1
expression levels. We evaluated the impact of CTDP1
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Figure 3.14: CTDP1 overexpression induce FANCI S556 phosphorylation in MDAMB-231 cells.
FANCI phosphorylation at S556 was evaluated with and without 0.4 μM MMC in MDAMB-231 cells transfected with either EV or DDK-CTDP1 expression constructs.
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Figure 3.15: CTDP1 knockdown promotes accumulation of FANCI onto chromatin,
even in the absence of DNA damage.
shScr and shCTDP1 HCT116 cells were treated with or without 100 µM melphalan for 6
hours and subjected to cellular fractionation and both CTDP1 and FANCI localization to
chromatin was determined by western blot. Total H2AX and tubulin are included as
fractionation control for chromatin and soluble protein fractions. Short exposure (S.E.).
Long exposure (L.E.)
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Figure 3.16: CTDP1 is important for correct localization of FANCI with g-H2AX
during DNA damage conditions.
FANCI association with the DNA damage marker γ-H2AX was evaluated by
immunoprecipitation of FANCI (IP:FANCI) followed by western blot for γ-H2AX 293FT
cells either untreated or treated with 50 μM cisplatin for 16 h. Dashed line in the CTDP1
blot indicates the image has only been modified to maintain the correct order of samples.
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Figure 3.17: Schematic of the DR-GFP reporter homologous recombination assay.
This homologous recombination assay requires transfection of a DR-GFP substrate into
cells. Stable-expressing DR-GFP HeLa and U20S cells were used for determining the
effect of CTDP1 expression on homologous recombination. The DR-GFP assay utilizes
a construct for I-SceI gene expression. SceGFP, which is non-active, does not express
GFP. Following transfection of I-SceI, double strand breaks are introduced within
SceGFP. If the cells are able to repair the double strand break, the iGFP sequence will
act a donor template for homologous recombination and GFP signal can be restored.
GFP signal could then be measured by flow cytometry.
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Figure 3.18: CTDP1 overexpression promotes homologous recombination repair.
(Left panel) Expression of transfected CTDP1-DDK in HeLa-DR cells. (Right panel) HR
efficiency of transfected cells validated in panel B was measured by flow cytometry
quantitation of GFP-positive cells. n = 3. Data represented as mean +/- standard error of
the mean (SEM); paired two-tailed student’s t-test.
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Figure 3.19: CTDP1 knockdown reduces homologous recombination efficiency.
(Left panel) Knockdown of CTDP1 (shCTDP1) and non-targeting scrambled shRNA
control (shScr) in HeLa-DR cells evaluated by western blot. (Right panel) HR efficiency
in response to CTDP1 knockdown from cells validated in panel D was measured by flow
cytometry quantitation of GFP-positive cells. n = 3; mean +/- SEM; paired two-tailed
student’s t-test.
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knockdown on HR in comparison to knockdown of either FANCA or BRCA2 proteins
using the same DR-GFP reporter system in the U2OS-DR cell line (Figure 3.20).
Individual knockdown of CTDP1, BRCA2, and FANCA protein expression significantly
impairs HR efficiency compared to control (Figure 3.20). These experiments provide
evidence that CTDP1 expression modifies HR efficiency, which could affect the
response of cancers to DNA damage-inducing therapies.
CTDP1 Expression in Response to Melphalan Does Not Affect ATM Activation
Breast cell lines were chosen for analysis in this study on CTDP1 because a
subset of BRCT domain-containing proteins are known hereditary breast and ovarian
cancer susceptibility genes, such as BRCA1 and BRCA2 251. Mutations in the BRCT
domain of BRCA1 increase susceptibility to breast cancer by altering its molecular
function through impaired protein interactions 27. CTDP1 transcript expression is
elevated in breast cancer samples compared to normal tissues in TCGA data queried
through UALCAN 252 (Figure 3.21). Increased CTDP1 expression occurs in stage 1
breast cancer and is maintained through stage 4 (Figure 3.21), and is elevated in both
luminal and triple-negative subclasses (Figure 3.21). Breast cancer survival in the
TCGA dataset was not significantly affected by CTDP1 expression (p=0.52) (Figure
3.22), but a separate database assembled by PRECOG 253 of 16 different breast cancer
studies determined that elevated CTDP1 expression correlates with decreased survival
(z-score=2.2, p=0.028) (Figure 3.23).
Regulation of protein expression and posttranslational modifications in response
to DNA damage are characteristics suggestive of DDR involvement 254-256. CTDP1
expression across a panel of seven breast cell lines revealed that 5/6 cancer lines
maintained their CTDP1 expression following ICL damage with melphalan (Figure 3.24).
Normal breast derived MCF-10A and ER-positive MCF-7 breast cancer cells exhibit a
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Figure 3.20: CTDP1 knockdown reduces homologous recombination efficiency
similar to BRCA2 and FANCA knockdown, respectively.
(Left panel) Confirmation of protein expression knock down in shScr, shCTDP1,
shFANCA, and shBRCA2 targeted cells by western blot for the indicated proteins. (Right
panel) HR efficiency was measured by flow cytometry quantitation of GFP-positive cells
in the cells validated in panel F. n = 3; mean +/- SEM; paired two-tailed student’s t-test.
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Figure 3.21: CTDP1 expression in clinical samples annotated in TCGA.
(Top panel) UALCAN (http://ualcan.path.uab.edu/cgi-bin/ualcan-res.pl) was used to
query TCGA level 3 RNA-seq data for breast cancer and corresponding normal tissues
for CTDP1 mRNA transcript expression levels. (Bottom left panel) Comparison of
CTDP1 transcript expression by disease stage (Stages 1-4) of breast cancer (BRCA).
(Bottom right panel) Comparison of CTDP1 transcript expression by disease subclasses
(Luminal, HER2, and Triple Negative) of breast cancer.
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Figure 3.22: CTDP1 expression as it relates to breast cancer patient survival.
Kaplan-Meier survival plot of breast cancer patients from TCGA data stratified into 2
groups corresponding to CTDP1 mRNA expression: 1) High Expression (n = 272), and
2) Low/Medium Expression (n = 809).
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Figure 3.23: Elevated CTDP1 expression is associated with decreased survival in
breast cancer.
PRECOG analysis of CTDP1 mRNA expression from studies on breast cancer. Positive
z-scores are associated with decreased survival when CTDP1 expression is elevated,
while negative z-scores are associated with increased survival.

126

Figure 3.24: CTDP1 expression is largely maintained in breast cancer cell lines
after melphalan treatment.
Western blot analysis of CTDP1 expression profiles across a panel of 7 breast cell lines
with and without treatment of 100 µM melphalan for 6 h. A long exposure (L.E.) and
short exposure (S.E.) for CTDP1 expression were both displayed in the figure.
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reduction of CTDP1 expression in response to melphalan (Figure 3.24). A small
decrease in the electrophoretic mobility of CTDP1 was observed by western blot when
the cells were treated with melphalan (Figure 3.24), which was abrogated by λphosphatase treatment (Figure 3.25), revealing that CTDP1 is actively phosphorylated
following the induction of DNA damage signaling. Since CTDP1 phosphorylation is
observed in all cell lines treated with melphalan, this modification may not correlate with
CTDP1 stability. CTDP1 has phosphorylation sites at S/TQ motifs (S338 and T340)
curated on PhosphoSitePlus (www.phosphosite.org) that could be targeted by ATM or
ATR. However, treatment with ATM or ATR inhibitors did not prevent the
phosphorylation or degradation of CTDP1 observed in control cells (Figure 3.26). The
reduction in CTDP1 expression in MCF-10A cells caused by melphalan treatment is
rescued by proteasomal inhibitor MG132 treatment (Figure 3.25).
Because of the interaction we observed between the CTDP1 BRCT and ATM
(Figure 3.6), we sought to evaluate whether loss CTDP1 expression is associated with
ATM activation in response to melphalan treatment in breast cells. Expression of CTDP1
is diminished after only two hours of melphalan treatment, which corresponds with the
induction of DNA damage signaling through ATM activation (Figure 3.27). However,
ATM activation in response to melphalan treatment was found to be independent of
CTDP1 expression in MCF-10A cells (Figure 3.27), which is in concordance with our
previous observations in 293FT cells using an overexpression system (Figure 3.11).
CTDP1 Expression Promotes ICL-induced FANCA and FANCD2 Foci Formation
Activated FANCA and FANCD2 localize to sites of ICL damage and are visible as
distinct nuclear foci by immunofluorescence 211,257. To evaluate the impact of CTDP1 on
FANCD2 foci formation, we knocked down either CTDP1 or FANCA, as a control, in
MCF-10A cells (Figure 3.28). The specificity of the FANCD2 antibody used to perform
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Figure 3.25: CTDP1 expression upon melphalan treatment is regulated by
phosphorylation and subjected to proteasomal degradation.
(Left panel) λ-phosphatase treatment of immunoprecipitated CTDP1 (IP: CTDP1) in T47D cells either untreated or treated with 100 μM melphalan for 6 h. (Right panel) MCF10A breast cells were treated with or without 100 μM melphalan in the presence or
absence of 50 μM proteasome inhibitor MG132 pretreatment for 6 h. Cell lysates were
analyzed by western blot for CTDP1 and β-actin protein expression.
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Figure 3.26. Evaluation of ATM and ATR inhibition on CTDP1 phosphorylation and
stability in response to melphalan.
MCF-10A cells were treated with 100 μM melphalan for 6 hours and the indicated
inhibitors: ATMi (KU55933), 25 µM; ATRi (AZD6738), 5 µM.
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Figure 3.27: ATM activation is independent of CTDP1 expression during DNA
damage.
(Left panel) Western blot of MCF-10A lysates for CTDP1, total and phospho-ATM
(pS1981), pSQ/pTQ motifs, and tubulin collected at the indicated times following
treatment with 100 μM melphalan. (Right panel) Western blot analysis of the indicated
proteins in MCF-10A cells expressing shScr control or shCTDP1 with and without
treatment of 100 μM melphalan for 6 h.
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Figure 3.28: Validation of non-targeting scrambled control, CTDP1, and FANCA
shRNAs and FANCD2 antibody used for immunofluorescence.
(Top left panel) Western blot demonstrating knockdown of CTDP1 and FANCA using
targeted shRNAs in MCF-10A cells. (Top right panel) Western blot demonstrating the
specificity of the FANCD2 antibody using FANCD2-deficient PD20 fibroblast cells with
and without stable expression of exogenous FANCD2. (Bottom panel) Representative
immunofluorescence of FANCD2 and DAPI (red and blue, respectively) in PD20 and
PD20 cells with FANCD2 reconstituted, exogenous expression in untreated cells.
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immunofluorescence was validated by western blot and immunofluorescence in
FANCD2-null PD20 cells with and without reconstitution of exogenous FANCD2
expression (Figure 3.28). The FANCA antibody was validated by immunofluorescence,
which did not detect FANCA signal in the shFANCA cells (Figure 3.29). Knockdown of
CTDP1 significantly impairs FANCA foci in response to MMC treatment (Figure 3.29).
CTDP1 knockdown also results in decreased FANCD2 foci formation compared to
control, but this was to a lesser extent when compared to the control FANCA knockdown
(Figure 3.30). Upstream γ-H2AX foci formation was not impacted by CTDP1 or FANCA
knockdown (Figure 3.31). CTDP1 knockdown only marginally affects FANCD2 monoubiquitination (Figure 3.32). CTDP1 cellular localization was also examined in T-47D
cells by immunofluorescence, and while some punctate CTDP1 foci were found that
localized to both the cytoplasm and the nucleus, their prevalence was not affected by
DNA damage and nuclear co-localization with FANCD2 foci is detectable only in a few
instances (Figure 3.33).
CTDP1 Knockdown Increases Sensitivity to DNA Damage
Cells with a defective DDR are more sensitive to DNA damaging agents 258,259.
We performed clonogenic survival assays in MCF-10A cells and found that targeted
knockdown of CTDP1 using two unique shRNAs decreases the number of surviving
colonies in comparison to control cells treated with melphalan (Figure 3.34). Similar
effects were also observed for other DNA damaging treatments, including IR to generate
double-strand breaks and mitomycin c to induce ICL, in which CTDP1 knockdown
decreases the survival of these cells following treatment (Figure 3.35). However,
survival in response to cyclobutane-pyrimidine dimers caused by ultraviolet radiation is
not affected by CTDP1 knockdown (Figure 3.35). In addition, survival in response to
cisplatin, generating intra-strand DNA crosslinks and ICL, or 5-
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Figure 3.29: CTDP1 knockdown significantly reduces FANCA foci.
Representative immunofluorescence of FANCA alone and merged with DAPI (white and
blue color, respectively) in MCF-10A cells expressing the indicated shRNAs (shScr (top
right panel), shCTDP1 (bottom left panel), or shFANCA (top right panel)) treated with 0.2
μM MMC for 24 h. Scale = 5 μm. (bottom right panel) Graph representing the percentage
of nuclei containing ≥5 FANCA foci with or without MMC treatment. n = 3 independent
experiments; mean +/- SEM; paired two-tailed student’s t-test; ≥200 cells
evaluated/experiment.
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Figure 3.30: CTDP1 knockdown significantly reduces FANCD2 foci.
Representative immunofluorescence of FANCD2 alone and merged with DAPI (white
and blue color, respectively) in MCF-10A cells expressing the indicated shRNAs (shScr
(top right panel), shCTDP1 (bottom left panel), or shFANCA (top right panel)) treated
with 0.2 μM MMC for 24 h. Scale = 5 μm. (bottom right panel) Graph representing the
percentage of nuclei containing ≥5 FANCD2 foci with or without MMC treatment. n = 3
independent experiments; mean +/- SEM; paired two-tailed student’s t-test; ≥100 cells
evaluated/experiment.

135

Figure 3.31: CTDP1 knockdown does not affect upstream g-H2AX foci.
Representative immunofluorescence of γ-H2AX alone and merged with DAPI (white and
blue color, respectively) in MCF-10A cells expressing the indicated shRNAs (shScr (top
right panel), shCTDP1 (bottom left panel), or shFANCA (top right panel)) treated with 0.2
μM MMC for 24 h. Scale = 5 μm. (bottom right panel) Graph representing the percentage
of nuclei containing ≥5 γ-H2AX foci with or without MMC treatment. n = 3 independent
experiments; mean +/- SEM; paired two-tailed student’s t-test; ≥200 cells
evaluated/experiment.
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Figure 3.32: CTDP1 knockdown marginally affects FANCD2 mono-ubiquitination.
Analysis of FANCD2 mono-ubiquitination using cellular fractionation of MCF-10A cells
(shScr and shCTDP1) with and without MMC treatment for 24 h by calculating the ratio
of Long (mono-ubiquitinated):Short (non-ubiquitinated) proteoforms quantified by LICOR signal intensities. (S, soluble protein fraction, including cytosol and nucleoplasm; P,
pellet protein fraction, contains chromatin).
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Figure 3.33: Cellular localization of CTDP1 determined by immunofluorescence.
T-47D cells were untreated or treated with 100 μM melphalan for either 2 or 6 hours to
induce FANCD2 DNA damage foci observed by immunofluorescence (green). CTDP1
expression was also evaluated by immunofluorescence (red). DAPI was used as a
nuclear counterstain. Images were captured on an inverted Zeiss microscope using a
100X oil immersion objective. Scale = 5 μm.
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Figure 3.34: CTDP1 knockdown promotes sensitivity to melphalan treatment.
(Top left panel) Western blot confirmation of shRNA targeting CTDP1 with two
independent shCTDP1 constructs (#1-TRCN0000002996 and #2-TRCN0000436164).
(Bottom left panel) Representative clonogenic survival assay in MCF-10A cells
expressing non-targeting shScr and shCTDP1 constructs treated with control or 5 μM
Melphalan. (Right panel) Quantification of the clonogenic survival assays using MCF10A cells expressing shScr or shCTDP1 #1 treated with 5 μM melphalan (Mel). n = 3
independent experiments. Data represented as mean +/- SEM; paired two-tailed
student’s t-test.
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Figure 3.35: CTDP1 knockdown promotes ICL sensitivity to IR, MMC, and UV,
respectively.
(Top panel) Clonogenic survival assay using MCF-10A cells expressing shScr or
shCTDP1 #1 treated with 0, 2, 4, 6, or 8 Gy ionizing radiation. n = 3; mean +/- SEM;
Asterisks indicate p-value ≤ 0.05; paired two-tailed student’s t-test. (Middle panel)
Clonogenic survival assay using MCF-10A cells expressing shScr or shCTDP1 #1
treated with 0, 0.1, 0.2, 0.3, 0.4, or 0.5 μM MMC. n = 3; mean +/- SEM; Asterisks
indicate p-value ≤ 0.05; paired two-tailed student’s t-test. (Bottom panel) Clonogenic
survival assay using MCF-10A cells expressing shScr or shCTDP1 #1 treated with 0, 10,
20, 30, 40, or 50 J/m2 ultraviolet radiation. n = 3; mean +/- SEM.
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fluorouracil (5-FU), that causes double-strand breaks and replication inhibition, is
decreased following CTDP1 knockdown (Figure 3.36).
To determine if ICL sensitivity observed upon CTDP1 knockdown is attributable
to an increase in cell death, caspase-3 activity was evaluated and found to be
significantly elevated when CTDP1 was knocked down in both MCF-10A and MDA-MB231 cell lines treated with melphalan in comparison to shScr control (Figure 3.37). We
also examined the sensitivity to ICL caused by knockdown of CTDP1 in the context of
FANCD2 deficiency using human fibroblast cells derived from a Fanconi anemia patient
which lack a functional FANCD2 gene (PD20) and the FANCD2-reconstituted cell line
(PD20+FANCD2) (Figure 3.38) 260. Knockdown of CTDP1 in FA pathway-proficient,
PD20+FANCD2 cells led to a decrease in cell survival, but this was intermediate to the
sensitivity caused by loss of FANCD2 expression in the PD20 shScr cells (Figure 3.38).
Knockdown of CTDP1 in FANCD2-deficient PD20 cells did not lead to a further decrease
in cell survival compared to PD20 shScr control (Figure 3.38), suggesting an intact FA
repair pathway is necessary to observe an increase in cell sensitivity to ICL caused by
knockdown of CTDP1.
CTDP1 Knockdown Impairs Breast Cancer Cell Growth In Vitro and In Vivo
To further validate CTDP1 as a potential target to sensitize breast cancer cells to
chemotherapy, we sought to evaluate the impact of targeted deletion or depletion of
CTDP1 expression on breast cell line growth. Repeated attempts to knockout CTDP1 by
CRISPR in MDA-MB-231 and MCF-7 cells failed to yield viable cultures. Information
available from Depmap.org indicates that CTDP1 is a “common essential” gene because
CRISPR-mediated knockout of this gene significantly reduced cell viability in 505 out of
517 cancer cell lines tested (Figure 3.39). Therefore, we have had to employ incomplete
knockdown techniques using shRNA to maintain viable cell cultures. We have
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Figure 3.36: CTDP1 knockdown promotes ICL sensitivity to cisplatin and 5-FU.
Clonogenic survival assay using MCF-10A cells expressing shScr or shCTDP1 #1
treated with 5 μM cisplatin or 12 μM 5-Fluorouracil (5-FU). n = 3; mean +/- SEM; paired
two-tailed student’s t-test.
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Figure 3.37: CTDP1 knockdown promotes ICL-induced apoptosis.
(Left panel) Caspase-3 activity assay using MCF-10A cells expressing shScr or
shCTDP1 treated with control or Melphalan for 24 h. Y-axis units are represented as the
change in fluorescent units per microgram protein extract per hour of reaction incubation
(ΔFU/μg protein/h). n = 3; mean +/- SEM; paired two-tailed student’s t-test. (Right panel)
Caspase-3 activity assay using MDA-MB-231 cells shScr or shCTDP1 treated with
control or Melphalan for 0, 6, and 24 h. n = 3; mean +/- SEM; paired two-tailed student’s
t-test.
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Figure 3.38: CTDP1 knockdown significantly reduces clonogenic survival in the
presence of an intact FA pathway.
(Top left panel) Western blot confirmation of CTDP1 knockdown and FANCD2
expression in PD20 (FANCD2 deficient) and PD20+FANCD2 fibroblasts. (Top right
panel) Clonogenic survival assay using PD20 and PD20+FANCD2 cells expressing
shScr or shCTDP1 #1 treated with 0, 25, 50, 75, 100, or 200 nM MMC. n = 3; mean +/SEM. (Bottom panel) Table of p-values determined using the paired two-tailed student’s
t-test for each listed comparison of treatment groups from the results.
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Figure 3.39: CTDP1 is a common essential gene necessary for cancer cell viability.
Dependency map (www.depmap.org) graph depicting the dependency score of CTDP1
across 517 cancer cell lines that have been tested using CRISPR knockout of CTDP1.
CTDP1 was determined to be a “common essential” gene due to the lethality of 505
cancer cell lines out of all 517 tested.
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determined that knockdown of CTDP1 is well-tolerated by the MCF-10A cell line with a
minor reduction in cell growth in vitro (Figure 3.40). However, T-47D and MCF-7 breast
cancer cell lines display reduced growth rates when CTDP1 is knocked down (Figure
3.40).
Breast cancer can be classified according to distinct molecular subtypes, and the
most aggressive subtype is triple-negative (ER-, PR-, HER2-) 261. We chose the MDAMB-231 and MCF-7 cell lines to interrogate 2 unique subtypes of breast cancer in vivo.
MDA-MB-231 is a triple-negative breast cancer cell line. Both the MCF-7 and T-47D
breast cancer cell lines interrogated above in the in vitro proliferation analysis are
classified as Luminal A (ER+, PR+/-, HER2-), and we chose to utilize MCF-7 to represent
this subtype for the in vivo analysis. The MDA-MB-231 and MCF-7 cancer cell lines were
subjected to CTDP1 knockdown and then injected into the mammary fat pad of
immunodeficient mice to evaluate in vivo growth (Figure 3.41). MDA-MB-231 shScr cells
formed tumors, but shCTDP1 cells did not, and at necropsy shCTDP1 tumors were
unidentifiable (Figure 3.42). MCF-7 cells were also subjected to CTDP1 knockdown for
this xenograft study (Figure 3.43). Palpable tumors were observed from the MCF-7
shScr cells at day 13 but were not observed in the shCTDP1 group until day 17 and only
5/6 injections resulted in tumors. (Figure 3.43). The shCTDP1 tumors were also found to
be significantly smaller by weight at necropsy (Figure 3.43). CTDP1 depletion in vitro
and in vivo diminishes tumorigenic potential of breast cancer models, which is also
consistent with previous findings in gastric and lung cancer in vitro experiments 262,263.
These data suggest that CTDP1 could be a promising target for cancer therapeutic
development.
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Figure 3.40: CTDP1 knockdown reduces growth potential and colony survival in
breast cancer cells.
In vitro growth curves of breast cell lines (top panel) MCF-10A, (middle panel) T-47D,
and (bottom panel) MCF-7 comparing cell proliferation between shScr and shCTDP1
expressing cells. n = 3; mean +/- SEM.
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Figure 3.41: Timeline and experimental design of the in vivo xenograft mouse
experiments.
After three days of lentiviral transduction, two million MCF-7 or MDA-MB-231 cells were
injected into the mammary fat pads of female mice. Mice were observed for subsequent
tumor growth. Mice with MCF-7 xenograft tumors were sacrificed after 17 days while
mice with MDA-MB-231 xenograft tumors were sacrificed after 21 days.
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Figure 3.42: CTDP1 knockdown reduces tumorigenic potential of MDA-MB-231
mouse xenografts.
(Top left panel) Western blot confirming CTDP1 knockdown in MDA-MB-231 cells used
for this xenograft study. (Top right panel) Tumors obtained from shScr or shCTDP1
MDA-MB-231 injected mice sacrificed at the end of the study on Day 21. (Bottom left
panel) Volumes of shScr (n = 10) and shCTDP1 (n = 12) MDA-MB-231 tumors grown in
mice at Day 0, 12, 16, and 21 using Vernier caliper measurements of palpable tumors.
Mean +/- SEM; Asterisks indicate p-value ≤ 0.05; two-tailed student’s t-test. (Bottom right
panel) Weights of shScr and shCTDP1 MDA-MB-231 tumors obtained at necropsy. Box
spans the interquartile range, horizontal line represents median, +/- highest and lowest
observations.
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Figure 3.43: CTDP1 knockdown reduces tumorigenic potential of MCF-7 mouse
xenografts.
(Top left panel) Western blot confirming CTDP1 knockdown in MCF-7 cells used for this
xenograft study. (Top right panel) Tumors obtained from shScr or shCTDP1 MCF-7
injected mice sacrificed at the end of the study on Day 17. (Bottom left panel) Volumes
of shScr (n = 10) and shCTDP1 (n = 6) MCF-7 tumors grown in mice at Day 0, 13, and
17 using Vernier caliper measurements of palpable tumors. Mean +/- SEM; Asterisks
indicate p-value ≤ 0.05; two-tailed student’s t-test. (Bottom right panel) Weights of shScr
and shCTDP1 MCF-7 tumors obtained at necropsy. Box spans the interquartile range,
horizontal line represents median, +/- highest and lowest observations.
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Discussion
Here we provide evidence that CTDP1 participates in the DDR through proteinprotein interactions with ICL repair proteins FANCA, FANCI, and FANCD2. CTDP1
expression levels directly correlate with cellular HR efficiency, and knockdown of CTDP1
promotes sensitivity to ICL DNA damage. CTDP1 knockdown also prevents the
formation of both FANCA and FANCD2 foci, which are essential for ICL repair. CTDP1
expression regulates FANCI S/TQ motif phosphorylation, chromatin localization, and
interaction with γ-H2AX. Together, these results suggest that CTDP1 plays an important
role in the regulation of the ICL repair pathway and reveal that that it may be a promising
therapeutic target for breast cancer.
Mutations in the CTDP1 gene have not been identified in FA patients. However,
mutation of human CTDP1 is associated with the rare congenital cataracts facial
dysmorphism neuropathy (CCFDN) syndrome 264-267. Homozygous mutation of an Alu
element in intron 6 (IVS6+389C>T) of CTDP1 leads to the generation of approximately
70% non-functional truncated protein and 30% functional full-length protein 264. CCFDN
affected individuals exhibit a number of phenotypic abnormalities and some features are
shared with FA patients including short stature, sub-normal weight, and hypogonadism
268

. However, there is no documented association of CCFDN with cancer incidence.

Complete functional loss of CTDP1 may be embryonic lethal in humans, as previously
observed in D. melanogaster 269. Currently, no mammalian genetic models of targeted
CTDP1 deletion exist, but will be important to decipher the in vivo role of CTDP1 in the
regulation of FA proteins and ICL repair.
CTDP1 expression promotes FANCI SQ motif phosphorylations at S556 in a
phosphatase-dependent manner. There are several possible explanations for this
seemingly contradictory observation. For instance, CTDP1 could dephosphorylate
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FANCI outside of the SQ motif sites interrogated in this study to regulate the substrate
accessibility or phosphorylation stability of SQ motif residues. Another potential
explanation for the increased SQ motif phosphorylations on FANCI caused by CTDP1
overexpression could be the impact on ATM or ATR kinase activation. Overexpression
of CTDP1 promotes increased pS428 ATR, but this does not appear to fully explain the
level of FANCI phosphorylation caused by CTDP1 overexpression. Previous studies in
D. melanogaster found that either CTDP1 overexpression or knockdown promotes cell
death in a manner independent of ATM or ATR function 270, but the role of FANCI in this
cell death process requires further analysis.
In conclusion, CTDP1 represents a unique BRCT domain-containing protein with
functional associations with the ICL repair pathway. Understanding the role
phosphatases play in the DDR could expand strategies to modify cancer sensitivity to
DNA damage-based therapies.
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Materials and Methods
Cell culture and transfection
The breast cell lines and HCT116 cells were purchased from ATCC. 293FT cells were
purchased from Invitrogen. MCF-10A cells were cultured in DMEM/F12 medium
(Invitrogen), containing 5% horse serum (Invitrogen, No. 16050-122), 20 ng/mL EGF
(Sigma), 0.5 μg/mL Hydrocortisone (Sigma), 100 ng/mL Cholera toxin (Sigma), 10
μg/mL insulin (Sigma), and 1% penicillin-streptomycin (Invitrogen) at 37 °C in 5%
humidified CO2 incubators. HCC1143, HCC1599 and MDA-MB-231 cells were cultured
in RPMI medium (Invitrogen), containing 10% FBS and 1% penicillin-streptomycin. BT549 cells were cultured in RPMI medium containing 10% FBS, 1% penicillinstreptomycin and 0.023 IU/mL insulin. MDA-MB-436 cells were cultured in DMEM
medium containing 10% FBS, 1% penicillin-streptomycin and 10% NEAA. T-47D cells
were cultured in RPMI medium containing 10% FBS, 1% penicillin-streptomycin and 0.2
U/mL insulin. MCF-7 and 293FT cells were cultured in DMEM medium (Invitrogen),
containing 10% FBS and 1% penicillin-streptomycin. HCT116 cells were cultured in
McCoy’s 5A medium (Invitrogen), containing 10% FBS, 1% penicillin-streptomycin.
PD20 and PD20 cells with reconstituted FANCD2 expression were a gift from the
laboratory of Dr. Alan D’Andrea. Transfection of 293FT cells to generate lentiviral
particles was performed using the calcium phosphate method and the ViraPower system
(Invitrogen). Target cells were transduced with virus, and 48 hours later, selected on 1
μg/mL puromycin for 7-10 days.
Plasmids, Primers, and shRNAs
The BRCT domain of CTDP1 with 10 amino acid additional sequence flanking the
domain regions (amino acids 619-738) was cloned into a pNTAP construct using

153
InterPlay N-Terminal Mammalian TAP Vectors (Agilent Technologies) using the EcoRI
and HindIII restriction sites. Primers: CTDP1-forward 5’TAGAATTCGCGCCGGACATCCGCAAGATCG-3’ and CTDP1-reverse 5’CTAAGCTTTCACTCCCTCTGTGCCTTGGTGTGA-3’. Full-length FANCI transcript
variant 1 C-terminal fusion with monomeric GFP (mGFP) construct in pLenti-C-mGFPP2A-Puro was purchased from Origene. Full-length CTDP1 transcript variant 1 Cterminal fusion with myc and DDK epitopes in pCMV6-Entry was purchased from
Origene. CTDP1 mutant plasmids were designed and made using the QuikChange II XL
Site-Directed Mutagenesis Kit (Agilent). The associated primers were generated by
using the online QuikChange Primer Design program (Agilent). Primers: CTDP1-R270Qforward 5’-CGAGAAGAAGCTTTTTTCTCACCAAATATTATCAAGGGATGAATGTA-3’
and CTDP1-R270Q-reverse 5’TACATTCATCCCTTHATAATATTTGGTGAGAAAAAAGCTTCTTCTCG-3’; CTDP1D30K-forward 5’GTGGAGACTCAATGGTTTGCATTATTAAGGATCGAGAAGATGTCTG-3’ and CTDP1D302K-reverse 5’CAGACATCTTCTCGATCCTTAATAATGCAAACCATTGAGTCTCCAC-3’; CTDP1V705M-forward 5’-GCGGACACCTGCACATGGTCAACCCTGAC-3’ and CTDP1-V705Mreverse 5’-GTCAGGGTTGACCATGTGCAGGTGTCCGC-3’. The shRNAs were
purchased from Sigma Aldrich and were provided by The RNA Consortium shRNA
Library. shRNAs: BRCA2 (TRCN0000009825), CTDP1 (TRCN0000002996) and
(TRCN0000436164), FANCA (TRCN0000296799), and non-targeting shRNA control
(shScr) (SHC016).
Mass Spectrometry
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The InterPlay TAP Purification Kit (Agilent Technologies) and NETN buffer was used to
purify pNTAP-CTDP1 and its interactors as previously described 72. Protein fractions (n =
4) created by SDS-PAGE were excised, destained, reduced with triscarboxyethylphosphine, alkylated with iodoacetamide, and digested overnight with
sequencing-grade trypsin (Promega). Tryptic peptides were eluted from the gel and
concentrated to 20 µL by vacuum centrifugation. A nanoflow liquid chromatograph
(U3000, Dionex) coupled to an electrospray ion trap mass spectrometer (LTQ-Orbitrap,
Thermo) was used for tandem mass spectrometry (MS/MS) peptide sequencing
experiments. Samples were first loaded onto a pre-column (5 mm Å~ 300 mm inside
diameter (ID), C18 PepMap100, Dionex) and washed for 8 min with aqueous 2%
acetonitrile and 0.04% trifluoroacetic acid. With a flow rate of 300 nL/min, the trapped
peptides were eluted onto the analytical column (75 mm ID Å~ 15 cm, C18 PepMap 100,
Dionex). The 60-min gradient program began at 95% solvent A (aqueous 2%
acetonitrile/0.1% formic acid) for 8 min; solvent B (aqueous 90% acetonitrile/0.1% formic
acid) was ramped from 5% to 50% over 35 min. Then, solvent B was ramped from 50%
to 90% B over 5 min, followed by washing and re-equilibration of the column. The mass
spectrometer cycled through a survey scan, and five tandem mass spectra were
collected in a data-dependent manner in the linear ion trap using 60-s exclusion for
previously sampled peptide peaks. The CTDP1 BRCT domain raw mass spectrometry
data files have been deposited to the ProteomeXchange Consortium via the PRIDE 271
partner repository with the project accession: PXD009541 and project DOI:
10.6019/PXD009541.
Mass Spectrometry Data Analysis
Database searches were conducted against human entries in the SwissProt database
(v.20130501) using Mascot (Matrix Science, version 2.2.04) 272, assuming the digestion
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enzyme trypsin was used and allowing as many as two missed cleavages. Tandem
mass spectra were matched to peptide sequences with a peptide ion mass tolerance of
1.2 Daltons and a fragment ion mass tolerance of 0.80 Dalton. Oxidation of methionine
and carbamidomethylation of cysteine were specified as variable modifications.
Assignments were manually verified by inspection of the tandem mass spectra and
coalesced into Scaffold reports (v4.8.4, available at http://www.proteomesoftware.com)
for statistical analysis and data presentation.
Scaffold was used to validate MS/MS-based peptide and protein identifications.
Peptide identifications were accepted if they could be established at greater than 95.0%
probability as specified by the PeptideProphet algorithm 273. Protein identifications were
accepted if they could be established at greater than 50.0% probability and contained at
least two identified peptides. Protein probabilities were assigned by the ProteinProphet
algorithm 274. Proteins that contained similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy the principles of parsimony.
Significance Analysis of INTeractome (SAINT, v2.4.0) 275 was used to score
CTDP1 BRCT domain interaction specificity from mass spectrometry results by
comparing proteins identified in the CTDP1 interaction screen to 6 negative control
pNTAP-GFP performed in-house and another 282 control interaction datasets
downloaded from the CRAPome (crapome.org) 240. The top 10 highest peptide counts
for each protein from the control datasets were used to evaluate interaction specificity.
Interactions obtained from the CORUM database were used to boost scores of known
protein complexes in the sample 276. The SAINT output was also manually inspected to
remove known calmodulin binding proteins and carryover contaminants. For visual and
analysis purposes, ProHits-viz was used to evaluate the output from SAINT 246.
Network Visualization and Gene Ontology Analysis
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The CTDP1 BRCT high confidence interaction network consisting of 103 proteins was
uploaded to Cytoscape for visualization and analysis. This set of 103 interacting proteins
was analyzed with ClueGO (version 2.2.5) 243 to determine GO Biological Processes
(version 09.02.2016) and KEGG Pathways (version 26.10.2017) with significant
enrichments in this dataset with evidence codes of “All_without_IEA”. GO Term fusion
was selected and only statistically significant enriched pathways with p-value ≤ 0.05
were shown. Statistical significance was determined using a two-sided hypergeometric
test corrected with Bonferroni step down method. BiNGO 244 was used for a similar
analysis using the hypergeometric test and Benjamini & Hochberg False Discovery
(FDR) correction at a significance level of 0.05. The output of BiNGO was used as the
input for Enrichment Map 245 as a network-based method to visualize and interpret the
protein-set enrichment results from BiNGO.
Homologous Recombination DR-GFP Reporter Assay
A HeLa-derived cell line, HeLa-DR-13-9 (generous gift from Dr. Jeffrey Parvin at the
Ohio State University) was used to measure HR activity. For overexpression
experiments, HeLa-DR-13-9 cells were seeded at 3 x 104 cells per well in a 6-well plate
one day before transfection. The cells were transfected with each pCMV6 expression
plasmid and incubated for two days. For suppression experiments, HeLa-DR-13-9 cells,
as well as U2OS cells with stable-expressing DR-GFP substrate, were seeded at 5 x 104
cells per well in a 12-well plate one day before lentiviral infection. The cells were infected
by each shRNA-containing lentivirus and incubated for one day. The infected cells were
grown for an additional one day in fresh medium. For the induction of double-strand
breaks and measurement of HR activity, the cells were transfected by the expression
plasmid of I-SceI endonuclease (generous gift from Dr. Maria Jasin at Memorial Sloan
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Kettering Cancer Center). HR activity was determined by FACS three days after
transfection.
Western blotting and antibodies
Whole cell lysates were prepared using NETN lysis buffer (10 mM HEPES pH 7.4, 10
mM KCl, 0.05% NP-40). The lysis buffer contained phosphatase inhibitors (50 mM NaF,
10 mM b-glycerophosphate, 0.1 mM NaVO4) and protease inhibitor cocktail (Sigma).
Samples were mixed 1:4 with 5X Laemmli buffer and incubated at 95°C for 5 minutes.
Approximately 50-100 μg of protein was prepared for loading. The membrane was
blocked in 5% non-fat milk and incubated with the primary antibody. BRCA2 (A300005A), CTDP1 (A301-172A), FANCA (A301-980A), FANCI (A300-212A), and H2AX
(A300-082A) antibodies were purchased from Bethyl Laboratories, Inc. ATM (#2873),
Phospho-(Ser/Thr) ATM/ATR Substrate Motif (#9607), Phospho-ATR (Ser 428) (#2853),
ATR (#13934), and phosphor-RPB1 CTD (Ser2) (#13499) antibodies were purchased
from Cell Signaling Technology. Phospho- ATM S1981 (AF1655) antibody was
purchased from R&D Systems, Inc. FANCD2 (ab108928) antibody was purchased from
Abcam. Gamma-H2AX (NB100-384) antibody was purchased from Novus Biologicals.
DDK (FLAG tag) (TA50011-100) and monomeric GFP(mGFP) (TA180076) antibodies
were purchased from OriGene Technologies, Inc. HSC70 (sc-7298), b-actin (sc-47778),
and α-tubulin (sc-53030) antibodies were purchased from Santa Cruz Biotechnology.
FANCI phospho-antibodies (pS556 and pS559) were kind gifts from the Taniguchi lab
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. Protein complexes were visualized with ECL (Thermo Scientific), or near-IR

secondary antibodies (LI-COR) on the Odyssey Fc Imaging System (LI-COR).
Immunoprecipitation
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For immunoprecipitation experiments, lysates were prepared with NETN lysis buffer with
protease and phosphatase inhibitors. One milligram of total protein was used for
immunoprecipitation and incubated with 5 μg anti-CTDP1 or 1 μg anti-DDK antibody on
ice for one hour followed by addition of Protein A/G beads (Santa Cruz Biotechnology)
and incubated at 4°C overnight with rotation. Immunoprecipitated protein complexes on
Protein A/G beads were washed a minimum of three times with NETN buffer. For
phosphatase-treated samples, one unit of λ-protein phosphatase was incubated with the
washed immunoprecipitated protein complexes on Protein A/G beads for one hour at
37°C, with agitation at 1000 rpm on a temperature controlled orbital shaker, then washed
an additional three times with NETN buffer. The immunoprecipitated complexes were
boiled at 95°C for five minutes to dissociate them from the Protein A/G beads and
analyzed by western blot.
Caspase-3 Apoptosis Assay
Cells were treated with 100 μM melphalan at ~50% confluence for 24 hours (h). The
cells were collected and lysed in CHAPS lysis buffer (1% CHAPS, 150 mM NaCl, 10 mM
HEPES pH 7.4) with protease and phosphatase inhibitors, as previously described 277.
Approximately 25-50 μg of protein were incubated in assay buffer with Caspase-3
substrate (Sigma) in 96-well plate in dark for one hour. The plate was read with
fluorometer set at excitation 360 nm, emission 460 nm. Caspase-3 activity was assayed
as DEVDase activity with the caspase-3 fluorescence assay kit (Sigma). Caspase-3
activity is reported as the change in fluorescent units per microgram protein lysate per
hour of reaction incubation (DFU/µg protein/h).
Clonogenic Survival Assay and Cell Proliferation
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One thousand MCF-10A shScr or shCTDP1 cells were seeded in each well of 6-well
plates. The following drugs and agents were used to treat cells for 48 hours: mitomycin
C, melphalan, cisplatin, 5-fluorouracil, paclitaxel, ultraviolet (UV) radiation, and ionizing
radiation. The cells recovered in fresh media for 7-10 days. The plates were stained with
Giemsa for 20 min, and colonies were counted. Each genotype and drug dose was done
in three independent experiments. Cell proliferation experiments were performed with
the indicated cell lines by plating 250 cells/well in 12-well plates. Individual wells were
trypsinized daily for 10 days and total cells/well were determined by counting using a
hemocytometer. Each data point was analyzed with three independent experiments.
Immunofluorescence
Cells were grown on coverslips and treated with 0.1 µM MMC or control and fixed in 4%
paraformaldehyde for 15 min. Coverslips were washed in 0.5% Triton X-100/PBS for one
minute. Coverslips were then incubated with antibodies directed toward FANCA (Bethyl,
A301-980A, 1:200 dilution), FANCD2 (Abcam ab108928, 1:200 dilution), or γ-H2AX
(Novus Biologicals NB100-78356, 1:200 dilution) in 3% BSA for one hour. After
coverslips were washed three times with PBS, donkey anti-rabbit AlexaFluor-647
(Abcam ab150075, dilution 1:500) or goat anti-mouse AlexaFlour-488 (Abcam
ab150113, 1:500 dilution) secondary antibody was added for one hour. Coverslips were
finally washed three times with PBS and mounted with DAPI counterstain mounting
solution onto microscope slides. Images were captured on a Zeiss 710 Confocal Laser
Scanning Microscope using a 63x oil objective.
Chromatin Extraction
The protocol for the acid extraction of chromatin proteins was adapted from the
Mostoslavsky lab protocol and performed as previously described 278,279. Cell pellets
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were suspended with lysis buffer (10 mM HEPES pH 7.4, 10 mM KCl, 0.05% NP-40)
three times the pellet volume and incubated on ice for 20 minutes. The lysates were then
centrifuged at 14,000 rpm for 10 minutes at 4ºC. The supernatant was collected
(cytoplasmic proteins) and the pellet was washed again and centrifuged. The remaining
pellet was suspended in Low Salt Buffer (10 mM Tris-HCl pH 7.4, 0.2 mM MgCl2, 1%
Triton-X 100) three times the pellet volume and incubated on ice for 15 minutes. The
lysates were centrifuged again at 14,000 rpm for 10 minutes at 4ºC. The supernatant
was collected (nucleoplasmic proteins) and the pellet was suspended in three pellet
volumes of 0.2 N HCl and incubated on ice for 20 minutes. After centrifugation at 14,000
rpm for 10 minutes at 4ºC, the supernatant was collected and neutralized with an equal
volume of 1M Tris-HCl pH 8 (chromatin-bound proteins).
CSK Fractionation
The protocol outlined and used was described previously 280. Cells were lysed with CSK
Buffer (10 mM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose, 1.5 mM MgCl2, 1 mM
EGTA, 1 mM EDTA, 1 mM PMSF, 50 mM NaF, 0.1 mM NaVO4, 0.1% Triton X-100, and
Protease Inhibitor Cocktail (Sigma Aldrich) (1:100 dilution)) and incubated on ice for five
minutes. After the lysate was centrifuged at 1500 x g for 5 min, the supernatant was
labeled “S.” The pellet was then washed with the same buffer, centrifuged at 1500 x g for
5 min, and labeled “P.”
Orthotopic Xenograft Tumor Model
NOD scid gamma (NSG) mice were purchased from Jackson Laboratory. MDA-MB-231
or MCF-7 breast cancer cells were transduced with shScr or shCTDP1 lentiviral
constructs and selected on 1.0 μg/mL puromycin for seven days. Four-week-old female
mice were injected with 2 x 106 MDA-MB-231 shScr (n = 5 mice) or shCTDP1 (n = 6
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mice) cells in 100 mL of 50:50 Matrigel/Collagen I into each of the left and right fourth
abdominal fat pads by a small surgery at the base of the nipple. For MCF-7 xenografts,
shScr (n = 5 mice) or shCTDP1 (n = 3 mice) were used. MDA-MB-231 tumor growth was
monitored externally using Vernier calipers at 12, 16, and 21 days and animals sacrificed
on day 21. MCF-7 tumor growth was monitored externally using Vernier calipers at day
13 and 17 and animals were sacrificed on day 17. Tumor weights were determined at
the time of necropsy. The experimental protocol for this animal procedure was reviewed
and approved by the Institutional Animal Care and Use Committee (IACUC) of Xiangya
Hospital of Central South University.
TCGA Data
UALCAN (http://ualcan.path.uab.edu/cgi-bin/ualcan-res.pl) was used to query The
Cancer Genome Atlas (TCGA) data for breast cancer and corresponding normal tissues
for CTDP1 mRNA transcript expression levels according to tumor stage and sub
classification as Luminal, HER2, or Triple Negative. Graphs were exported from
UALCAN and modified for visual clarity.
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS
The Uniqueness of BRCT Domains
Modular domains are essential to study because these are the functional units of
proteins. When the functionality of the modular domain is disrupted, the function of the
protein and the pathways in which it participates are affected. This can lead to many
detrimental outcomes, including genetic diseases, syndromes, or cancer. BRCT
domains are protein modular domains that are structurally conserved and actively play
key roles in DDR pathways and mechanisms. The importance of BRCT domains spans
further than just in the DDR response. BRCT domains have other associated roles in cell
cycle regulation, cytokinesis, and transcription 72. The purpose of this dissertation work is
to explore functions of BRCT domains have as scaffolding domains and how they use
their protein-protein interactions with other regulatory proteins, such as phosphoproteins,
kinases, ubiquitin ligases, polymerases, and phosphatases.
The DDR has a profound effect in the regulation of DNA damage, replication
stress, and cell cycle progression. There are many post-translational modifications
(PTMs) that signal molecules to direct, recruit, and command particular signaling events
to occur. While BRCT domains do not exhibit enzymatic activity, these domains serve as
scaffolds to recruit and interact with their target proteins to elicit a signaling response.
BRCT domains, especially tandem BRCT domains, have the ability to scaffold proteins
by binding to phosphorylated Ser-X-X-Phe/Tyr (pSXXF/Y) motifs of their target proteins.
This ability requires a specific fold which only these domains have. While there is one
specific BRCT domain superfamily, this superfamily has proteins that have a multiplicity
of BRCT domains within their protein structure. This allows for a more specific binding
capacity. This feature is also what makes the BRCT domain superfamily unique amongst
other modular domains.

163
Many of the BRCT domain-containing proteins have been previously observed in
regulatory roles of various DNA damage repair pathways. However, there are some
BRCT domains that have little to no known roles in DNA repair pathways. For example,
PARP4 and PES1 have yet to be associated with roles in DNA damage repair. There
have been published works in recent years that have identified germline variants in
PARP4 in cases of both breast and thyroid cancers 281-283. Yet, the function of the BRCT
domain in PARP4 has yet to be determined. While it has been assumed to be similar to
its fellow PARP family member PARP1 because of its common BRCT domain, there has
not been any published evidence of its involvement in BER with PARP1. In contrast,
there have been some published findings about the importance of the PES1 BRCT
domain. The BRCT domain in PES1 has been essential for its nucleolar localization,
chromatin unfolding, rRNA processing, protein stability, and incorporation into the Pes1Bop1-WDR12 (PeBoW) complex 284-287. However, although it has a chromatin
decondensation function like BRCA1, it has not been found to be associated with a DNA
repair pathway. PES1 may possibly have an upstream function that allows for damaged
DNA to be unwound and accessible for subsequent repair.
Functional Implications of BRCA1 and the mTORC2 Complex
BRCA1 is the most widely studied BRCT domain-containing protein in the BRCT
superfamily. TAP-MS has identified the BRCT domain of BRCA1 as interacting with
members of the mTORC2 complex 72. While it was found that BRCA1 dissociates the
mTORC2 complex and impairs Akt activation, the mechanistic implications require
further study. It could be possible that the mTORC2 complex phosphorylates BRCA1 to
negatively regulate its function. The mTORC2 complex is largely associated with its
cytosolic localization. However, there have been findings that have shown mTORC2 to
be in the nucleus as well 288. Since Akt has been found to inhibit BRCA1 nuclear
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localization, this could be a possible reason for BRCA1 to dissociate the members of the
mTORC2 complex 165,166. Akt is also a known regulator of the progression from G2 to M
phase 157. BRCA1 could be regulating Akt phosphorylation to prevent progression to
mitosis while aiding in DNA repair. Moreover, BRCA1 may require one of the mTORC2
proteins, such as RICTOR, to help it fulfill a particular DDR-related function in the
nucleus. More experiments will have to be conducted to determine the mechanistic role
of RICTOR and mTORC2 complex within the nucleus.
Our research has determined that BRCA1-deficient breast cancer cells are more
sensitive to mTOR inhibitors than breast cancer cells with full-length BRCA1. This
sensitivity could be a feature of BRCA1-deficient cells because of possible chromosomal
instability promoted by Akt activation 167. This signaling axis could be studied in other
cancers, especially cancers that exhibit high levels of Akt activation and/or BRCA1 lossof-function mutations. BRCA1 has also been known as an ovarian cancer susceptibility
gene. Ovarian cancer patients with germline BRCA1 mutations may also benefit from the
use of mTOR inhibitors.
Potential Implications for the Novel DDR Functions of CTDP1
These novel findings delineate the molecular mechanisms underlying the cellular
role of the CTDP1 BRCT domain through pathways identifiable in its protein interaction
network. Our previous analysis of 7 tandem BRCT domains using the same TAP-MS
approach did not yield any interactions with FANCI, FANCA, or FANCD2 72, indicating
that this is a unique functional association between the CTDP1 BRCT domain and the
FA pathway that does not exist for the previously studied tandem BRCT domains. It
should be noted that while the interaction between the CTDP1 BRCT domain and FANCI
is unique, the interaction between BRCT domains and FA proteins is not. For instance,
the tandem BRCT domains of BRCA1, a FA protein itself, interact with FANCJ (BRIP1),
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and the BRCT domains of ECT2 interact with FANCM 72. This suggests that BRCT
domains may have evolved plasticity in terms of their individual protein partners while
maintaining associations with specific DNA repair pathways.
The impact of CTDP1 knockdown on FANCI is particularly intriguing because it
promotes the localization of FANCI to chromatin even in the absence of exogenous ICL
caused by MMC. This observation is reminiscent of previous studies examining the
effect of USP1 silencing on FANCD2 localization to chromatin 226. Additionally, CTDP1
knockdown prevents the normal interaction of FANCI with γH2AX following DNA
damage induction, which would effectively prevent the FA repair pathway. This indicates
that correct localization of FANCI to sites of DNA damage marked by γH2AX is regulated
by CTDP1, potentially through regulation of its phosphorylation PTM profile (Figure 4.1).
Indeed, preliminary data from our group has identified five phosphorylation sites on
FANCI regulated in a CTDP1 phosphatase-dependent manner (Figure 4.2). Our work
continues to functionally classify these phosphorylation sites on FANCI.
There are ongoing efforts to evaluate the mechanistic role of proteins involved in
the reset of the FA pathway. In order to determine if CTDP1 a true phosphatase
regulating this pathway, its role in replication fork restart must be explored. We have
found in one BrdU-EdU pulse chase experiment that CTDP1 knockdown prevents
replication fork restart in HCT116 cells (unpublished data). Also, because the USP1UAF1 deubiquitinating enzyme is essential for replication fork restart, more experiments
would have to be conducted to determine if CTDP1 is required for this deubiquitination
or vice versa. Dormant origin firing is necessary in order to occur prior to repair and
replication restart. Because CTDP1 promotes FANCI phosphorylation at sites that are
required for dormant origin firing, it would also be important to determine the role of
CTDP1 in this process.

166

Figure 4.1: CTDP1 regulates FANCI SQ phosphorylations to promote ICL repair.
This is a model of the findings in Hu & Krieger, et al. that represents the role of CTDP1
in ICL repair. When CTDP1 interacts with FANCI, this promotes the activation of FANCI
via phosphorylations at the Ser-556 and Ser-559 sites in the SQ motif. Phosphorylated
FANCI precedes the mono-ubiquitination of FANCI and FANCD2. The FANCI-FANCD2
complex, when activated via mono-ubiquitination, promotes ICL repair in the Fanconi
anemia pathway. When CTDP1 is not present, FANCI and FANCD2 cannot become
activated. This leads to impairment of the ICL repair pathway.
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Figure 4.2: CTDP1 regulates the FANCI phosphoproteome.
FANCI contains a serine-glutamine (SQ) motif that is a preferred phosphorylation motif
for DNA damage kinases ATM and ATR. Phosphorylation of FANCI and monoubiquitination of FANCI at Lysine-523 (K523) is also required for FANCI activity. Using
tandem affinity purification coupled to mass spectrometry (TAP-MS), we have identified
phosphorylations on FANCI that are regulated by CTDP1 overexpression. With mass
spectrometry, we have identified peptides that cover 54% of the FANCI protein
(identified in yellow). Post-translational modifications of FANCI that were detected from
the experiment are identified with green bars. Comparing experiments with
overexpression of empty vector control, CTDP1 WT, and phosphatase-dead mutant
CTDP1 D302K, we have found five candidate phosphorylations that are regulated by
CTDP1 phosphatase activity. Future experiments will help to determine how CTDP1regulation of FANCI phosphorylation at these particular sites contribute to FANCImediated ICL repair.
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The DDR is regulated by many different PTMs that are important for signaling
events for activation, recruitment, and DNA repair. CTDP1 has been shown to promote
FANCI phosphorylation at sites within its SQ motif 1. It is not an anomaly for a
phosphatase to promote the activation of DDR proteins. Freeman & Monteiro have
identified a few known phosphatases in the DDR that positively regulate DDR signaling
molecules 289. PP5 was found to be important to bind to ATR in order for ATR to
phosphorylate and activate CHK1 and promote the S-phase replication checkpoint 289.
PP5 was also important for ATM autophosphorylation and progression through the G2/M
checkpoint 289. Phosphatases PP1, PP6, and PP2A have also been found to promote
DNA-PK activity in the DDR to promote DSB repair 289. These findings show an
importance for the activation of DDR kinases by not only kinase activity, but also
phosphatase activity.
Currently, there are no reported cancer-associated mutations in CTDP1.
According to The Cancer Genome Atlas (TCGA), CTDP1 has been found to be altered
in a wide array of cancers. There is a cohort of malignant peripheral nerve sheath tumor
patients in which 20% of patients have CTDP1 amplifications (Figure 4.3). This finding is
intriguing since the only disease association with CTDP1 is with CCFDN, a neuropathy
that is characterized from demyelination of nerve sheaths. Perhaps, there is a cell typespecific function that CTDP1 executes in Schwann cell development or differentiation, in
regard to myelin sheaths. The molecular phenotype correlative with CTDP1 amplification
in Schwann cells or neuropathies in general have yet to be explored.
The inhibition of in vitro and in vivo growth of breast cancer cell lines but not
normal breast derived MCF-10A also suggests that CTDP1 could become an important
target for breast cancer therapeutic development. The only breast cell line we tested that
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Figure 4.3: CTDP1 alterations found in cancers, according to The Cancer Genome
Atlas.

This graph generated with cBIOPORTAL encompasses data from multiple cancer
studies deposited into The Cancer Genome Atlas (TCGA). These data reveal CTDP1
mutations, deletions, and amplications. Interestingly, cancers derived from nerve sheath
tumors, usually referred to as malignant peripheral nerve sheath tumors or MPNSTs,
have 20% frequency of CTDP1 amplification.
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tolerated CTDP1 knockdown well was the MCF-10A cell line, which is derived from
normal breast tissue and is considered immortalized but not transformed. Breast cancer
cell dependence on CTDP1 expression for survival is congruent with previous findings in
gastric and lung cancer 262,263, but the effects of CTDP1 expression on non-cancerderived human cells had not been previously examined. Tumor cells may preferentially
require CTDP1 to survive increased levels of DNA damage brought on by deregulated
checkpoints and elevated metabolic stress, although the impact of CTDP1 on other
cellular processes, such as transcription, should not be ruled out. Additional findings and
experiments are needed to decouple CTDP1’s transcription-related function from its
DNA damage-related function to determine what the Achilles’ heel could be.
It is likely that CTDP1 affects multiple cellular processes important for cancer as
evidenced by the numerous unexplored BRCT-mediated interactions we have
uncovered. It is not mechanistically clear how CTDP1 knockdown ultimately leads to
cancer cell death. It is possible that CTDP1 knockdown could be causing catastrophic
chromosomal instability, with numerous aberrations that leads to massive amounts of
DNA damage that is not able to be repaired. Also, more experiments will be needed to
address how cell death pathways are induced after massive amounts of DNA damage
caused by CTDP1 knockdown. Since it is already known that cell death induced by
CTDP1 knockdown is ATM- and ATR-independent, other signaling molecules, such as
p53, may need to be explored. Thus, additional studies of CTDP1 BRCT interactions,
including FANCI, have the potential to reveal new functional insights into the role this
unique BRCT domain-containing phosphatase plays in the DDR and cancer biology.

171
REFERENCES
1

Hu, W. F., Krieger, K. L., Lagundzin, D., Li, X., Cheung, R. S., Taniguchi, T.,
Johnson, K. R., Bessho, T., Monteiro, A. N. A. & Woods, N. T. CTDP1 regulates
breast cancer survival and DNA repair through BRCT-specific interactions with
FANCI. Cell Death Discov 5, 105, doi:10.1038/s41420-019-0185-3 (2019).

2

Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70,
doi:10.1016/s0092-8674(00)81683-9 (2000).

3

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).

4

Knudson, A. G., Jr. Mutation and cancer: statistical study of retinoblastoma. Proc
Natl Acad Sci U S A 68, 820-823, doi:10.1073/pnas.68.4.820 (1971).

5

Corrie, P. G. Cytotoxic chemotherapy: clinical aspects. Medicine 36, 24-28,
doi:10.1016/j.mpmed.2007.10.012 (2008).

6

Ding, Y. C., Steele, L., Chu, L. H., Kelley, K., Davis, H., John, E. M., Tomlinson,
G. E. & Neuhausen, S. L. Germline mutations in PALB2 in African-American
breast cancer cases. Breast Cancer Res Treat 126, 227-230,
doi:10.1007/s10549-010-1271-7 (2011).

7

Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A.,
Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., Welch, M.
W., Reilly, E., McCabe, D., Marini, L., Anderka, K., Helvie, K., Oliver, N., Babic,
A., Da Silva, A., Nadres, B. et al. Real-time Genomic Characterization of
Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8,
1096-1111, doi:10.1158/2159-8290.CD-18-0275 (2018).

8

Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W.,
Lin, J. C., Palmisano, E., Brune, K., Jaffee, E. M., Iacobuzio-Donahue, C. A.,
Maitra, A., Parmigiani, G., Kern, S. E., Velculescu, V. E., Kinzler, K. W.,

172
Vogelstein, B., Eshleman, J. R., Goggins, M. & Klein, A. P. Exomic sequencing
identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217,
doi:10.1126/science.1171202 (2009).
9

Al-Sukhni, W., Rothenmund, H., Borgida, A. E., Zogopoulos, G., O'Shea, A. M.,
Pollett, A. & Gallinger, S. Germline BRCA1 mutations predispose to pancreatic
adenocarcinoma. Hum Genet 124, 271-278, doi:10.1007/s00439-008-0554-0
(2008).

10

Janezic, S. A., Ziogas, A., Krumroy, L. M., Krasner, M., Plummer, S. J., Cohen,
P., Gildea, M., Barker, D., Haile, R., Casey, G. & Anton-Culver, H. Germline
BRCA1 alterations in a population-based series of ovarian cancer cases. Hum
Mol Genet 8, 889-897, doi:10.1093/hmg/8.5.889 (1999).

11

Valarmathi, M. T., Sawhney, M., Deo, S. S., Shukla, N. K. & Das, S. N. Novel
germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breastovarian cancer families. Hum Mutat 23, 205, doi:10.1002/humu.9213 (2004).

12

Meyer, P., Voigtlaender, T., Bartram, C. R. & Klaes, R. Twenty-three novel
BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer
families in Southern Germany. Hum Mutat 22, 259, doi:10.1002/humu.9174
(2003).

13

Foo, T. K., Tischkowitz, M., Simhadri, S., Boshari, T., Zayed, N., Burke, K. A.,
Berman, S. H., Blecua, P., Riaz, N., Huo, Y., Ding, Y. C., Neuhausen, S. L.,
Weigelt, B., Reis-Filho, J. S., Foulkes, W. D. & Xia, B. Compromised BRCA1PALB2 interaction is associated with breast cancer risk. Oncogene 36, 41614170, doi:10.1038/onc.2017.46 (2017).

14

Tischkowitz, M., Capanu, M., Sabbaghian, N., Li, L., Liang, X., Vallee, M. P.,
Tavtigian, S. V., Concannon, P., Foulkes, W. D., Bernstein, L., Group, W. S. C.,
Bernstein, J. L. & Begg, C. B. Rare germline mutations in PALB2 and breast

173
cancer risk: a population-based study. Hum Mutat 33, 674-680,
doi:10.1002/humu.22022 (2012).
15

Erkko, H., Xia, B., Nikkila, J., Schleutker, J., Syrjakoski, K., Mannermaa, A.,
Kallioniemi, A., Pylkas, K., Karppinen, S. M., Rapakko, K., Miron, A., Sheng, Q.,
Li, G., Mattila, H., Bell, D. W., Haber, D. A., Grip, M., Reiman, M., JukkolaVuorinen, A., Mustonen, A. et al. A recurrent mutation in PALB2 in Finnish
cancer families. Nature 446, 316-319, doi:10.1038/nature05609 (2007).

16

Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., Cao, S. & Li, X. Association
Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.
Front Pharmacol 9, 909, doi:10.3389/fphar.2018.00909 (2018).

17

Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy:
lessons learned from the development of PARP inhibitors. Annu Rev Med 66,
455-470, doi:10.1146/annurev-med-050913-022545 (2015).

18

Christou, C. M. & Kyriacou, K. BRCA1 and Its Network of Interacting Partners.
Biology (Basel) 2, 40-63, doi:10.3390/biology2010040 (2013).

19

Baer, R. & Ludwig, T. The BRCA1/BARD1 heterodimer, a tumor suppressor
complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 12, 86-91 (2002).

20

Saha, J. & Davis, A. J. Unsolved mystery: the role of BRCA1 in DNA end-joining.
J Radiat Res 57 Suppl 1, i18-i24, doi:10.1093/jrr/rrw032 (2016).

21

Caestecker, K. W. & Van de Walle, G. R. The role of BRCA1 in DNA doublestrand repair: past and present. Exp Cell Res 319, 575-587,
doi:10.1016/j.yexcr.2012.11.013 (2013).

22

Starita, L. M., Horwitz, A. A., Keogh, M. C., Ishioka, C., Parvin, J. D. & Chiba, N.
BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem
280, 24498-24505, doi:10.1074/jbc.M414020200 (2005).

174
23

Mallery, D. L., Vandenberg, C. J. & Hiom, K. Activation of the E3 ligase function
of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J 21, 6755-6762,
doi:10.1093/emboj/cdf691 (2002).

24

Clark, S. L., Rodriguez, A. M., Snyder, R. R., Hankins, G. D. & Boehning, D.
Structure-Function Of The Tumor Suppressor BRCA1. Comput Struct Biotechnol
J 1, doi:10.5936/csbj.201204005 (2012).

25

Hartlerode, A. J. & Scully, R. Mechanisms of double-strand break repair in
somatic mammalian cells. Biochem J 423, 157-168, doi:10.1042/BJ20090942
(2009).

26

Anantha, R. W., Simhadri, S., Foo, T. K., Miao, S., Liu, J., Shen, Z., Ganesan, S.
& Xia, B. Functional and mutational landscapes of BRCA1 for homology-directed
repair and therapy resistance. Elife 6, doi:10.7554/eLife.21350 (2017).

27

Woods, N. T., Baskin, R., Golubeva, V., Jhuraney, A., De-Gregoriis, G., Vaclova,
T., Goldgar, D. E., Couch, F. J., Carvalho, M. A., Iversen, E. S. & Monteiro, A. N.
A. Functional assays provide a robust tool for the clinical annotation of genetic
variants of uncertain significance. Npj Genomic Medicine 1, 16001,
doi:10.1038/npjgenmed.2016.1

http://www.nature.com/articles/npjgenmed20161#supplementary-information (2016).
28

Sy, S. M., Huen, M. S. & Chen, J. PALB2 is an integral component of the BRCA
complex required for homologous recombination repair. Proc Natl Acad Sci U S
A 106, 7155-7160, doi:10.1073/pnas.0811159106 (2009).

29

Phelan, C. M., Dapic, V., Tice, B., Favis, R., Kwan, E., Barany, F., Manoukian,
S., Radice, P., van der Luijt, R. B., van Nesselrooij, B. P., Chenevix-Trench, G.,
kConFab, Caldes, T., de la Hoya, M., Lindquist, S., Tavtigian, S. V., Goldgar, D.,
Borg, A., Narod, S. A. & Monteiro, A. N. Classification of BRCA1 missense

175
variants of unknown clinical significance. J Med Genet 42, 138-146,
doi:10.1136/jmg.2004.024711 (2005).
30

Koonin, E. V., Altschul, S. F. & Bork, P. BRCA1 protein products ... Functional
motifs. Nat Genet 13, 266-268, doi:10.1038/ng0796-266 (1996).

31

Makiniemi, M., Hillukkala, T., Tuusa, J., Reini, K., Vaara, M., Huang, D.,
Pospiech, H., Majuri, I., Westerling, T., Makela, T. P. & Syvaoja, J. E. BRCT
domain-containing protein TopBP1 functions in DNA replication and damage
response. J Biol Chem 276, 30399-30406, doi:10.1074/jbc.M102245200 (2001).

32

Schar, P., Herrmann, G., Daly, G. & Lindahl, T. A newly identified DNA ligase of
Saccharomyces cerevisiae involved in RAD52-independent repair of DNA
double-strand breaks. Genes & development 11, 1912-1924 (1997).

33

Ramadan, K., Shevelev, I. V., Maga, G. & Hubscher, U. DNA polymerase lambda
from calf thymus preferentially replicates damaged DNA. J Biol Chem 277,
18454-18458, doi:10.1074/jbc.M200421200 (2002).

34

Fabbro, M., Rodriguez, J. A., Baer, R. & Henderson, B. R. BARD1 induces
BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1
nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 277, 2131521324, doi:10.1074/jbc.M200769200 (2002).

35

Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. & Elledge, S. J. MDC1 is a
mediator of the mammalian DNA damage checkpoint. Nature 421, 961-966,
doi:10.1038/nature01446 (2003).

36

Mochan, T. A., Venere, M., DiTullio, R. A., Jr. & Halazonetis, T. D. 53BP1 and
NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxiatelangiectasia mutated (ATM) in response to DNA damage. Cancer research 63,
8586-8591 (2003).

176
37

Tatsumoto, T., Xie, X., Blumenthal, R., Okamoto, I. & Miki, T. Human ECT2 is an
exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved
in cytokinesis. J Cell Biol 147, 921-928 (1999).

38

Cho, E. A., Prindle, M. J. & Dressler, G. R. BRCT domain-containing protein
PTIP is essential for progression through mitosis. Mol Cell Biol 23, 1666-1673
(2003).

39

Rodriguez, M., Yu, X., Chen, J. & Songyang, Z. Phosphopeptide binding
specificities of BRCA1 COOH-terminal (BRCT) domains. J Biol Chem 278,
52914-52918, doi:10.1074/jbc.C300407200 (2003).

40

Manke, I. A., Lowery, D. M., Nguyen, A. & Yaffe, M. B. BRCT repeats as
phosphopeptide-binding modules involved in protein targeting. Science 302, 636639, doi:10.1126/science.1088877 (2003).

41

Clapperton, J. A., Manke, I. A., Lowery, D. M., Ho, T., Haire, L. F., Yaffe, M. B. &
Smerdon, S. J. Structure and mechanism of BRCA1 BRCT domain recognition of
phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11, 512518, doi:10.1038/nsmb775 (2004).

42

Stucki, M., Clapperton, J. A., Mohammad, D., Yaffe, M. B., Smerdon, S. J. &
Jackson, S. P. MDC1 directly binds phosphorylated histone H2AX to regulate
cellular responses to DNA double-strand breaks. Cell 123, 1213-1226,
doi:10.1016/j.cell.2005.09.038 (2005).

43

Williams, R. S., Green, R. & Glover, J. N. Crystal structure of the BRCT repeat
region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8, 838842, doi:10.1038/nsb1001-838 (2001).

44

Cantor, S. B., Bell, D. W., Ganesan, S., Kass, E. M., Drapkin, R., Grossman, S.,
Wahrer, D. C., Sgroi, D. C., Lane, W. S., Haber, D. A. & Livingston, D. M.

177
BACH1, a novel helicase-like protein, interacts directly with BRCA1 and
contributes to its DNA repair function. Cell 105, 149-160 (2001).
45

Dore, A. S., Furnham, N., Davies, O. R., Sibanda, B. L., Chirgadze, D. Y.,
Jackson, S. P., Pellegrini, L. & Blundell, T. L. Structure of an Xrcc4-DNA ligase
IV yeast ortholog complex reveals a novel BRCT interaction mode. DNA Repair
(Amst) 5, 362-368, doi:10.1016/j.dnarep.2005.11.004 (2006).

46

Goldberg, M., Stucki, M., Falck, J., D'Amours, D., Rahman, D., Pappin, D.,
Bartek, J. & Jackson, S. P. MDC1 is required for the intra-S-phase DNA damage
checkpoint. Nature 421, 952-956, doi:10.1038/nature01445 (2003).

47

Huen, M. S., Sy, S. M. & Chen, J. BRCA1 and its toolbox for the maintenance of
genome integrity. Nat Rev Mol Cell Biol 11, 138-148, doi:10.1038/nrm2831
(2010).

48

Wang, B. BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci 2, 6,
doi:10.1186/2045-3701-2-6 (2012).

49

Leung, C. C. & Glover, J. N. BRCT domains: easy as one, two, three. Cell Cycle
10, 2461-2470, doi:10.4161/cc.10.15.16312 (2011).

50

Bigot, N., Day, M., Baldock, R. A., Watts, F. Z., Oliver, A. W. & Pearl, L. H.
Phosphorylation-mediated interactions with TOPBP1 couple 53BP1 and 9-1-1 to
control the G1 DNA damage checkpoint. Elife 8, doi:10.7554/eLife.44353 (2019).

51

Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B. &
King, M. C. Linkage of early-onset familial breast cancer to chromosome 17q21.
Science 250, 1684-1689 (1990).

52

Narod, S. A., Feunteun, J., Lynch, H. T., Watson, P., Conway, T., Lynch, J. &
Lenoir, G. M. Familial breast-ovarian cancer locus on chromosome 17q12-q23.
Lancet 338, 82-83 (1991).

178
53

Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K.,
Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W. & et al. A strong
candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science
266, 66-71 (1994).

54

Welcsh, P. L. & King, M. C. BRCA1 and BRCA2 and the genetics of breast and
ovarian cancer. Hum Mol Genet 10, 705-713 (2001).

55

Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K.,
Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y. & et al.
BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120122 (1994).

56

Wilson, C. A., Ramos, L., Villasenor, M. R., Anders, K. H., Press, M. F., Clarke,
K., Karlan, B., Chen, J. J., Scully, R., Livingston, D., Zuch, R. H., Kanter, M. H.,
Cohen, S., Calzone, F. J. & Slamon, D. J. Localization of human BRCA1 and its
loss in high-grade, non-inherited breast carcinomas. Nat Genet 21, 236-240,
doi:10.1038/6029 (1999).

57

Bienstock, R. J., Darden, T., Wiseman, R., Pedersen, L. & Barrett, J. C.
Molecular modeling of the amino-terminal zinc ring domain of BRCA1. Cancer
research 56, 2539-2545 (1996).

58

Stewart, M. D., Duncan, E. D., Coronado, E., DaRosa, P. A., Pruneda, J. N.,
Brzovic, P. S. & Klevit, R. E. Tuning BRCA1 and BARD1 activity to investigate
RING ubiquitin ligase mechanisms. Protein Sci 26, 475-483,
doi:10.1002/pro.3091 (2017).

59

Domchek, S. M., Tang, J., Stopfer, J., Lilli, D. R., Hamel, N., Tischkowitz, M.,
Monteiro, A. N., Messick, T. E., Powers, J., Yonker, A., Couch, F. J., Goldgar, D.
E., Davidson, H. R., Nathanson, K. L., Foulkes, W. D. & Greenberg, R. A.

179
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian
cancer. Cancer Discov 3, 399-405, doi:10.1158/2159-8290.CD-12-0421 (2013).
60

Keupp, K., Hampp, S., Hubbel, A., Maringa, M., Kostezka, S., Rhiem, K., Waha,
A., Wappenschmidt, B., Pujol, R., Surralles, J., Schmutzler, R. K., Wiesmuller, L.
& Hahnen, E. Biallelic germline BRCA1 mutations in a patient with early onset
breast cancer, mild Fanconi anemia-like phenotype, and no chromosome
fragility. Mol Genet Genomic Med 7, e863, doi:10.1002/mgg3.863 (2019).

61

Sawyer, S. L., Tian, L., Kahkonen, M., Schwartzentruber, J., Kircher, M.,
University of Washington Centre for Mendelian, G., Consortium, F. C., Majewski,
J., Dyment, D. A., Innes, A. M., Boycott, K. M., Moreau, L. A., Moilanen, J. S. &
Greenberg, R. A. Biallelic mutations in BRCA1 cause a new Fanconi anemia
subtype. Cancer Discov 5, 135-142, doi:10.1158/2159-8290.CD-14-1156 (2015).

62

Bondavalli, D., Malvestiti, F., Pensotti, V., Feroce, I. & Bonanni, B. BRCA1
homozygous unclassified variant in a patient with non-Fanconi anemia: A case
report. Oncol Lett 15, 3329-3332, doi:10.3892/ol.2017.7711 (2018).

63

Freire, B. L., Homma, T. K., Funari, M. F. A., Lerario, A. M., Leal, A. M., Velloso,
E., Malaquias, A. C. & Jorge, A. A. L. Homozygous loss of function BRCA1
variant causing a Fanconi-anemia-like phenotype, a clinical report and review of
previous patients. Eur J Med Genet 61, 130-133, doi:10.1016/j.ejmg.2017.11.003
(2018).

64

Seo, A., Steinberg-Shemer, O., Unal, S., Casadei, S., Walsh, T., Gumruk, F.,
Shalev, S., Shimamura, A., Akarsu, N. A., Tamary, H. & King, M. C. Mechanism
for survival of homozygous nonsense mutations in the tumor suppressor gene
BRCA1. Proc Natl Acad Sci U S A 115, 5241-5246,
doi:10.1073/pnas.1801796115 (2018).

180
65

Goldgar, D. E., Easton, D. F., Deffenbaugh, A. M., Monteiro, A. N., Tavtigian, S.
V., Couch, F. J. & Breast Cancer Information Core Steering, C. Integrated
evaluation of DNA sequence variants of unknown clinical significance: application
to BRCA1 and BRCA2. Am J Hum Genet 75, 535-544, doi:10.1086/424388
(2004).

66

Evers, B. & Jonkers, J. Mouse models of BRCA1 and BRCA2 deficiency: past
lessons, current understanding and future prospects. Oncogene 25, 5885-5897,
doi:10.1038/sj.onc.1209871 (2006).

67

Rodriguez, M. C. & Songyang, Z. BRCT domains: phosphopeptide binding and
signaling modules. Front Biosci 13, 5905-5915 (2008).

68

Glover, J. N., Williams, R. S. & Lee, M. S. Interactions between BRCT repeats
and phosphoproteins: tangled up in two. Trends Biochem Sci 29, 579-585,
doi:10.1016/j.tibs.2004.09.010 (2004).

69

Mesquita, R. D., Woods, N. T., Seabra-Junior, E. S. & Monteiro, A. N. Tandem
BRCT Domains: DNA's Praetorian Guard. Genes Cancer 1, 1140-1146,
doi:10.1177/1947601910392988 (2010).

70

Gerloff, D. L., Woods, N. T., Farago, A. A. & Monteiro, A. N. BRCT domains: A
little more than kin, and less than kind. FEBS Lett 586, 2711-2716,
doi:10.1016/j.febslet.2012.05.005 (2012).

71

Zou, Y., Shao, Z., Peng, J., Li, F., Gong, D., Wang, C., Zuo, X., Zhang, Z., Wu,
J., Shi, Y. & Gong, Q. Crystal structure of triple-BRCT-domain of ECT2 and
insights into the binding characteristics to CYK-4. FEBS Lett 588, 2911-2920,
doi:10.1016/j.febslet.2014.07.019 (2014).

72

Woods, N. T., Mesquita, R. D., Sweet, M., Carvalho, M. A., Li, X., Liu, Y.,
Nguyen, H., Thomas, C. E., Iversen, E. S., Jr., Marsillac, S., Karchin, R.,
Koomen, J. & Monteiro, A. N. Charting the landscape of tandem BRCT domain-

181
mediated protein interactions. Science signaling 5, rs6,
doi:10.1126/scisignal.2002255 (2012).
73

Mermershtain, I. & Glover, J. N. Structural mechanisms underlying signaling in
the cellular response to DNA double strand breaks. Mutat Res 750, 15-22,
doi:10.1016/j.mrfmmm.2013.07.004 (2013).

74

Thompson, L. H. Recognition, signaling, and repair of DNA double-strand breaks
produced by ionizing radiation in mammalian cells: the molecular choreography.
Mutat Res 751, 158-246, doi:10.1016/j.mrrev.2012.06.002 (2012).

75

Panier, S. & Boulton, S. J. Double-strand break repair: 53BP1 comes into focus.
Nat Rev Mol Cell Biol 15, 7-18, doi:10.1038/nrm3719 (2014).

76

Nepomuceno, T. C., Fernandes, V. C., Gomes, T. T., Carvalho, R. S., SuarezKurtz, G., Monteiro, A. N. & Carvalho, M. A. BRCA1 recruitment to damaged
DNA sites is dependent on CDK9. Cell Cycle 16, 665-672,
doi:10.1080/15384101.2017.1295177 (2017).

77

Yu, X., Chini, C. C., He, M., Mer, G. & Chen, J. The BRCT domain is a phosphoprotein binding domain. Science 302, 639-642, doi:10.1126/science.1088753
(2003).

78

Mossi, R., Jonsson, Z. O., Allen, B. L., Hardin, S. H. & Hubscher, U. Replication
factor C interacts with the C-terminal side of proliferating cell nuclear antigen. J
Biol Chem 272, 1769-1776, doi:10.1074/jbc.272.3.1769 (1997).

79

Sisakova, A., Altmannova, V., Sebesta, M. & Krejci, L. Role of PCNA and RFC in
promoting Mus81-complex activity. BMC Biol 15, 90, doi:10.1186/s12915-0170429-8 (2017).

80

Williams, R. S., Lee, M. S., Hau, D. D. & Glover, J. N. Structural basis of
phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol
11, 519-525, doi:10.1038/nsmb776 (2004).

182
81

Huyton, T., Bates, P. A., Zhang, X., Sternberg, M. J. & Freemont, P. S. The
BRCA1 C-terminal domain: structure and function. Mutat Res 460, 319-332,
doi:10.1016/s0921-8777(00)00034-3 (2000).

82

Derbyshire, D. J., Basu, B. P., Serpell, L. C., Joo, W. S., Date, T., Iwabuchi, K. &
Doherty, A. J. Crystal structure of human 53BP1 BRCT domains bound to p53
tumour suppressor. EMBO J 21, 3863-3872, doi:10.1093/emboj/cdf383 (2002).

83

Joo, W. S., Jeffrey, P. D., Cantor, S. B., Finnin, M. S., Livingston, D. M. &
Pavletich, N. P. Structure of the 53BP1 BRCT region bound to p53 and its
comparison to the Brca1 BRCT structure. Genes & development 16, 583-593,
doi:10.1101/gad.959202 (2002).

84

Huo, Y. G., Bai, L., Xu, M. & Jiang, T. Crystal structure of the N-terminal region of
human Topoisomerase IIbeta binding protein 1. Biochem Biophys Res Commun
401, 401-405, doi:10.1016/j.bbrc.2010.09.066 (2010).

85

Rappas, M., Oliver, A. W. & Pearl, L. H. Structure and function of the Rad9binding region of the DNA-damage checkpoint adaptor TopBP1. Nucleic Acids
Res 39, 313-324, doi:10.1093/nar/gkq743 (2011).

86

Munoz, I. M., Jowsey, P. A., Toth, R. & Rouse, J. Phospho-epitope binding by
the BRCT domains of hPTIP controls multiple aspects of the cellular response to
DNA damage. Nucleic Acids Res 35, 5312-5322, doi:10.1093/nar/gkm493
(2007).

87

Jowsey, P. A., Doherty, A. J. & Rouse, J. Human PTIP facilitates ATM-mediated
activation of p53 and promotes cellular resistance to ionizing radiation. J Biol
Chem 279, 55562-55569, doi:10.1074/jbc.M411021200 (2004).

88

Chapman, M. S. & Verma, I. M. Transcriptional activation by BRCA1. Nature 382,
678-679, doi:10.1038/382678a0 (1996).

183
89

Monteiro, A. N., August, A. & Hanafusa, H. Evidence for a transcriptional
activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 93,
13595-13599, doi:10.1073/pnas.93.24.13595 (1996).

90

Haile, D. T. & Parvin, J. D. Activation of transcription in vitro by the BRCA1
carboxyl-terminal domain. J Biol Chem 274, 2113-2117,
doi:10.1074/jbc.274.4.2113 (1999).

91

Lane, T. F. BRCA1 and transcription. Cancer Biol Ther 3, 528-533,
doi:10.4161/cbt.3.6.843 (2004).

92

Scully, R., Anderson, S. F., Chao, D. M., Wei, W., Ye, L., Young, R. A.,
Livingston, D. M. & Parvin, J. D. BRCA1 is a component of the RNA polymerase
II holoenzyme. Proc Natl Acad Sci U S A 94, 5605-5610,
doi:10.1073/pnas.94.11.5605 (1997).

93

Anderson, S. F., Schlegel, B. P., Nakajima, T., Wolpin, E. S. & Parvin, J. D.
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA
helicase A. Nat Genet 19, 254-256, doi:10.1038/930 (1998).

94

Chai, Y. L., Cui, J., Shao, N., Shyam, E., Reddy, P. & Rao, V. N. The second
BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription
from the p21WAF1/CIP1 promoter. Oncogene 18, 263-268,
doi:10.1038/sj.onc.1202323 (1999).

95

Li, S., Chen, P. L., Subramanian, T., Chinnadurai, G., Tomlinson, G., Osborne,
C. K., Sharp, Z. D. & Lee, W. H. Binding of CtIP to the BRCT repeats of BRCA1
involved in the transcription regulation of p21 is disrupted upon DNA damage. J
Biol Chem 274, 11334-11338, doi:10.1074/jbc.274.16.11334 (1999).

96

Nadeau, G., Boufaied, N., Moisan, A., Lemieux, K. M., Cayanan, C., Monteiro, A.
N. & Gaudreau, L. BRCA1 can stimulate gene transcription by a unique
mechanism. EMBO Rep 1, 260-265, doi:10.1093/embo-reports/kvd059 (2000).

184
97

Monteiro, A. N. BRCA1: exploring the links to transcription. Trends Biochem Sci
25, 469-474 (2000).

98

Monteiro, A. N. Participation of BRCA1 in the DNA repair response...via
transcription. Cancer Biol Ther 1, 187-188, doi:10.4161/cbt.66 (2002).

99

Moiola, C., De Luca, P., Cotignola, J., Gardner, K., Vazquez, E. & De Siervi, A.
Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM
transcription. Cell Physiol Biochem 30, 596-608, doi:10.1159/000341441 (2012).

100

Somasundaram, K. Breast cancer gene 1 (BRCA1): role in cell cycle regulation
and DNA repair--perhaps through transcription. J Cell Biochem 88, 1084-1091,
doi:10.1002/jcb.10469 (2003).

101

Yoshida, K. & Miki, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair,
transcription, and cell cycle in response to DNA damage. Cancer Sci 95, 866871, doi:10.1111/j.1349-7006.2004.tb02195.x (2004).

102

Ouchi, T., Lee, S. W., Ouchi, M., Aaronson, S. A. & Horvath, C. M. Collaboration
of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in
differential regulation of IFN-gamma target genes. Proc Natl Acad Sci U S A 97,
5208-5213, doi:10.1073/pnas.080469697 (2000).

103

Aprelikova, O., Pace, A. J., Fang, B., Koller, B. H. & Liu, E. T. BRCA1 is a
selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic
stem cells. J Biol Chem 276, 25647-25650, doi:10.1074/jbc.C100265200 (2001).

104

Benezra, M., Chevallier, N., Morrison, D. J., MacLachlan, T. K., El-Deiry, W. S. &
Licht, J. D. BRCA1 augments transcription by the NF-kappaB transcription factor
by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 278, 2633326341, doi:10.1074/jbc.M303076200 (2003).

105

Kim, J., Lee, D., Gwan Hwang, S., Hwang, E. S. & Choe, J. BRCA1 associates
with human papillomavirus type 18 E2 and stimulates E2-dependent

185
transcription. Biochem Biophys Res Commun 305, 1008-1016,
doi:10.1016/s0006-291x(03)00880-5 (2003).
106

Johnston, R., D'Costa, Z., Ray, S., Gorski, J., Harkin, D. P., Mullan, P. & Panov,
K. I. The identification of a novel role for BRCA1 in regulating RNA polymerase I
transcription. Oncotarget 7, 68097-68110, doi:10.18632/oncotarget.11770
(2016).

107

Cabart, P., Chew, H. K. & Murphy, S. BRCA1 cooperates with NUFIP and PTEFb to activate transcription by RNA polymerase II. Oncogene 23, 5316-5329,
doi:10.1038/sj.onc.1207684 (2004).

108

Veras, I., Rosen, E. M. & Schramm, L. Inhibition of RNA polymerase III
transcription by BRCA1. J Mol Biol 387, 523-531, doi:10.1016/j.jmb.2009.02.008
(2009).

109

Kawai, H., Li, H., Chun, P., Avraham, S. & Avraham, H. K. Direct interaction
between BRCA1 and the estrogen receptor regulates vascular endothelial growth
factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21,
7730-7739, doi:10.1038/sj.onc.1205971 (2002).

110

Schayek, H., Haugk, K., Sun, S., True, L. D., Plymate, S. R. & Werner, H. Tumor
suppressor BRCA1 is expressed in prostate cancer and controls insulin-like
growth factor I receptor (IGF-IR) gene transcription in an androgen receptordependent manner. Clin Cancer Res 15, 1558-1565, doi:10.1158/10780432.CCR-08-1440 (2009).

111

Park, M. A., Seok, Y. J., Jeong, G. & Lee, J. S. SUMO1 negatively regulates
BRCA1-mediated transcription, via modulation of promoter occupancy. Nucleic
Acids Res 36, 263-283, doi:10.1093/nar/gkm969 (2008).

186
112

Fabbro, M. & Henderson, B. R. BARD1 regulates BRCA1-mediated
transactivation of the p21WAF1/CIP1 and Gadd45 promoters. Cancer Lett 263,
189-196, doi:10.1016/j.canlet.2008.01.001 (2008).

113

Chambers, R. S. & Dahmus, M. E. Purification and characterization of a
phosphatase from HeLa cells which dephosphorylates the C-terminal domain of
RNA polymerase II. J Biol Chem 269, 26243-26248 (1994).

114

Chambers, R. S., Wang, B. Q., Burton, Z. F. & Dahmus, M. E. The activity of
COOH-terminal domain phosphatase is regulated by a docking site on RNA
polymerase II and by the general transcription factors IIF and IIB. J Biol Chem
270, 14962-14969, doi:10.1074/jbc.270.25.14962 (1995).

115

Chambers, R. S. & Kane, C. M. Purification and characterization of an RNA
polymerase II phosphatase from yeast. J Biol Chem 271, 24498-24504,
doi:10.1074/jbc.271.40.24498 (1996).

116

Archambault, J., Chambers, R. S., Kobor, M. S., Ho, Y., Cartier, M., Bolotin, D.,
Andrews, B., Kane, C. M. & Greenblatt, J. An essential component of a Cterminal domain phosphatase that interacts with transcription factor IIF in
Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 94, 14300-14305,
doi:10.1073/pnas.94.26.14300 (1997).

117

Lin, P. S., Dubois, M. F. & Dahmus, M. E. TFIIF-associating carboxyl-terminal
domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA
polymerase II. J Biol Chem 277, 45949-45956, doi:10.1074/jbc.M208588200
(2002).

118

Seifried, A., Schultz, J. & Gohla, A. Human HAD phosphatases: structure,
mechanism, and roles in health and disease. The FEBS journal 280, 549-571,
doi:10.1111/j.1742-4658.2012.08633.x (2013).

187
119

Kobor, M. S., Simon, L. D., Omichinski, J., Zhong, G., Archambault, J. &
Greenblatt, J. A motif shared by TFIIF and TFIIB mediates their interaction with
the RNA polymerase II carboxy-terminal domain phosphatase Fcp1p in
Saccharomyces cerevisiae. Mol Cell Biol 20, 7438-7449,
doi:10.1128/mcb.20.20.7438-7449.2000 (2000).

120

Majello, B. & Napolitano, G. Control of RNA polymerase II activity by dedicated
CTD kinases and phosphatases. Front Biosci 6, D1358-1368 (2001).

121

Robertson, A. B., Klungland, A., Rognes, T. & Leiros, I. DNA repair in
mammalian cells: Base excision repair: the long and short of it. Cell Mol Life Sci
66, 981-993, doi:10.1007/s00018-009-8736-z (2009).

122

Christmann, M., Tomicic, M. T., Roos, W. P. & Kaina, B. Mechanisms of human
DNA repair: an update. Toxicology 193, 3-34, doi:10.1016/s0300-483x(03)002877 (2003).

123

Jagannathan, I., Cole, H. A. & Hayes, J. J. Base excision repair in nucleosome
substrates. Chromosome Res 14, 27-37, doi:10.1007/s10577-005-1020-7 (2006).

124

Carter, R. J. & Parsons, J. L. Base Excision Repair, a Pathway Regulated by
Posttranslational Modifications. Mol Cell Biol 36, 1426-1437,
doi:10.1128/MCB.00030-16 (2016).

125

Moor, N. A. & Lavrik, O. I. Protein-Protein Interactions in DNA Base Excision
Repair. Biochemistry (Mosc) 83, 411-422, doi:10.1134/S0006297918040120
(2018).

126

Wallace, S. S., Murphy, D. L. & Sweasy, J. B. Base excision repair and cancer.
Cancer Lett 327, 73-89, doi:10.1016/j.canlet.2011.12.038 (2012).

127

Campalans, A., Kortulewski, T., Amouroux, R., Menoni, H., Vermeulen, W. &
Radicella, J. P. Distinct spatiotemporal patterns and PARP dependence of

188
XRCC1 recruitment to single-strand break and base excision repair. Nucleic
Acids Res 41, 3115-3129, doi:10.1093/nar/gkt025 (2013).
128

Kunz, B. A., Straffon, A. F. & Vonarx, E. J. DNA damage-induced mutation:
tolerance via translesion synthesis. Mutat Res 451, 169-185, doi:10.1016/s00275107(00)00048-8 (2000).

129

Yagi, T., Fujikawa, Y., Sawai, T., Takamura-Enya, T., Ito-Harashima, S. &
Kawanishi, M. Error-Prone and Error-Free Translesion DNA Synthesis over SiteSpecifically Created DNA Adducts of Aryl Hydrocarbons (3-Nitrobenzanthrone
and 4-Aminobiphenyl). Toxicol Res 33, 265-272, doi:10.5487/TR.2017.33.4.265
(2017).

130

Guo, C., Sonoda, E., Tang, T. S., Parker, J. L., Bielen, A. B., Takeda, S., Ulrich,
H. D. & Friedberg, E. C. REV1 protein interacts with PCNA: significance of the
REV1 BRCT domain in vitro and in vivo. Mol Cell 23, 265-271,
doi:10.1016/j.molcel.2006.05.038 (2006).

131

Yang, K., Weinacht, C. P. & Zhuang, Z. Regulatory role of ubiquitin in eukaryotic
DNA translesion synthesis. Biochemistry 52, 3217-3228, doi:10.1021/bi400194r
(2013).

132

Korzhnev, D. M. & Hadden, M. K. Targeting the Translesion Synthesis Pathway
for the Development of Anti-Cancer Chemotherapeutics. J Med Chem 59, 93219336, doi:10.1021/acs.jmedchem.6b00596 (2016).

133

Lehmann, A. R. Replication of damaged DNA by translesion synthesis in human
cells. FEBS Lett 579, 873-876, doi:10.1016/j.febslet.2004.11.029 (2005).

134

Yamanaka, K., Chatterjee, N., Hemann, M. T. & Walker, G. C. Inhibition of
mutagenic translesion synthesis: A possible strategy for improving
chemotherapy? PLoS Genet 13, e1006842, doi:10.1371/journal.pgen.1006842
(2017).

189
135

Daley, J. M. & Sung, P. 53BP1, BRCA1, and the choice between recombination
and end joining at DNA double-strand breaks. Mol Cell Biol 34, 1380-1388,
doi:10.1128/MCB.01639-13 (2014).

136

Ma, Y., Lu, H., Tippin, B., Goodman, M. F., Shimazaki, N., Koiwai, O., Hsieh, C.
L., Schwarz, K. & Lieber, M. R. A biochemically defined system for mammalian
nonhomologous DNA end joining. Mol Cell 16, 701-713,
doi:10.1016/j.molcel.2004.11.017 (2004).

137

Lee, K. Y., Im, J. S., Shibata, E. & Dutta, A. ASF1a Promotes Non-homologous
End Joining Repair by Facilitating Phosphorylation of MDC1 by ATM at DoubleStrand Breaks. Mol Cell 68, 61-75 e65, doi:10.1016/j.molcel.2017.08.021 (2017).

138

Kim, J. E., Minter-Dykhouse, K. & Chen, J. Signaling networks controlled by the
MRN complex and MDC1 during early DNA damage responses. Mol Carcinog
45, 403-408, doi:10.1002/mc.20221 (2006).

139

Coster, G. & Goldberg, M. The cellular response to DNA damage: a focus on
MDC1 and its interacting proteins. Nucleus 1, 166-178,
doi:10.4161/nucl.1.2.11176 (2010).

140

Callen, E., Di Virgilio, M., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H. T.,
Faryabi, R. B., Polato, F., Santos, M., Starnes, L. M., Wesemann, D. R., Lee, J.
E., Tubbs, A., Sleckman, B. P., Daniel, J. A., Ge, K., Alt, F. W., FernandezCapetillo, O., Nussenzweig, M. C. & Nussenzweig, A. 53BP1 mediates
productive and mutagenic DNA repair through distinct phosphoprotein
interactions. Cell 153, 1266-1280, doi:10.1016/j.cell.2013.05.023 (2013).

141

Kleiner, R. E., Verma, P., Molloy, K. R., Chait, B. T. & Kapoor, T. M. Chemical
proteomics reveals a gammaH2AX-53BP1 interaction in the DNA damage
response. Nat Chem Biol 11, 807-814, doi:10.1038/nchembio.1908 (2015).

190
142

Wu, J., Prindle, M. J., Dressler, G. R. & Yu, X. PTIP regulates 53BP1 and SMC1
at the DNA damage sites. J Biol Chem 284, 18078-18084,
doi:10.1074/jbc.M109.002527 (2009).

143

De Gregoriis, G., Ramos, J. A., Fernandes, P. V., Vignal, G. M., Brianese, R. C.,
Carraro, D. M., Monteiro, A. N., Struchiner, C. J., Suarez-Kurtz, G., ViannaJorge, R. & de Carvalho, M. A. DNA repair genes PAXIP1 and TP53BP1
expression is associated with breast cancer prognosis. Cancer Biol Ther 18, 439449, doi:10.1080/15384047.2017.1323590 (2017).

144

McVey, M. & Lee, S. E. MMEJ repair of double-strand breaks (director's cut):
deleted sequences and alternative endings. Trends Genet 24, 529-538,
doi:10.1016/j.tig.2008.08.007 (2008).

145

McVey, M. RPA puts the brakes on MMEJ. Nat Struct Mol Biol 21, 348-349,
doi:10.1038/nsmb.2802 (2014).

146

Sfeir, A. & Symington, L. S. Microhomology-Mediated End Joining: A Back-up
Survival Mechanism or Dedicated Pathway? Trends Biochem Sci 40, 701-714,
doi:10.1016/j.tibs.2015.08.006 (2015).

147

Sharma, S., Javadekar, S. M., Pandey, M., Srivastava, M., Kumari, R. &
Raghavan, S. C. Homology and enzymatic requirements of microhomologydependent alternative end joining. Cell Death Dis 6, e1697,
doi:10.1038/cddis.2015.58 (2015).

148

Ceccaldi, R., Rondinelli, B. & D'Andrea, A. D. Repair Pathway Choices and
Consequences at the Double-Strand Break. Trends Cell Biol 26, 52-64,
doi:10.1016/j.tcb.2015.07.009 (2016).

149

Dutta, A., Eckelmann, B., Adhikari, S., Ahmed, K. M., Sengupta, S., Pandey, A.,
Hegde, P. M., Tsai, M. S., Tainer, J. A., Weinfeld, M., Hegde, M. L. & Mitra, S.
Microhomology-mediated end joining is activated in irradiated human cells due to

191
phosphorylation-dependent formation of the XRCC1 repair complex. Nucleic
Acids Res 45, 2585-2599, doi:10.1093/nar/gkw1262 (2017).
150

Durant, S. T. & Nickoloff, J. A. Good timing in the cell cycle for precise DNA
repair by BRCA1. Cell Cycle 4, 1216-1222, doi:10.4161/cc.4.9.2027 (2005).

151

Savage, K. I. & Harkin, D. P. BRCA1, a 'complex' protein involved in the
maintenance of genomic stability. The FEBS journal 282, 630-646,
doi:10.1111/febs.13150 (2015).

152

Biehs, R., Steinlage, M., Barton, O., Juhasz, S., Kunzel, J., Spies, J., Shibata, A.,
Jeggo, P. A. & Lobrich, M. DNA Double-Strand Break Resection Occurs during
Non-homologous End Joining in G1 but Is Distinct from Resection during
Homologous Recombination. Mol Cell 65, 671-684 e675,
doi:10.1016/j.molcel.2016.12.016 (2017).

153

Chen, R. & Wold, M. S. Replication protein A: single-stranded DNA's first
responder: dynamic DNA-interactions allow replication protein A to direct singlestrand DNA intermediates into different pathways for synthesis or repair.
Bioessays 36, 1156-1161, doi:10.1002/bies.201400107 (2014).

154

Zhao, W., Steinfeld, J. B., Liang, F., Chen, X., Maranon, D. G., Jian Ma, C.,
Kwon, Y., Rao, T., Wang, W., Sheng, C., Song, X., Deng, Y., Jimenez-Sainz, J.,
Lu, L., Jensen, R. B., Xiong, Y., Kupfer, G. M., Wiese, C., Greene, E. C. & Sung,
P. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature
550, 360-365, doi:10.1038/nature24060 (2017).

155

Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and
human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring
Harb Perspect Biol 7, a016600, doi:10.1101/cshperspect.a016600 (2015).

156

Hall, M. N. mTOR-what does it do? Transplant Proc 40, S5-8,
doi:10.1016/j.transproceed.2008.10.009 (2008).

192
157

Xu, N., Lao, Y., Zhang, Y. & Gillespie, D. A. Akt: a double-edged sword in cell
proliferation and genome stability. J Oncol 2012, 951724,
doi:10.1155/2012/951724 (2012).

158

Wander, S. A., Hennessy, B. T. & Slingerland, J. M. Next-generation mTOR
inhibitors in clinical oncology: how pathway complexity informs therapeutic
strategy. J Clin Invest 121, 1231-1241, doi:10.1172/JCI44145 (2011).

159

Borders, E. B., Bivona, C. & Medina, P. J. Mammalian target of rapamycin:
biological function and target for novel anticancer agents. Am J Health Syst
Pharm 67, 2095-2106, doi:10.2146/ajhp100020 (2010).

160

Xu, K., Liu, P. & Wei, W. mTOR signaling in tumorigenesis. Biochim Biophys
Acta 1846, 638-654, doi:10.1016/j.bbcan.2014.10.007 (2014).

161

Xie, J., Wang, X. & Proud, C. G. mTOR inhibitors in cancer therapy. F1000Res 5,
doi:10.12688/f1000research.9207.1 (2016).

162

Hinton, C. V., Fitzgerald, L. D. & Thompson, M. E. Phosphatidylinositol 3kinase/Akt signaling enhances nuclear localization and transcriptional activity of
BRCA1. Exp Cell Res 313, 1735-1744, doi:10.1016/j.yexcr.2007.03.008 (2007).

163

Mueck, K., Rebholz, S., Harati, M. D., Rodemann, H. P. & Toulany, M. Akt1
Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in
a Rad51-Dependent Manner. Int J Mol Sci 18, doi:10.3390/ijms18112473 (2017).

164

Udayakumar, D., Pandita, R. K., Horikoshi, N., Liu, Y., Liu, Q., Wong, K. K., Hunt,
C. R., Gray, N. S., Minna, J. D., Pandita, T. K. & Westover, K. D. Torin2
Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiat Res 185,
527-538, doi:10.1667/RR14373.1 (2016).

165

Plo, I., Laulier, C., Gauthier, L., Lebrun, F., Calvo, F. & Lopez, B. S. AKT1 inhibits
homologous recombination by inducing cytoplasmic retention of BRCA1 and

193
RAD51. Cancer research 68, 9404-9412, doi:10.1158/0008-5472.CAN-08-0861
(2008).
166

Tonic, I., Yu, W. N., Park, Y., Chen, C. C. & Hay, N. Akt activation emulates
Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint
by inhibiting BRCA1 foci. J Biol Chem 285, 23790-23798,
doi:10.1074/jbc.M110.104372 (2010).

167

Jia, Y., Song, W., Zhang, F., Yan, J. & Yang, Q. Akt1 inhibits homologous
recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
Oncogene 32, 1943-1949, doi:10.1038/onc.2012.211 (2013).

168

Golding, S. E., Morgan, R. N., Adams, B. R., Hawkins, A. J., Povirk, L. F. &
Valerie, K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII
enhances DNA double-strand break repair in human glioma cells. Cancer Biol
Ther 8, 730-738, doi:10.4161/cbt.8.8.7927 (2009).

169

Toulany, M., Kehlbach, R., Florczak, U., Sak, A., Wang, S., Chen, J., Lobrich, M.
& Rodemann, H. P. Targeting of AKT1 enhances radiation toxicity of human
tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
Mol Cancer Ther 7, 1772-1781, doi:10.1158/1535-7163.MCT-07-2200 (2008).

170

Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homologydirected DNA repair. Mol Cell 4, 511-518 (1999).

171

Xiang, T., Ohashi, A., Huang, Y., Pandita, T. K., Ludwig, T., Powell, S. N. &
Yang, Q. Negative Regulation of AKT Activation by BRCA1. Cancer research 68,
10040-10044, doi:10.1158/0008-5472.CAN-08-3009 (2008).

172

Grunt, T. W. & Mariani, G. L. Novel approaches for molecular targeted therapy of
breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug
Targets 13, 188-204 (2013).

194
173

Chen, H., Ma, Z., Vanderwaal, R. P., Feng, Z., Gonzalez-Suarez, I., Wang, S.,
Zhang, J., Roti Roti, J. L., Gonzalo, S. & Zhang, J. The mTOR inhibitor
rapamycin suppresses DNA double-strand break repair. Radiat Res 175, 214224 (2011).

174

Bensimon, A., Schmidt, A., Ziv, Y., Elkon, R., Wang, S. Y., Chen, D. J.,
Aebersold, R. & Shiloh, Y. ATM-dependent and -independent dynamics of the
nuclear phosphoproteome after DNA damage. Science signaling 3, rs3,
doi:10.1126/scisignal.2001034 (2010).

175

Schonbrun, M., Kolesnikov, M., Kupiec, M. & Weisman, R. TORC2 is required to
maintain genome stability during S phase in fission yeast. J Biol Chem 288,
19649-19660, doi:10.1074/jbc.M113.464974 (2013).

176

Rosen, E. M., Fan, S. & Ma, Y. BRCA1 regulation of transcription. Cancer Lett
236, 175-185, doi:10.1016/j.canlet.2005.04.037 (2006).

177

Mylavarapu, S., Das, A. & Roy, M. Role of BRCA Mutations in the Modulation of
Response to Platinum Therapy. Front Oncol 8, 16, doi:10.3389/fonc.2018.00016
(2018).

178

Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M. &
Bonner, W. M. A critical role for histone H2AX in recruitment of repair factors to
nuclear foci after DNA damage. Curr Biol 10, 886-895 (2000).

179

Lagundzin, D., Hu, W. F., Law, H. C. H., Krieger, K. L., Qiao, F., Clement, E. J.,
Drincic, A. T., Nedic, O., Naldrett, M. J., Alvarez, S. & Woods, N. T. Delineating
the role of FANCA in glucose-stimulated insulin secretion in beta cells through its
protein interactome. PLoS One 14, e0220568, doi:10.1371/journal.pone.0220568
(2019).

180

Soulier, J. Fanconi Anemia. American Society of Hematology, 492-497 (2011).

195
181

Bogliolo, M. & Surralles, J. Fanconi anemia: a model disease for studies on
human genetics and advanced therapeutics. Curr Opin Genet Dev 33, 32-40,
doi:10.1016/j.gde.2015.07.002 (2015).

182

Nepal, M., Che, R., Zhang, J., Ma, C. & Fei, P. Fanconi Anemia Signaling and
Cancer. Trends Cancer 3, 840-856, doi:10.1016/j.trecan.2017.10.005 (2017).

183

Park, J. Y., Virts, E. L., Jankowska, A., Wiek, C., Othman, M., Chakraborty, S. C.,
Vance, G. H., Alkuraya, F. S., Hanenberg, H. & Andreassen, P. R.
Complementation of hypersensitivity to DNA interstrand crosslinking agents
demonstrates that XRCC2 is a Fanconi anaemia gene. J Med Genet 53, 672680, doi:10.1136/jmedgenet-2016-103847 (2016).

184

Lopez-Martinez, D., Liang, C. C. & Cohn, M. A. Cellular response to DNA
interstrand crosslinks: the Fanconi anemia pathway. Cell Mol Life Sci 73, 30973114, doi:10.1007/s00018-016-2218-x (2016).

185

Kottemann, M. C. & Smogorzewska, A. Fanconi anaemia and the repair of
Watson and Crick DNA crosslinks. Nature 493, 356-363,
doi:10.1038/nature11863 (2013).

186

Shukla, P., Solanki, A., Ghosh, K. & Vundinti, B. R. DNA interstrand cross-link
repair: understanding role of Fanconi anemia pathway and therapeutic
implications. Eur J Haematol 91, 381-393, doi:10.1111/ejh.12169 (2013).

187

Oostra, A. B., Nieuwint, A. W., Joenje, H. & de Winter, J. P. Diagnosis of fanconi
anemia: chromosomal breakage analysis. Anemia 2012, 238731,
doi:10.1155/2012/238731 (2012).

188

Mi, J. & Kupfer, G. M. The Fanconi anemia core complex associates with
chromatin during S phase. Blood 105, 759-766, doi:10.1182/blood-2004-01-0001
(2005).

196
189

Thomashevski, A., High, A. A., Drozd, M., Shabanowitz, J., Hunt, D. F., Grant, P.
A. & Kupfer, G. M. The Fanconi anemia core complex forms four complexes of
different sizes in different subcellular compartments. J Biol Chem 279, 2620126209, doi:10.1074/jbc.M400091200 (2004).

190

Waisfisz, Q., de Winter, J. P., Kruyt, F. A., de Groot, J., van der Weel, L.,
Dijkmans, L. M., Zhi, Y., Arwert, F., Scheper, R. J., Youssoufian, H., Hoatlin, M.
E. & Joenje, H. A physical complex of the Fanconi anemia proteins
FANCG/XRCC9 and FANCA. Proc Natl Acad Sci U S A 96, 10320-10325,
doi:10.1073/pnas.96.18.10320 (1999).

191

Medhurst, A. L., Laghmani el, H., Steltenpool, J., Ferrer, M., Fontaine, C., de
Groot, J., Rooimans, M. A., Scheper, R. J., Meetei, A. R., Wang, W., Joenje, H. &
de Winter, J. P. Evidence for subcomplexes in the Fanconi anemia pathway.
Blood 108, 2072-2080, doi:10.1182/blood-2005-11-008151 (2006).

192

Leveille, F., Blom, E., Medhurst, A. L., Bier, P., Laghmani el, H., Johnson, M.,
Rooimans, M. A., Sobeck, A., Waisfisz, Q., Arwert, F., Patel, K. J., Hoatlin, M. E.,
Joenje, H. & de Winter, J. P. The Fanconi anemia gene product FANCF is a
flexible adaptor protein. J Biol Chem 279, 39421-39430,
doi:10.1074/jbc.M407034200 (2004).

193

Collins, N. B., Wilson, J. B., Bush, T., Thomashevski, A., Roberts, K. J., Jones,
N. J. & Kupfer, G. M. ATR-dependent phosphorylation of FANCA on serine 1449
after DNA damage is important for FA pathway function. Blood 113, 2181-2190,
doi:10.1182/blood-2008-05-154294 (2009).

194

Leung, J. W., Wang, Y., Fong, K. W., Huen, M. S., Li, L. & Chen, J. Fanconi
anemia (FA) binding protein FAAP20 stabilizes FA complementation group A
(FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci U S
A 109, 4491-4496, doi:10.1073/pnas.1118720109 (2012).

197
195

Wang, J., Jo, U., Joo, S. Y. & Kim, H. FBW7 regulates DNA interstrand cross-link
repair by modulating FAAP20 degradation. Oncotarget 7, 35724-35740,
doi:10.18632/oncotarget.9595 (2016).

196

Yan, Z., Guo, R., Paramasivam, M., Shen, W., Ling, C., Fox, D., 3rd, Wang, Y.,
Oostra, A. B., Kuehl, J., Lee, D. Y., Takata, M., Hoatlin, M. E., Schindler, D.,
Joenje, H., de Winter, J. P., Li, L., Seidman, M. M. & Wang, W. A ubiquitinbinding protein, FAAP20, links RNF8-mediated ubiquitination to the Fanconi
anemia DNA repair network. Mol Cell 47, 61-75,
doi:10.1016/j.molcel.2012.05.026 (2012).

197

Huang, Y., Leung, J. W., Lowery, M., Matsushita, N., Wang, Y., Shen, X., Huong,
D., Takata, M., Chen, J. & Li, L. Modularized functions of the Fanconi anemia
core complex. Cell Rep 7, 1849-1857, doi:10.1016/j.celrep.2014.04.029 (2014).

198

van Twest, S., Murphy, V. J., Hodson, C., Tan, W., Swuec, P., O'Rourke, J. J.,
Heierhorst, J., Crismani, W. & Deans, A. J. Mechanism of Ubiquitination and
Deubiquitination in the Fanconi Anemia Pathway. Mol Cell 65, 247-259,
doi:10.1016/j.molcel.2016.11.005 (2017).

199

Meetei, A. R., de Winter, J. P., Medhurst, A. L., Wallisch, M., Waisfisz, Q., van de
Vrugt, H. J., Oostra, A. B., Yan, Z., Ling, C., Bishop, C. E., Hoatlin, M. E., Joenje,
H. & Wang, W. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet
35, 165-170, doi:10.1038/ng1241 (2003).

200

Meetei, A. R., Yan, Z. & Wang, W. FANCL replaces BRCA1 as the likely ubiquitin
ligase responsible for FANCD2 monoubiquitination. Cell Cycle 3, 179-181 (2004).

201

Deans, A. J. & West, S. C. FANCM connects the genome instability disorders
Bloom's Syndrome and Fanconi Anemia. Mol Cell 36, 943-953,
doi:10.1016/j.molcel.2009.12.006 (2009).

198
202

Xue, Y., Li, Y., Guo, R., Ling, C. & Wang, W. FANCM of the Fanconi anemia core
complex is required for both monoubiquitination and DNA repair. Hum Mol Genet
17, 1641-1652, doi:10.1093/hmg/ddn054 (2008).

203

Li, X. & Heyer, W. D. Homologous recombination in DNA repair and DNA
damage tolerance. Cell Res 18, 99-113, doi:10.1038/cr.2008.1 (2008).

204

Ishiai, M., Sato, K., Tomida, J., Kitao, H., Kurumizaka, H. & Takata, M. Activation
of the FA pathway mediated by phosphorylation and ubiquitination. Mutat Res
803-805, 89-95, doi:10.1016/j.mrfmmm.2017.05.003 (2017).

205

Machida, Y. J., Machida, Y., Chen, Y., Gurtan, A. M., Kupfer, G. M., D'Andrea, A.
D. & Dutta, A. UBE2T is the E2 in the Fanconi anemia pathway and undergoes
negative autoregulation. Mol Cell 23, 589-596, doi:10.1016/j.molcel.2006.06.024
(2006).

206

Alpi, A., Langevin, F., Mosedale, G., Machida, Y. J., Dutta, A. & Patel, K. J.
UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited
independently to chromatin: a basis for the regulation of FANCD2
monoubiquitination. Mol Cell Biol 27, 8421-8430, doi:10.1128/MCB.00504-07
(2007).

207

Ishiai, M., Kitao, H., Smogorzewska, A., Tomida, J., Kinomura, A., Uchida, E.,
Saberi, A., Kinoshita, E., Kinoshita-Kikuta, E., Koike, T., Tashiro, S., Elledge, S.
J. & Takata, M. FANCI phosphorylation functions as a molecular switch to turn on
the Fanconi anemia pathway. Nat Struct Mol Biol 15, 1138-1146,
doi:10.1038/nsmb.1504 (2008).

208

Chen, Y. H., Jones, M. J., Yin, Y., Crist, S. B., Colnaghi, L., Sims, R. J., 3rd,
Rothenberg, E., Jallepalli, P. V. & Huang, T. T. ATR-mediated phosphorylation of
FANCI regulates dormant origin firing in response to replication stress. Mol Cell
58, 323-338, doi:10.1016/j.molcel.2015.02.031 (2015).

199
209

Andreassen, P. R., D'Andrea, A. D. & Taniguchi, T. ATR couples FANCD2
monoubiquitination to the DNA-damage response. Genes & development 18,
1958-1963, doi:10.1101/gad.1196104 (2004).

210

Sareen, A., Chaudhury, I., Adams, N. & Sobeck, A. Fanconi anemia proteins
FANCD2 and FANCI exhibit different DNA damage responses during S-phase.
Nucleic Acids Res 40, 8425-8439, doi:10.1093/nar/gks638 (2012).

211

Castella, M., Jacquemont, C., Thompson, E. L., Yeo, J. E., Cheung, R. S.,
Huang, J. W., Sobeck, A., Hendrickson, E. A. & Taniguchi, T. FANCI Regulates
Recruitment of the FA Core Complex at Sites of DNA Damage Independently of
FANCD2. PLoS Genet 11, e1005563, doi:10.1371/journal.pgen.1005563 (2015).

212

Cheung, R. S. & Taniguchi, T. Recent insights into the molecular basis of
Fanconi anemia: genes, modifiers, and drivers. Int J Hematol 106, 335-344,
doi:10.1007/s12185-017-2283-4 (2017).

213

Zou, Y., Liu, Y., Wu, X. & Shell, S. M. Functions of human replication protein A
(RPA): from DNA replication to DNA damage and stress responses. J Cell
Physiol 208, 267-273, doi:10.1002/jcp.20622 (2006).

214

Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of
RPA-ssDNA complexes. Science 300, 1542-1548, doi:10.1126/science.1083430
(2003).

215

Shigechi, T., Tomida, J., Sato, K., Kobayashi, M., Eykelenboom, J. K., Pessina,
F., Zhang, Y., Uchida, E., Ishiai, M., Lowndes, N. F., Yamamoto, K., Kurumizaka,
H., Maehara, Y. & Takata, M. ATR-ATRIP kinase complex triggers activation of
the Fanconi anemia DNA repair pathway. Cancer research 72, 1149-1156,
doi:10.1158/0008-5472.CAN-11-2904 (2012).

200
216

Yuan, F., El Hokayem, J., Zhou, W. & Zhang, Y. FANCI protein binds to DNA and
interacts with FANCD2 to recognize branched structures. J Biol Chem 284,
24443-24452, doi:10.1074/jbc.M109.016006 (2009).

217

Cheung, R. S., Castella, M., Abeyta, A., Gafken, P. R., Tucker, N. & Taniguchi,
T. Ubiquitination-Linked Phosphorylation of the FANCI S/TQ Cluster Contributes
to Activation of the Fanconi Anemia I/D2 Complex. Cell Rep 19, 2432-2440,
doi:10.1016/j.celrep.2017.05.081 (2017).

218

Liang, C. C., Li, Z., Lopez-Martinez, D., Nicholson, W. V., Venien-Bryan, C. &
Cohn, M. A. The FANCD2-FANCI complex is recruited to DNA interstrand
crosslinks before monoubiquitination of FANCD2. Nat Commun 7, 12124,
doi:10.1038/ncomms12124 (2016).

219

Thompson, E. L., Yeo, J. E., Lee, E. A., Kan, Y., Raghunandan, M., Wiek, C.,
Hanenberg, H., Scharer, O. D., Hendrickson, E. A. & Sobeck, A. FANCI and
FANCD2 have common as well as independent functions during the cellular
replication stress response. Nucleic Acids Res 45, 11837-11857,
doi:10.1093/nar/gkx847 (2017).

220

Sato, K., Shimomuki, M., Katsuki, Y., Takahashi, D., Kobayashi, W., Ishiai, M.,
Miyoshi, H., Takata, M. & Kurumizaka, H. FANCI-FANCD2 stabilizes the RAD51DNA complex by binding RAD51 and protects the 5'-DNA end. Nucleic Acids Res
44, 10758-10771, doi:10.1093/nar/gkw876 (2016).

221

Chaudhury, I., Sareen, A., Raghunandan, M. & Sobeck, A. FANCD2 regulates
BLM complex functions independently of FANCI to promote replication fork
recovery. Nucleic Acids Res 41, 6444-6459, doi:10.1093/nar/gkt348 (2013).

222

Kim, H., Yang, K., Dejsuphong, D. & D'Andrea, A. D. Regulation of Rev1 by the
Fanconi anemia core complex. Nat Struct Mol Biol 19, 164-170,
doi:10.1038/nsmb.2222 (2012).

201
223

Cantor, S. B. & Nayak, S. FANCJ at the FORK. Mutat Res 788, 7-11,
doi:10.1016/j.mrfmmm.2016.02.003 (2016).

224

Niraj, J., Farkkila, A. & D'Andrea, A. D. The Fanconi Anemia Pathway in Cancer.
Annu Rev Cancer Biol 3, 457-478, doi:10.1146/annurev-cancerbio-030617050422 (2019).

225

Mamrak, N. E., Shimamura, A. & Howlett, N. G. Recent discoveries in the
molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi
anemia. Blood Rev 31, 93-99, doi:10.1016/j.blre.2016.10.002 (2017).

226

Oestergaard, V. H., Langevin, F., Kuiken, H. J., Pace, P., Niedzwiedz, W.,
Simpson, L. J., Ohzeki, M., Takata, M., Sale, J. E. & Patel, K. J. Deubiquitination
of FANCD2 is required for DNA crosslink repair. Mol Cell 28, 798-809,
doi:10.1016/j.molcel.2007.09.020 (2007).

227

Arkinson, C., Chaugule, V. K., Toth, R. & Walden, H. Specificity for
deubiquitination of monoubiquitinated FANCD2 is driven by the N-terminus of
USP1. Life Sci Alliance 1, e201800162, doi:10.26508/lsa.201800162 (2018).

228

Tan, W. & Deans, A. J. A defined role for multiple Fanconi anemia gene products
in DNA-damage-associated ubiquitination. Exp Hematol 50, 27-32,
doi:10.1016/j.exphem.2017.03.001 (2017).

229

Nakanishi, K., Yang, Y. G., Pierce, A. J., Taniguchi, T., Digweed, M., D'Andrea,
A. D., Wang, Z. Q. & Jasin, M. Human Fanconi anemia monoubiquitination
pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 102, 11101115, doi:10.1073/pnas.0407796102 (2005).

230

Yang, Y. G., Herceg, Z., Nakanishi, K., Demuth, I., Piccoli, C., Michelon, J.,
Hildebrand, G., Jasin, M., Digweed, M. & Wang, Z. Q. The Fanconi anemia group
A protein modulates homologous repair of DNA double-strand breaks in

202
mammalian cells. Carcinogenesis 26, 1731-1740, doi:10.1093/carcin/bgi134
(2005).
231

Palovcak, A., Liu, W., Yuan, F. & Zhang, Y. Stitching up broken DNA ends by
FANCA. Mol Cell Oncol 5, e1518101, doi:10.1080/23723556.2018.1518101
(2018).

232

Benitez, A., Liu, W., Palovcak, A., Wang, G., Moon, J., An, K., Kim, A., Zheng,
K., Zhang, Y., Bai, F., Mazin, A. V., Pei, X. H., Yuan, F. & Zhang, Y. FANCA
Promotes DNA Double-Strand Break Repair by Catalyzing Single-Strand
Annealing and Strand Exchange. Mol Cell 71, 621-628 e624,
doi:10.1016/j.molcel.2018.06.030 (2018).

233

Bagby, G. Recent advances in understanding hematopoiesis in Fanconi Anemia.
F1000Res 7, 105, doi:10.12688/f1000research.13213.1 (2018).

234

Garaycoechea, J. I. & Patel, K. J. Why does the bone marrow fail in Fanconi
anemia? Blood 123, 26-34, doi:10.1182/blood-2013-09-427740 (2014).

235

Sumpter, R., Jr., Sirasanagandla, S., Fernandez, A. F., Wei, Y., Dong, X.,
Franco, L., Zou, Z., Marchal, C., Lee, M. Y., Clapp, D. W., Hanenberg, H. &
Levine, B. Fanconi Anemia Proteins Function in Mitophagy and Immunity. Cell
165, 867-881, doi:10.1016/j.cell.2016.04.006 (2016).

236

Jeong, S. J., Kim, H. J., Yang, Y. J., Seol, J. H., Jung, B. Y., Han, J. W., Lee, H.
W. & Cho, E. J. Role of RNA polymerase II carboxy terminal domain
phosphorylation in DNA damage response. Journal of microbiology 43, 516-522
(2005).

237

Huttlin, E. L., Bruckner, R. J., Paulo, J. A., Cannon, J. R., Ting, L., Baltier, K.,
Colby, G., Gebreab, F., Gygi, M. P., Parzen, H., Szpyt, J., Tam, S., Zarraga, G.,
Pontano-Vaites, L., Swarup, S., White, A. E., Schweppe, D. K., Rad, R.,
Erickson, B. K., Obar, R. A. et al. Architecture of the human interactome defines

203
protein communities and disease networks. Nature 545, 505-509,
doi:10.1038/nature22366 (2017).
238

Liu, Y., Woods, N. T., Kim, D., Sweet, M., Monteiro, A. N. & Karchin, R. Yeast
two-hybrid junk sequences contain selected linear motifs. Nucleic Acids Res 39,
e128, doi:10.1093/nar/gkr600 (2011).

239

Teo, G., Liu, G., Zhang, J., Nesvizhskii, A. I., Gingras, A. C. & Choi, H.
SAINTexpress: improvements and additional features in Significance Analysis of
INTeractome software. J Proteomics 100, 37-43, doi:10.1016/j.jprot.2013.10.023
(2014).

240

Mellacheruvu, D., Wright, Z., Couzens, A. L., Lambert, J. P., St-Denis, N. A., Li,
T., Miteva, Y. V., Hauri, S., Sardiu, M. E., Low, T. Y., Halim, V. A., Bagshaw, R.
D., Hubner, N. C., Al-Hakim, A., Bouchard, A., Faubert, D., Fermin, D., Dunham,
W. H., Goudreault, M., Lin, Z. Y. et al. The CRAPome: a contaminant repository
for affinity purification-mass spectrometry data. Nat Methods 10, 730-736,
doi:10.1038/nmeth.2557 (2013).

241

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D.,
Amin, N., Schwikowski, B. & Ideker, T. Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome Res 13, 24982504, doi:10.1101/gr.1239303 (2003).

242

Martin, A., Ochagavia, M. E., Rabasa, L. C., Miranda, J., Fernandez-de-Cossio,
J. & Bringas, R. BisoGenet: a new tool for gene network building, visualization
and analysis. BMC Bioinformatics 11, 91, doi:10.1186/1471-2105-11-91 (2010).

243

Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A.,
Fridman, W. H., Pages, F., Trajanoski, Z. & Galon, J. ClueGO: a Cytoscape plugin to decipher functionally grouped gene ontology and pathway annotation

204
networks. Bioinformatics 25, 1091-1093, doi:10.1093/bioinformatics/btp101
(2009).
244

Maere, S., Heymans, K. & Kuiper, M. BiNGO: a Cytoscape plugin to assess
overrepresentation of gene ontology categories in biological networks.
Bioinformatics 21, 3448-3449, doi:10.1093/bioinformatics/bti551 (2005).

245

Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a
network-based method for gene-set enrichment visualization and interpretation.
PLoS One 5, e13984, doi:10.1371/journal.pone.0013984 (2010).

246

Knight, J. D. R., Choi, H., Gupta, G. D., Pelletier, L., Raught, B., Nesvizhskii, A. I.
& Gingras, A. C. ProHits-viz: a suite of web tools for visualizing interaction
proteomics data. Nat Methods 14, 645-646, doi:10.1038/nmeth.4330 (2017).

247

Williams, S. A., Longerich, S., Sung, P., Vaziri, C. & Kupfer, G. M. The E3
ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of
FANCD2 and FANCI. Blood 117, 5078-5087, doi:10.1182/blood-2010-10-311761
(2011).

248

Vuono, E. A., Mukherjee, A., Vierra, D. A., Adroved, M. M., Hodson, C., Deans,
A. J. & Howlett, N. G. The PTEN phosphatase functions cooperatively with the
Fanconi anemia proteins in DNA crosslink repair. Sci Rep 6, 36439,
doi:10.1038/srep36439 (2016).

249

Okamoto, S., Narita, T., Sasanuma, H., Takeda, S., Masunaga, S., Bessho, T. &
Tano, K. Impact of DNA repair pathways on the cytotoxicity of piperlongumine in
chicken DT40 cell-lines. Genes Cancer 5, 285-292,
doi:10.18632/genesandcancer.26 (2014).

250

Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes
homology-directed repair of DNA damage in mammalian cells. Genes &
development 13, 2633-2638 (1999).

205
251

Barroso, E., Pita, G., Arias, J. I., Menendez, P., Zamora, P., Blanco, M., Benitez,
J. & Ribas, G. The Fanconi anemia family of genes and its correlation with breast
cancer susceptibility and breast cancer features. Breast Cancer Res Treat 118,
655-660, doi:10.1007/s10549-009-0439-5 (2009).

252

Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J.,
Ponce-Rodriguez, I., Chakravarthi, B. & Varambally, S. UALCAN: A Portal for
Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia
19, 649-658, doi:10.1016/j.neo.2017.05.002 (2017).

253

Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D.,
Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, S.
K. & Alizadeh, A. A. The prognostic landscape of genes and infiltrating immune
cells across human cancers. Nat Med 21, 938-945, doi:10.1038/nm.3909 (2015).

254

Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The Trinity at the
Heart of the DNA Damage Response. Mol Cell 66, 801-817,
doi:10.1016/j.molcel.2017.05.015 (2017).

255

Sirbu, B. M. & Cortez, D. DNA damage response: three levels of DNA repair
regulation. Cold Spring Harb Perspect Biol 5, a012724,
doi:10.1101/cshperspect.a012724 (2013).

256

Le, J., Perez, E., Nemzow, L. & Gong, F. Role of deubiquitinases in DNA
damage response. DNA Repair (Amst) 76, 89-98,
doi:10.1016/j.dnarep.2019.02.011 (2019).

257

Taniguchi, T. & D'Andrea, A. D. Molecular pathogenesis of fanconi anemia. Int J
Hematol 75, 123-128 (2002).

258

Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J.,
Jakubowicz, J., Cybulski, C., Wisniowski, R., Godlewski, D., Lubinski, J. & Narod,
S. A. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive

206
breast cancer patients. Breast Cancer Res Treat 147, 401-405,
doi:10.1007/s10549-014-3100-x (2014).
259

Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo,
H. S., Liu, M. C., Stearns, V., Come, S. E., Timms, K. M., Hartman, A. R., Borger,
D. R., Finkelstein, D. M., Garber, J. E., Ryan, P. D., Winer, E. P., Goss, P. E. &
Ellisen, L. W. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum
Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast
Cancer. J Clin Oncol 33, 1902-1909, doi:10.1200/JCO.2014.57.6660 (2015).

260

Timmers, C., Taniguchi, T., Hejna, J., Reifsteck, C., Lucas, L., Bruun, D., Thayer,
M., Cox, B., Olson, S., D'Andrea, A. D., Moses, R. & Grompe, M. Positional
cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 7, 241-248 (2001).

261

Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer
research. Breast Cancer Res 13, 215, doi:10.1186/bcr2889 (2011).

262

Fu, H., Yang, D., Wang, C., Xu, J., Wang, W., Yan, R. & Cai, Q. Carboxyterminal domain phosphatase 1 silencing results in the inhibition of tumor
formation ability in gastric cancer cells. Oncology letters 10, 2947-2952,
doi:10.3892/ol.2015.3693 (2015).

263

Zhong, R., Ge, X., Chu, T., Teng, J., Yan, B., Pei, J., Jiang, L., Zhong, H. & Han,
B. Lentivirus-mediated knockdown of CTDP1 inhibits lung cancer cell growth in
vitro. J Cancer Res Clin Oncol 142, 723-732, doi:10.1007/s00432-015-2070-7
(2016).

264

Varon, R., Gooding, R., Steglich, C., Marns, L., Tang, H., Angelicheva, D., Yong,
K. K., Ambrugger, P., Reinhold, A., Morar, B., Baas, F., Kwa, M., Tournev, I.,
Guerguelcheva, V., Kremensky, I., Lochmuller, H., Mullner-Eidenbock, A.,
Merlini, L., Neumann, L., Burger, J. et al. Partial deficiency of the C-terminaldomain phosphatase of RNA polymerase II is associated with congenital

207
cataracts facial dysmorphism neuropathy syndrome. Nat Genet 35, 185-189,
doi:10.1038/ng1243 (2003).
265

Kalaydjieva, L. Congenital cataracts-facial dysmorphism-neuropathy. Orphanet J
Rare Dis 1, 32, doi:10.1186/1750-1172-1-32 (2006).

266

Mastroyianni, S. D., Garoufi, A., Voudris, K., Skardoutsou, A., Stefanidis, C. J.,
Katsarou, E., Gooding, R. & Kalaydjieva, L. Congenital cataracts facial
dysmorphism neuropathy (CCFDN) syndrome: a rare cause of parainfectious
rhabdomyolysis. Eur J Pediatr 166, 747-749, doi:10.1007/s00431-006-0307-9
(2007).

267

Lassuthova, P., Siskova, D., Haberlova, J., Sakmaryova, I., Filous, A. & Seeman,
P. Congenital cataract, facial dysmorphism and demyelinating neuropathy
(CCFDN) in 10 Czech Gypsy children--frequent and underestimated cause of
disability among Czech Gypsies. Orphanet J Rare Dis 9, 46, doi:10.1186/17501172-9-46 (2014).

268

Kalaydjieva, L. & Chamova, T. in GeneReviews((R)) (eds M. P. Adam et al.)
(1993).

269

Tombacz, I., Schauer, T., Juhasz, I., Komonyi, O. & Boros, I. The RNA Pol II
CTD phosphatase Fcp1 is essential for normal development in Drosophila
melanogaster. Gene 446, 58-67, doi:10.1016/j.gene.2009.07.012 (2009).

270

Schauer, T., Tombacz, I., Ciurciu, A., Komonyi, O. & Boros, I. M. Misregulated
RNA Pol II C-terminal domain phosphorylation results in apoptosis. Cell Mol Life
Sci 66, 909-918, doi:10.1007/s00018-009-8670-0 (2009).

271

Vizcaino, J. A., Deutsch, E. W., Wang, R., Csordas, A., Reisinger, F., Rios, D.,
Dianes, J. A., Sun, Z., Farrah, T., Bandeira, N., Binz, P. A., Xenarios, I.,
Eisenacher, M., Mayer, G., Gatto, L., Campos, A., Chalkley, R. J., Kraus, H. J.,
Albar, J. P., Martinez-Bartolome, S. et al. ProteomeXchange provides globally

208
coordinated proteomics data submission and dissemination. Nat Biotechnol 32,
223-226, doi:10.1038/nbt.2839 (2014).
272

Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based
protein identification by searching sequence databases using mass spectrometry
data. Electrophoresis 20, 3551-3567, doi:10.1002/(SICI)15222683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2 (1999).

273

Keller, A., Nesvizhskii, A. I., Kolker, E. & Aebersold, R. Empirical statistical model
to estimate the accuracy of peptide identifications made by MS/MS and database
search. Anal Chem 74, 5383-5392 (2002).

274

Nesvizhskii, A. I., Keller, A., Kolker, E. & Aebersold, R. A statistical model for
identifying proteins by tandem mass spectrometry. Anal Chem 75, 4646-4658
(2003).

275

Choi, H., Larsen, B., Lin, Z. Y., Breitkreutz, A., Mellacheruvu, D., Fermin, D., Qin,
Z. S., Tyers, M., Gingras, A. C. & Nesvizhskii, A. I. SAINT: probabilistic scoring of
affinity purification-mass spectrometry data. Nat Methods 8, 70-73,
doi:10.1038/nmeth.1541 (2011).

276

Ruepp, A., Waegele, B., Lechner, M., Brauner, B., Dunger-Kaltenbach, I., Fobo,
G., Frishman, G., Montrone, C. & Mewes, H. W. CORUM: the comprehensive
resource of mammalian protein complexes--2009. Nucleic Acids Res 38, D497501, doi:10.1093/nar/gkp914 (2010).

277

Woods, N. T., Yamaguchi, H., Lee, F. Y., Bhalla, K. N. & Wang, H. G. Anoikis,
initiated by Mcl-1 degradation and Bim induction, is deregulated during
oncogenesis. Cancer research 67, 10744-10752, doi:10.1158/0008-5472.CAN07-3148 (2007).

209
278

Zhong, L., Martinez-Pastor, B., Silberman, D. M., Sebastian, C. & Mostoslavsky,
R. Assaying chromatin sirtuins. Methods Mol Biol 1077, 149-163,
doi:10.1007/978-1-62703-637-5_10 (2013).

279

Huang, J. H., M.S.; Kim, H.; Leung, C.C.; Glover, J. N.; Yu, X.; Chen, J. RAD18
transmits DNA damage signalling to elicit homologous recombination repair.
Nature Cell Biology 11, 592-603 (2009).

280

Kim, J. M., Kee, Y., Gurtan, A. & D'Andrea, A. D. Cell cycle-dependent chromatin
loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood 111,
5215-5222, doi:10.1182/blood-2007-09-113092 (2008).

281

Ikeda, Y., Kiyotani, K., Yew, P. Y., Kato, T., Tamura, K., Yap, K. L., Nielsen, S.
M., Mester, J. L., Eng, C., Nakamura, Y. & Grogan, R. H. Germline PARP4
mutations in patients with primary thyroid and breast cancers. Endocr Relat
Cancer 23, 171-179, doi:10.1530/ERC-15-0359 (2016).

282

Cirello, V., Colombo, C., Pogliaghi, G., Proverbio, M. C., Rossi, S., Mussani, E.,
Tosi, D., Bulfamante, G., Bonoldi, E., Gherardi, G., Persani, L. & Fugazzola, L.
Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with
multiple primary tumors including thyroid cancer. Mutat Res 816-818, 111672,
doi:10.1016/j.mrfmmm.2019.111672 (2019).

283

Prawira, A., Munusamy, P., Yuan, J., Chan, C. H. T., Koh, G. L., Shuen, T. W.
H., Hu, J., Yap, Y. S., Tan, M. H., Ang, P. & Lee, A. S. G. Assessment of PARP4
as a candidate breast cancer susceptibility gene. Breast Cancer Res Treat 177,
145-153, doi:10.1007/s10549-019-05286-w (2019).

284

Haque, J., Boger, S., Li, J. & Duncan, S. A. The murine Pes1 gene encodes a
nuclear protein containing a BRCT domain. Genomics 70, 201-210,
doi:10.1006/geno.2000.6375 (2000).

210
285

Zhang, H., Fang, Y., Huang, C., Yang, X. & Ye, Q. Human pescadillo induces
large-scale chromatin unfolding. Sci China C Life Sci 48, 270-276 (2005).

286

Rohrmoser, M., Holzel, M., Grimm, T., Malamoussi, A., Harasim, T., Orban, M.,
Pfisterer, I., Gruber-Eber, A., Kremmer, E. & Eick, D. Interdependence of Pes1,
Bop1, and WDR12 controls nucleolar localization and assembly of the PeBoW
complex required for maturation of the 60S ribosomal subunit. Mol Cell Biol 27,
3682-3694, doi:10.1128/MCB.00172-07 (2007).

287

Holzel, M., Grimm, T., Rohrmoser, M., Malamoussi, A., Harasim, T., GruberEber, A., Kremmer, E. & Eick, D. The BRCT domain of mammalian Pes1 is
crucial for nucleolar localization and rRNA processing. Nucleic Acids Res 35,
789-800, doi:10.1093/nar/gkl1058 (2007).

288

Rosner, M. & Hengstschlager, M. Cytoplasmic and nuclear distribution of the
protein complexes mTORC1 and mTORC2: rapamycin triggers
dephosphorylation and delocalization of the mTORC2 components rictor and
sin1. Hum Mol Genet 17, 2934-2948, doi:10.1093/hmg/ddn192 (2008).

289

Freeman, A. K. & Monteiro, A. N. Phosphatases in the cellular response to DNA
damage. Cell Commun Signal 8, 27, doi:10.1186/1478-811X-8-27 (2010).

